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Advisor: Tatiana K. Bronich, Ph.D. 
Multiple myeloma (MM) is a hematological malignancy of plasma cells that are 
predominantly located in bone marrow (BM). Despite recent improvements in MM 
treatment by introduction of several novel agents including immunomodulatory drugs, 
proteasome inhibitors and the use of the drug combinations, MM remains incurable and 
almost all patients eventually relapse or become refractory to the current treatment 
regimens. So the current challenge of MM treatments is to maintain treatment response, 
prevent relapse and eventually prolong survival.  
Here we demonstrated that Pluronic block copolymers ((Pluronic L61: Pluronic 
F127 = 1:8 w/w, SP1017) significantly increase cytotoxicity of proteasome inhibitors 
(Bortezomib, BTZ or Carfilzomib, CFZ) in a panel of MM cells. Specifically, SP1017 
(0.005%) co-treatment triggered 2-fold increase in drug cytotoxicity to MM cells. Lower 
concentrations of SP1017 (0.002%) showed lower, but still significant cytotoxicity when 
combined with proteasome inhibitors. The mechanistic basis for sensitization effect of 
SP1017 was multifactorial and included: 1) augmented inhibition of chymotrypsin-like 
proteolytic activity, concomitant with increased accumulation of poly-ubiquitinated 
proteins and proteotoxic stress; 2) translocation of Pluronic L61 into the endoplasmic 
reticulum (ER) and increase of ER stress response; 3) translocation of Pluronic L61 into 
the Golgi apparatus and increase of rate of Golgi fragmentation, concomitant with 
reduction of secretion of paraprotein; 4) enhanced depletion of reduced glutathione, that 
is essential for mitigation of drug-induced oxidative stress; 5) enhanced pro-apoptotic 
VII 
 
activity of the proteasome inhibitors and; 6) decreased anti-apoptotic defense in MM 
cells. Importantly, SP1017 co-treatments restore drug sensitivity in BTZ/CFZ-resistant 
MM cells. Further studies have revealed that SP1017 co-treatment could also sensitize 
MM cells in co-culture models of the BM microenvironment, which triggers cytokine- and 
adhesion-mediated MM drug resistance. These results provide support for the design of 
therapeutic strategies aimed to counteract the drug resistance mechanisms in MM. We 
also demonstrated that combination of BTZ and SP1017 exerted enhanced antitumor 
efficacy in human MM/SCID mice model compared to BTZ alone, delaying the disease 
progression without causing systemic toxicity or hematological toxicity. Moreover, we 
observed the accumulation of the Cy5-L61 in the BM, which was proved by both 
fluorescence imaging and flow cytometry, indicating that Pluronic L61 could target and 
accumulate within the BM, thus playing an important role in sensitizing MM cells in the 
bone microenvironment to proteasome inhibitors.  
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CHAPTER I: INTRODUCTION 
 
1.1 Mutlidrug resistant (MDR) tumors 
Chemotherapy currently remains the main treatment option for cancers. 
However, patients suffer from its severe side effects, systemic toxicity and limited 
efficacy due to poor delivery of drug to cancer cells and/or intracellular targets. Multidrug 
resistance (MDR) to chemotherapy, as a result of intrinsic or acquired drug resistance of 
the tumor to chemotherapeutic agents, is a major obstacle in the treatment of cancer 
patients. Many primary tumors and metastatic lesions often relapse and develop drug 
resistance though they respond well to the chemotherapeutic treatment. The resistance 
of tumors occurs not only to a single cytotoxic drug used, but also occurs as a cross-
resistance to a whole range of drugs with different mechanisms of action and cellular 
targets. The most investigated mechanisms with known clinical significance are: pump 
resistance and non-pump resistance (Fig.1.1). 
 
1.1.1 Pump resistance 
Pump resistance depends on membrane-bound active drug efflux pumps that 
expel anticancer drugs out of the cells. The major efflux pumps belong to mammalian 
adenosine triphosphate (ATP)-binding cassette (ABC) transporters, a large member of 
functionally diverse transmembrane proteins that are associated with the plasma 
membrane of cells. There are 48 known human ABC transporters, classified into seven 
distinct subfamilies of proteins (ABC-A through ABC-G) on the basis of their sequence 
homology and domain organization [1]. The ABC transporters associated with MDR 
include (a) P-glycoprotein (P-gp, ABCB1), multidrug resistance-associated protein 1  
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Fig.1.1 Mechanisms of multidrug resistance. (Adapted from [4])  
 
 
 
 
 
 
 
 
3 
 
 
(MRP1, ABCC1), and breast cancer resistance protein (BCRP, ABCG2). The most 
typical efflux pump in the cell membrane is P-gp, with a molecular weight of 170kDa due 
to the amplification of ABCB1 (MDR1) gene. P-gp has a typical structure for ABC 
transporter, glycosylated at the first extracellular loop and composed of 12 
transmembrane domains (TMDs) and 2 intracellular nucleotide-binding domains (NBDs), 
which bind and hydrolyze ATP providing energy for transmembrane movement of the 
drugs [2]. The drug-binding pocket of P-gp is localized in the TM domain of the protein. 
The inward-open conformation of P-gp allows for substrate access both from cytoplasm 
and from the inner leaflet of the membrane but not from the upper leaflet or extracellular 
space. After the drug enters P-gp’s binding site from the inner leaflet of the membrane, it 
stimulates the binding of the two molecules of ATP by NBDs followed by their 
dimerization, which causes the major conformational change in the protein and formation 
of the outward-facing structure, open to the extracellular space. The drug is released 
due to the change of the affinity of the protein to it or is facilitated by ATP hydrolysis, 
which brings the protein back to the initial state [3]. MRP1, a 190-kDa protein, belong to 
the C group of the ABC transporters. MRP1 is consist of 17 TMDs having P-gp like cores 
and acts as an ATP-dependent glutathione S-conjugate export pump, thus its MDR 
mechanism is entirely different from that of P-gp mediated resistance. However, many of 
the anticancer drugs are the substrates for both P-gp and MRP1 except taxanes which 
are poor substrates for MPR1 [2]. BCRP, also called the mitoxantrone resistance 
associated protein (MXR) or ABC transporter in placenta (ABC-P), belongs to a member 
of the G subfamily of ABC transporters. It is a half transporter consisting of six TMDs 
and an ATP-binding site and functions as either homodimers or homomultimers bridged 
by disulfide bonds [2, 4].  
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A 110 kDa protein originally named as lung resistance-related protein /major 
vault protein (LRP/MVP) is not an ABC transporter. It is a complex ribonucleoprotein 
located in the cytoplasm membrane, nuclear membrane and nuclear pore complex, not 
on the cell membrane like P-gp and MRP. It is involved in intracellular transport 
processes, the bidirectional distribution of compounds between the nucleus and the 
cytoplasm, which might confer MDR by transporting drugs away from their intracellular 
targets and by the sequestration of drugs [5]. It has been demonstrated that LRP is 
involved in resistance to DNA interacting drugs such as doxorubicin (DOX) by the 
redistribution of DOX from the nucleus to the cytoplasm [6].  
 
1.1.2 Non-pump resistance  
In addition to enhanced drug efflux by different drug transporters associated with 
tumor cells, several mechanisms of drug resistance exist that are independent from drug 
efflux transporters, and are classified as non-pump resistance mechanisms. Such 
mechanisms decrease the ability of anticancer drugs to induce cells death without 
interfering with the entry and accumulation of drugs in tumor cells. The mechanisms 
include but are not limited to the following classes: (1) altered drug targets such as 
decreased topoisomerase II levels and activity; (2) increased drug metabolism by 
detoxification systems, such as glutathione-medicated reduction; (3) alterations in cell 
cycle checkpoints as a result of mutated cell cycle proteins such as p53; (4) increased 
DNA repair capacity; (5) reduced ability to undergo apoptosis (6) chromosomal 
abnormalities in cancer cells lead to over-expression of anti-apoptotic genes; (7) altered 
signal transduction pathways in cancer cells governed via integrin receptors, growth 
factor receptors etc. leads to blockage of apoptosis and expression of MDR-linked genes 
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those involved in DNA repair and drug-efflux pumps; (8) hypoxia up-regulated 
expression of MDR-linked genes through activation of transcription factor hypoxia 
inducible factor 1 (HIF1) [7, 8, 9, 10].  
Drug detoxification/inactivation is one of the contributing factors, where the toxic 
effect of cytotoxic drugs that gain entry inside the cells are successfully reduced with 
drug-metabolizing enzymes that are overexpressed in cancer cells such as isoforms of 
aldehyde dehydrogenase ( ALDH1A1 and ALDH3A1) [11], glutathione-S-transferases 
(GST) [12], and cytochrome P4503A [13].  Enhanced DNA damage repair efficiency also 
pays a major role in MDR resistance. A widely used anticancer drug DOX exhibit 
topoisomerases (Topo II) inhibitory effect, which is a critical enzyme that is involved in 
DNA replication and repair. DOX stabilizes the Topo II complex preventing the release of 
DNA double helix and stopping the process of replication. However, resistant cancer 
cells can activate Topo II in response to DOX treatment to compensate for the damage 
and thereby increase the resistance against the treatment [ 14 , 15 ]. Antiapoptotic 
defense, involving a huge complex of proteins, represents another important mechanism 
of MDR resistance to prevent transformation of a damage induced by anticancer drugs 
into apoptotic cell death. The anti-apoptotic members of this family, such as B-cell 
CLL/lymphoma 2 (Bcl-2) and BCL2-like 1 (Bcl-XL), prevent apoptosis either by 
sequestering proforms of death-driving cysteine proteases called caspases (a complex 
called the apoptosome) or by preventing the release of mitochondrial apoptogenic 
factors such as cytochrome c and apoptosis-inducing factor (AIF) into the cytoplasm. 
After entering the cytoplasm, cytochrome c and AIF directly activate caspases that 
cleave a set of cellular proteins to cause apoptotic changes [16]. It is evident that Bcl-2 
overexpression results in the resistance of cells to different drugs, including DOX [17], 
paclitaxel [18], cisplatin [19], mitoxantrone [20], etc. Solid tumors are found within a 
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tumor microenvironment that is comprised of cancer cells and stromal cells (including 
fibroblasts, immune and inflammatory cells, etc.), embedded in an extracellular matrix 
[21].The tumor microenvironment is characterized not only by marked gradients in drug 
concentration but also by gradients in the rate of cell proliferation and by regions of 
hypoxia and acidity, all of which can influence tumor cell sensitivity to drug treatment 
[ 22 ]. The hypoxic situation which results from the reduced blood flow caused by 
abnormal angiogenesis or the compression/closing of blood vessels, can lead to the 
activation of genes such as ABC transporters, Bcl-2 family genes, glutathione, etc that 
contribute to a drug-resistant phenotype [23, 24, 25, 26].  
 
1.2 Strageties to overcome MDR in cancer cells  
Extensive studies have been conducted during the last several decades to 
enhance the efficacy of chemotherapy by suppressing or evading these MDR 
mechanisms including the use of new anticancer drugs that could escape from the efflux 
reaction, MDR modulators, chemosensitizers, multifunctional nanocarriers, and RNA 
interference (RNAi) therapy[27]. 
 
1.2.1 Anticancer drugs capable of overcoming MDR  
Anticancer drugs that are not substrates of drug efflux transporters may offer 
improved therapeutic outcomes for patients by circumventing MDR. For instance, 
alkylating drugs (cyclophosphamide), antimetabolites (5-fluorouracil), and the 
anthracycline modified drugs (annamycin and doxorubicin-peptide) are among this 
category of anticancer drugs [28, 29, 30]. Novel camptothecin analogs with low polarity 
can circumvent ABCG2-associated drug resistance in ABCG2-overexpressing human 
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cell lines [ 31 ].  Taxanes, such as paclitaxel and docetaxel, are widely prescribed 
chemotherapeutic drugs to treat many forms of cancer including breast, ovarian and lung 
cancers [32].  Both paclitaxel and docetaxel are substrates for the ATP binding cassette 
multidrug transporters [33]. The novel taxane analog Tesetaxel (DJ-927) exhibited 
stronger cytotoxicity than paclitaxel and docetaxel in various tumor cells, especially 
against P-gp-expressing cells.  The cytoxicity of DJ-927 was not affected by the P-gp 
expression level in tumor cells, or by the co-presence of a P-gp modulator [ 34 ]. 
Cabazitaxel (Jevtana), a novel tubulin-binding taxane with poor affinity for P-glycoprotein, 
was approved by US Food and Drug Administration (FDA) in June 2010 for second line 
use in advanced hormone refractory prostate cancer in docetaxel-pretreated men and is 
the first clinically approved taxane that can circumvent resistance caused by the 
overexpression of the P-gp drug efflux pump [35]. Other novel taxane analogs such as 
BMS-184476, RPR109881A, Ortataxel, Trabectedin-ET-743 are evaluated in clinical 
trials for their broad spectrum activity in sensitive and resistant tumor cell lines to 
overcome MDR [36].  
 
1.2.2 MDR modulator  
MDR modulators, also named as MDR inhibitors or chemosensitizor, are the 
compounds that have the ability to reverse the resistance against anticancer drugs by 
inhibiting ABC transporters but are not cytotoxic themselves [2]. Modulators targeting P-
gp directed MDR belong to a number of chemical classes and have been classified as 
first, second and third generation MDR modulators based on their affinity for transporter 
proteins and their relative side effects [37]. First geneartion modulators includes drugs 
that were not specifically developed for inhibiting MDR but were used for other 
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pharmacological activities, such as calcium channel blockers (eg, verapamil), 
immunosuppressants (eg, cyclosporin A), antibiotics (eg,erythromycin), antimalarials 
(eg, quinine), psychotropic phenothiazines and indole alkaloids (eg, fluphenazine and 
reserpine), steroid hormones and anti-steroids (eg, progesterone and tamoxifen) and 
detergents (eg, cremophor EL) [ 38 ]. However, since their low affinity for ABC 
transporters required high doses to achieve the desired effect, first-geneartion 
modulators caused unacceptable high toxicity which limit their application. In addition, 
many of these chemosensitizers are substrates for other transporters and enzyme 
systems, resulting in unpredictable or adverse pharmacokinetic interactions in the 
presence of chemotherapy agents [39,40]. Clinical trials with first-generation MDR drugs 
failed for various reasons, often due to side effects [39, 41, 42]. The second-generation 
modulators include valspodar (PSC 833), dexverapamil, dexniguldipine, and biricodar 
(VX-710), which are more potent and less toxic than their predecessors [40]. A novel 
nonimmunosuppressive cyclosporin A, PSC-833, is shown to be a highly potent 
resistance modifier, being 7-10-fold more potent than the parent compound cyclosporin 
A, whilst approximately equal to cyclosporin A in the growth inhibitory effects of 
compound alone [ 43 ]. Valspodar has been studied in numerous clinical trials in 
combination with cytotoxic agents such as mitoxantrone, paclitaxel, dexamethasone, 
etoposide, cytarabine, in patients with various refractory carcinomas [ 44 , 45 ]. 
Dexverapamil is a stereoisomer of racemic verapamil and has approxiamately 25% of 
the cardiac activity of the racemic mixture, but appears to be equally potent in reversing 
MDR [46]. Second-generation P-gp modulators have a better pharmacologic profile than 
the first generation compounds, but they also retain some characteristics that limit their 
clinical usefulness. In particular, these compounds significantly inhibit the metabolism 
and excretion of cytotoxic agents due to the effect on cytochrome P450 isoenzyme 3A4-
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mediated drug metabolism, thus leading to unacceptable toxicity in clinical trials [39]. For 
example, the combination of dexverapamil and etoposide, prednisone, vincristine, 
cyclophosphamide, and doxorubicin (EPOCH) produced more hematologic toxicity 
compared with EPOCH alone [47]. The third generation modulator is highly specific for 
MDR efflux pumps sparing any interaction with drug-metabolizing enzymes that do not 
alter pharmacokinetic interaction with other therapeutic agents. Tariquidar (XR9576), 
zosuquidar (LY335976), ONX-093 (OC144-093) and laniquidar (R101933) are among 
the third generation MDR modulators with increased specificity, potency, and fewer 
pharmacokinetic interactions [27].  LY335979 significantly enhanced the survival of mice 
implanted with P-gp-expressing murine leukemia (P388/ADR) when administered in 
combination with either daunorubicin or DOX or etoposide without any significant effect 
on the pharmacokinetics of these anticancer agents [48]. OC144-093 increased the life 
span of doxorubicin-treated mice engrafted with MDR P388 leukemia cells by >100% 
and significantly enhanced the in vivo antitumor activity of paclitaxel in MDR human 
breast and colon carcinoma xenograft models, without a significant increase in DOX or 
paclitaxel toxicity [49]. Clinical trials with these new third generation agents are ongoing, 
but none of them has found a general clinical use so far [27]. Recently, the fourth 
generation MDR modulator have been developed originating from natural resources 
such as plants, fungi and even marine organisms to lower the toxicity for better tolerance 
by the human body [50]. Curcumin is a common term used for a mixture of curcuminoids 
that are purified from the Indian spice turmeric powder, are known to have many 
biological activities, including anti-inflammatory, anti-cancer, and anti-viral properties 
[50]. In addition, both curcumin and its major metabolite tertrahydrocurcumin were found 
to restore drug sensitivity in cancer cells overexpressing the MDR-linked ABC 
transporters P-gp, MRP1 and ABCG2 by directly inhibiting their functions [51]. More 
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recently, curcumin was found to have the modulatory effect on ABCG2 efflux activity in 
vivo [52]. Flavonoids, the main group of polyphenolic compounds present in plants as 
well as marine bio source, has been studied and characterized extensively by numerous 
research groups to determine their ability to inhibit P-gp-, MRP1- and ABCG2-mediated 
efflux and restore drug sensitivity in MDR cancer cells [50]. Flavonoids was found to be 
bi-functional in reversing the MDR not only by competitively binding to the substrate-
binding sites of transporters but also inhibiting the ATPases activity involved in drug 
efflux, thus enhancing the therapeutic index [53]. However, further studies are needed to 
elucidate the potential usage of natural products as chemosensitizers in MDR cancer 
chemotherapy. 
 
1.2.3 Gene silencing by RNA interference (RNAi) or antisense oligonucleotides 
(ASOs) to overcome MDR 
RNAi and ASOs are the two most widely used strategies for silencing gene 
expression. RNAi is a biological process that cells use to inhibit or silence specific gene 
expression through the destruction of specific mRNA molecules triggered by RNA 
molecules. Typically, RNAi can be achieved through two different pathways: 1) a RNA-
based approach where effector small interfering RNA (siRNAs) are delivered to the 
target cells; 2) a DNA-based approach in which effector siRNAs are generated by the 
intracellular processing of RNA hairpin transcipts [27]. When a double strandard RNA 
(dsRNA) molecule is introduced into a cell, it is recognized and cleaved by the enzyme 
Dicer, a member of the RNaseIII family of dsRNA-specific endonucleases into short 
fragments of 21-23 nucleotides. These small fragments, referred to as siRNA, bind to 
proteins from a special family: the Argonaute proteins and form RNA-induced silencing 
complexes (RISC). Within the RISC, one strand of the dsRNA is removed, leaving the 
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remaining strand available to bind to messenger RNA (mRNA) target sequences 
according to the rules of base pairing: A binds U, G binds C, and vice versa. Once 
bound, the Argonaute protein can cleave and destroy the mRNA, thereby preventing it 
from being used as a translational template and silencing the expression of the gene 
from which the mRNA was transcribed [54]. The latter approach is primarily based on 
nuclear synthesis of short-hairpin RNAs (shRNAs) using gene expressing vectors, which 
are transcribed in the nucleus and transported to the cytoplasm via the miRNA export 
pathway and are processed into siRNAs by Dicer [55]. ASOs share the fundamental 
principle with RNAi: a single-stranded oligonucleotide binds a target RNA through 
Watson-Crick base pairing, then cleaves and destroys the target RNA [56].  
RNAi has been extensively investigated in down-regulating the expression of 
MDR genes to restore drug sensitivity in cancer cells. Several effective sequences of 
siRNA and ASOs targeted to major drug efflux transporters (e.g. P-gp, MRP, BCRP, 
LRP proteins) were developed and successfully used in order to inhibit the expression of 
main drug efflux transporters. Nieth et al designed siRNA duplexes against two regions 
of the P-gp-encoding mRNA for disruption of P-gp-mediated drug extrusion and re-
sensitization of gastrointestinal tumor cells to treatment with the antineoplastic agent 
daunorubicin [57]. Pichelr et al demonstrated two tested shRNAi constructs targeted 
against human MDR1 mRNA inhibited expression of P-gp by >90%, whereas control 
shRNAi had no effect [58]. Lv et al proved stable shRNA-medicated RNAi increased the 
sensitivity to mitoxantrone of anti-BCRP shRNA treated MCF-7/BCRP cells about 14.6-
fold compared with the control [59]. Pan et al developed pSUPER-shRNA/mdr1 vector 
system to achieve knockdown of P-gp by RNAi in malignant cells and animals to restore 
their sensitivity to Adriamycin [60]. As unmodified, naked siRNA are relatively unstable in 
blood are rapidly degraded by endo-and exonucleases and they can hardly cross the cell 
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membrane due to their polyanionic and hydrophilic nature and relatively large molecular 
weight [61]. Typically, chemical modifications can be introduced into the RNA duplex 
structure so as to enhance biological stability without adversely affecting gene-silencing 
activity. Alternatively, they can be formulated with a delivery system that could enhance 
biological stability, facilitate intracellular uptake and specifically target to the tumor site of 
action [61]. Non-viral vectors are more promising because of their low toxicity, 
biodegradability, biocompatibility as well as availability as viral vectors (e.g. retrovirus, 
lentivirus, adenovirus, adeno-associated virus, and herpes simplex virus) due to their 
inflammatory and immunogenic effects [62].  Chemical non-viral vectors are broadly 
classified into inorganic particles, lipid based, polymer based and peptide based 
[ 63 ]. Nanocarriers designed for gene delivery can be synthesized from variety of 
materials including polymers, dendrimers, liposomes, carbon nanotubes, metal and 
metal-oxide nanoparticles [64]. For instance, novel biocompatible, lipid-modified dextran-
based polymeric nanoparticles were used as the platform for MDR1 siRNA delivery, 
which efficiently suppresses P-gp expression in the drug resistant osteosarcoma cell 
lines [65]. The cationic polymers, namely lipid-substituted low molecular weight (2 kDa) 
polyethyleneimine (PEI) was used as a carrier for siRNA-mediated BCRP down-
regulation, which sensitized the drug-resistant cells to cytotoxic effect of mitoxantrone by 
a ∼14-fold decrease in the IC50 value [66].  
RNAi and ASOs can be also used for suppression of proteins mainly responsible 
for nonpump resistance in order to sensitize MDR tumor cells. The siRNA-based 
therapeutics can induce apoptosis of cancer cells by targeting anti-apoptotic factors, 
such as survivin, Bcl-2, X-linked inhibitor of apoptosis (XIAP), and HIF1α [67]. siRNA-
based silencing of the survivin splice variant 2B inhibits cell growth in vitro and reduces 
tumor growth in orthotopic models of taxane-resistant ovarian cancer [68]. Bcl-2 siRNA 
13 
 
 
and Bcl-xl siRNA in transfected HepG2 cells blocked the target gene, induced apoptosis 
in HepG2 cells and increased the sensitivity to chemotherapeutic drugs 5-fluorouracil 
and 10-hydroxycamptothecin [69].XIAP gene silencing enhanced chemosensitivity of P-
gp expressing chondrosarcoma cells to DOX in comparison to nonsilencing control 
group [70]. Silencing the HIF-1α gene reversed MDR in colon cancer cells by increasing 
the sensitivities to Adriamycin, vincristine, 5-fluorouracil and inducing a marked increase 
in the apoptotic level of each corresponding drug [71].  
 
1.2.4 Multifunctional nanoparticles for chemotherapy 
Nanoparticles such as polymeric nanoparticles, solid lipid nanoparticles, 
magnetic nanoparticles, dendrimers, liposomes, micelles, quantum dots, etc. are 
extensively explored for cancer diagnosis, treatment, imaging, and as ideal vectors to 
overcome drug resistance by diverting ABC-transporter mediated drug efflux 
mechanisms [72]. Nanoparticles enhance the therapeutic efficacy of anticancer agents 
at the target site of action due to their passive and active tumor targeting abilities, which 
can reduce systemic toxicity and potentially circumvent the problem of drug resistance 
[27]. Passive targeting takes advantage of the unique pathophysiological characteristics 
of tumor vessels, enabling nanodrugs to accumulate in tumor tissues. Typically, tumor 
vessels are highly disorganized and dilated with a high number of pores, resulting in 
enlarged gap junctions between endothelial cells and compromised lymphatic drainage. 
The 'leaky' vascularization, which refers to the enhanced permeability and retention 
(EPR) effect, allows migration of macromolecules up to 400 nm in diameter into the 
surrounding tumor region [73]. Long circulation times will allow for effective transport of 
the nanoparticles to the tumor site through the EPR effect, which can be modulated by 
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the interactions of the nanoparticles with the environment and can be modified by 
changing the nanoparticles’ size, particle shape, and surface characteristics [74]. Well-
designed nanoparticles in the 10–100 nm size range and with a surface charge either 
slightly positive or slightly negative should have accessibility to and within disseminated 
tumors when dosed into the circulatory system [74].  The lower bound is on the basis of 
sieving coefficients for the glomerular capillary wall, as it is estimated that the diameter 
threshold for first-pass elimination by the kidneys is 10nm [75]. Moreover, researchers 
determined that the nanoparticle's capacity to navigate between the tumor interstitium 
after extravasation increased with decreasing size. By contrast, larger nanoparticles 
(diameter>100 nm) do not extravasate far beyond the blood vessel because they remain 
trapped in the extracellular matrix between cells [76]. When nanoparticles enter the 
bloodstream, the particle surface may experience nonspecific protein adsorption 
(opsonization), thereby making them more visible to phagocytic cells. After opsonization, 
nanoparticles, especially the large ones (diameter>200 nm [77]) could be rapidly cleared 
through phagocytosis by macrophages of the reticuloendothelial system (RES; also 
known as the mononuclear phagocyte system (MPS)) in the liver and spleen. The 
surface of nanoparticles can be modified by hydrophilic polymers that results in 
decreased clearance by the RES/ MPS system, thus increased circulation time. When 
attached to the surface of nanoparticles, the hydrophilic polymer poly (ethylene glycol) 
PEG improves the solubility and stability of the nanocarriers in an aqueous solution and 
imparts stealth characteristics by shielding the nanoparticles from opsonin adsorption 
and subsequent clearance by the RES/ MPS, leading to longer blood circulation times 
and improved pharmacokinetic properties [78]. However, targeting cancer cells using the 
EPR effect is not feasible in all tumors as the degree of tumor vascularization and 
porosity of tumor vessels can vary with the tumor type and status [79]. To overcome the 
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limitation of passive targeting, nanoparticles with active targeting were developed by 
conjugation of peripherally conjugated targeting moieties (folate, transferrin, aptamers, 
antibodies, peptides, or other small molecules that only bind to specific receptors on the 
cell surface) for increase endocytosis of the nanoparticles [80].  The folate receptor, a 
glycosylphosphatidylinositol anchored cell surface receptor with extremely high affinity 
binding to folate molecule, is overexpressed on a variety of tumors such as epithelial, 
ovarian, cervical, breast, lung, kidney, colorectal, and etc. , while its expression is limited 
in healthy tissues and organs [81]. Therefore, modification of nanocarrier with folate 
molecules has been extensively investigated for targeted drug delivery 
systems.  Poly(lactide-co-glycolide) (PLGA)–PEG micelles with folate conjugated at the 
PEG terminal end of PEG–PLGA di-block copolymer, entrapping a high loading amount 
of DOX demonstrated superior cellular uptake over DOX and DOX micelles against a 
folate-receptor positive cell line. The enhanced cellular uptake was caused by a folate-
receptor mediated endocytosis process, which also resulted in increased cytotoxicity. 
The decrease of cardiotoxicity indicates that the targeting moiety was able to 
differentiate between healthy and tumor tissue with greater specificity than untargeted 
DOX [82 ].Studies from our group also demonstrated a tumor-specific delivery and 
superior antitumor effect in vivo of an anti-cancer drug using diblock copolymer 
poly(ethylene oxide)-b-poly(methacrylic acid) (PEO-b-PMA) to form nanogels decorated 
with folate targeting groups for ovarian cancer treatment [ 83 ].  Folate-decorated 
polypeptide-based nanogels formed by biodegradable amphiphilic block copolymers, 
poly(ethylene glycol)-b-poly(L-glutamic acid)-b-poly(L-phenylalanine) significantly 
suppressed the growth of intraperitoneal ovarian tumor xenografts outperforming their 
nontargeted counterparts without extending their cytotoxicity to the normal tissues [84].  
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Moreover, nanoparticles can bypass drug efflux by ABC transporter as they are 
internalized via either non-specific or specific endocytosis which results in a higher 
intracellular accumulation of the drug. Endocytosis involves multiple steps. First, the 
cargo is engulfed in membrane invaginations that are pinched off to form membrane-
bound vesicles, also known as endosomes (or phagosomes in case of 
phagocytosis).  Second, the endosomes deliver the cargo to various specialized 
vesicular structures, which enables sorting of cargo towards different 
destinations. Finally, the cargo is delivered to various intracellular compartments, 
recycled to the extracellular milieu or delivered across cells [85]. There are four main 
mechanisms of endocytosis: clathrin-mediated endocytosis, caveolae-mediated 
endocytosis, micropinocytosis and other clathrin-and caveolea-independent endocytosis 
[ 86 ]. Clathrin- and caveolae-mediated endocytosis indicates receptor-mediated 
endocytosis. Many types of cells use the clathrin- and caveolae-mediated endocytosis 
pathways to internalize nanoscale materials, including viruses and nanoparticles [87]. 
Mechanistically, Clathrin-mediated endocytosis involves engulfment of receptors (such 
as transferrin  receptor, low density lipoprotein  receptor, epidermal growth factor 
receptors, human epidermal growth factor receptor 2 and etc.) associated with their 
ligands to a coated pit, which forms due to polymerization of a cytosolic protein called 
clathrin-1 and assembly proteins like AP180 and AP-2. The assembled vesicle (ca. 120 
nm) is pinched off from the plasma membrane and the vesicles fuse with the early 
endosomes where they are sorted to late endosomes/lysosomes, to trans-Golgi network 
or to the recycling endosomes to be transported back to plasma membrane [85]. 
Clathrin-mediated endocytosis appears to be defined as the most prominent mechanism 
for the PEG-PLA nanoparticles, PLGA nanoparticles, silica-based nanomaterials, 
chitosan nanoparticles, Pluronic® micelles and surface modified nanoparticles with the 
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surface ligand such as transferrin [85, 88]. Caveole-mediated endocytosis is the most 
common type of clathrin-independent receptor-mediated endocytosis. After binding to 
the cell membrane, nanocarrier move along the membrane to the caveolar invagination 
and form caveolar endocytic vesicles. The released caveolar vesicle can fuse with early 
endosome or caveosome, an endosomal compartment with neutral pH. Several 
nanomaterials are reported to enter cells via caveolae, including polymeric micelles with 
cross-linked anionic core, DOXIL®, polysiolxane nanoparticles, quantum dots, 
Abraxane®, Pluronic® unimers and surface-modified nanoparticles with the surface 
ligands include folic acid, albumin, and cholesterol [85, 88].  
The majority of anticancer agents including paclitaxel, etoposide and 
docetaxel are highly hydrophobic, which leads to poor aqueous solubility and low 
bioavailability at the target site and limits the use of intravenous (IV) administration. The 
use of nanocarriers such as lipid- or phospholipid-based nanocarriers, polymer-or 
dendrimer-based nanocarriers and albumin-based nanoformulation can enhance the 
solubility of hydrophobic drugs in aqueous solutions, prevent drugs from premature in 
vivo degradation and provide sustained and controlled drug release over a long period of 
time [ 89 ]. Acidic extracellular pH is a major feature of tumor tissue, extracellular 
acidification being primarily considered to be due to lactate secretion from anaerobic 
glycolysis [90].  Much research effort has been directed to the development of pH-
sensitive polymeric nanoparticles for intracellular drug delivery in that there exist natural 
pH gradients in the tumor microenvironment (pH 6.5–7.2) and in the 
endosomal/lysosomal compartments of tumor cells (pH 4.0–6.5).  Taking advantage of 
acidic extracellular pH (6.5–7.2) in the tumor compared with the normal tissues, pH-
sensitive nanoparticles have been developed to achieve accelerated drug release at the 
tumor site. Moreover, polymeric nanoparticles are usually internalized by cancer cells via 
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endocytosis. Following endocytosis, rapid endosomal acidification occurs due to a 
vacuolar proton ATPase-mediated proton influx, which leads to a drop of pH levels in the 
endosomes to approximately 5.0–6.5 and 4.0–5.0 in the lysosomes [91]. In the past few 
years, acid-sensitive nanoparticles that are prone to swelling, dissolution or degradation 
at endosomal/lysosomal pH (4.0–6.5) have been devised to obtain fast intracellular drug 
release in tumor cells in order to enhance the therapeutic efficacy, reverse multidrug 
resistance in tumors and resolve the extracellular stability and intracellular drug release 
dilemma.  One type of pH-sensitive nanoparticles has been designed based on polymers 
containing protonable amine groups, such as primary, secondary and tertiary amines 
[88]. For example, pH-sensitive nanoparticles of poly(ethylene glycol)-poly(L-histidine)-
poly(L-lactide) (PEG45-PHis45-PLLA82) triblock copolymers had higher release rate at pH 
5.0 compared to pH 7.4 due to protonation of the imidazole groups in the PHis block, 
inducing a high antitumor effect in HepG2 cells [92].   DOX-loaded PEGylated nanogels 
containing a pH-sensitive polyamine core exhibited superior antitumor activity against 
drug-resistant human hepatoma HuH-7 cells compared with their free DOX and 
the DOX-loaded, pH-insensitive, PEGylated nanogel. Using fluorescence microscopy, 
pH-sensitive PEGylated nanogel in HuH-7 cells was found to be initially localized within 
the endosome and/or lysosome, with subsequent release of DOX from the nanogel in 
response to the endosomal pH, and ultimately, diffusion via the cytoplasm into the cell 
nucleus [93]. Our lab also has developed the DOX-loaded PEO-b-PMA polymer micelles 
that exhibited noticeable pH-sensitive behavior with accelerated release of DOX in acidic 
environment due to the protonation of carboxylic groups in the cores of the micelles, 
resulting in a potent cytotoxicity against human A2780 ovarian carcinoma cells [94]. 
Another type of pH-sensitive nanoparticles has also been developed by incorporating 
acid-cleavable bonds such as hydrazone, acetal, imine and oxime bonds onto polymer 
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main or side chains [91]. For example, DOX was conjugated via pH-sensitive hydrazone 
linkage along with PEG to a biodegradable, non-toxic and non-immunogenic 
nanoconjugate platform: poly (β-L-malic acid) (PMLA). DOX-nanoconjugates were found 
stable under physiological conditions.  The majority of DOX (>80%) was released from 
the PMLA-platform under acidic pH prevalent in late endosome and lysosomes [95]. 
Benzoinc imine bond was used cholate grafted poly (L-lysine), (PLL-CA)/PEG-DOX 
vesicle, resulting in pH respnisive permeability and dissociation of the nanoparticles 
following an environmental pH dropping from 7.4 to 5.0 [96].  
1.2.5 Combinatorial nanoparticles against MDR in cancer 
Many combinatorial nanoparticle formulations have been developed by co-
delivering combination of chemosensitizing agents and chemotherapy agents to reverse 
MDR in in vitro and in vivo cancer models, including combinations of MDR modulators 
with chemotherapeutics and combination of MDR-targeted siRNA with 
chemotherapeutics [97].  
 
1.2.5.1 Combinations of MDR modulators with chemotherapeutics 
The combination of a chemotherapeutic drug with a MDR modulator has 
emerged as a promising strategy to restore the sensitivity of tumor cells and enhance 
the therapeutic efficacy of cancer treatment both in vitro and in vivo. The first attempt to 
co-deliver a MDR modulator with chemotherapeutics was 
polyalkylcyanoacrylate nanoparticles loaded with P-gp inhibitor cyclosporine A (CyA) 
and DOX. The incorporation of DOX and CyA in the same nanoparticle formulation 
elicited the most effective growth rate inhibition to multidrug-resistant 
murine P388/ADR leukemia cell line compared to other alternative approaches such as 
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mixed solution of DOX + CyA, DOX-only nanoparticles or DOX-nanoparticles with free 
CyA, probably as a result of a synergistic effect due to the rapid release of a high 
amount of CyA at the surface of the cell membrane allowing a facilitated intracellular 
diffusion of DOX [ 98 ]. Paclitaxel and tariquidar (P-gp inhibitor) loaded PLGA 
nanoparticles showed significantly higher cytotoxicity in vitro than nanoparticles loaded 
with paclitaxel alone, which could be correlated with increased accumulation of paclitaxel 
in drug-resistant adenocarcinoma cells.  Paclitaxel and tariquidar (P-gp inhibitor) biotin-
functionalized loaded PLGA nanoparticles showed significantly greater anti-tumor 
efficacy and higher overall survival rate in a mouse model of drug-resistant tumor at a 
paclitaxel dose that was ineffective in the absence of tariquidar [99].  To ensure two 
drugs could be simultaneously delivered to tumor region at the optimum ratio, and the 
MDR modulator could be released earlier and faster than the chemotherapeutic drug to 
inactivate P-gp and subsequently inhibit the pumping out of the chemotherapeutic drug, 
a smart pH-sensitive polymeric micelles system loaded with DOX and disulfiram (DSF) 
(P-gp inhibitor) was developed. DOX was conjugated to poly (styrene-co-maleic 
anhydride) (SMA) derivative with adipic dihydrazide (ADH) through an acid-cleavable 
hydrazone bond, and then DSF was encapsulated into the micelles formed by the self-
assembly of SMA-ADH-DOX conjugate. The co-delivery system enabled a temporal 
release of two drugs: encapsulated DSF was released fast to inhibit the activity of P-gp 
and restore cell apoptotic signaling pathways, while the conjugated DOX was released in 
a sustained and pH-dependent manner and highly accumulated in cancer cells to exert 
therapeutic effect. It was proved that the co-delivery system exhibited superior anti-
tumor activity high tumor accumulation and excellent antitumor effect in MDR tumor with 
low systemic toxicity in MCF-7/ADR tumor-bearing mice [100].  Except for being as 
inhibitors of drug efflux transporters, some compounds also sensitize the MDR tumor by 
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repairing the dysfunctional apoptotic associated with MDR. Curcumin, an inhibitor of 
nuclear factor kappa B (NFκB) as well as a potent down-regulator of ABC transporters, 
was encapsulated in flaxseed oil containing nanoemulsion formulations with paclitaxel. 
The coadministration system increased accumulation of paclitaxel and enhanced 
apoptosis within MDR-1 positive SKOV3TR ovarian adenocarcinoma cells [ 101 ]. 
Curcumin was observed to not only inhibit the nuclear efflux of DOX but also 
downregulate the gradual expression of MDR1 and BCL-2 at the mRNA level, leading 
higher cytotoxicity of K562 human leukemia cells treated with DOX /curcumin loaded 
PLGA nanoparticles. Both the drugs induced a number of apoptotic pathways, leading to 
a higher expression of a number of apoptotic proteins [ 102 ]. Curcumin was also 
demonstrated to reverse cis-platin resistance and trigger apoptotic death of human lung 
adenocarcinoma A549/DDP cells by promoting HIF-1α degradation and activating 
caspase-3, respectively [103].  
 
1.2.5.2 Combinations of MDR-targeted siRNA with chemotherapeutics  
Coadministration of anticancer drugs and siRNAs offer another very promising 
strategy to enhance the therapeutic efficacy in various MDR tumor models. As discussed 
above, siRNAs can down-regulate the expression of MDR proteins to overcome both 
pump resistance and nonpump resistance. For example, PEI-coated mesoporous silica 
nanoparticles loaded with P-gp siRNA and DOX restore the DOX sensitivity in drug-
resistant KB-V1 squamous carcinoma cell line where the delivered siRNA silenced the 
expression of P-gp which consequently increased the intracellular concentration of DOX 
[104]. In vivo studies demonstrated significantly greater inhibition of tumor growth in a 
drug-resistant tumor bearing mouse model following treatment with biotin-functionalized 
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PLGA-PEI nanoparticles encapsulating both paclitaxel and P-gp targeted siRNA at a 
paclitaxel dose that was ineffective in the absence of gene silencing [105]. siRNAs that 
overcome nonpump resistance of MDR have been encapsulated in nanocarriers 
combined with anti-cancer therapeutics. Zheng et al. reported the co-delivery of Bcl-2 
siRNA and docetaxel using polymer micelles formed by poly (ethylene glycol)-b-poly(L-
lysine)-b-poly(L-leucine)  (PEG-PLL-PLLeu)  triblock copolymers. The hydrophobic 
PLLeu core entrapped with anticancer drugs, while the PLL polypeptide cationic 
backbone allowed for electrostatic interaction with the negatively charged siRNA. The 
co-delivery system downregulated the anti-apoptotic Bcl-2 gene and enhanced antitumor 
activity with a smaller dose of DTX, resulting in the significantly inhibited tumor growth of 
MCF-7 xenograft murine model as compared to the individual siRNA and only DTX 
treatments [106]. Wang et al. developed a new nanocarrier platform E-NP, composed of 
amphiphilic block copolymer of methoxy poly(ethylene glycol)–poly(lactide-co-glycolide) 
(mPEG–PLGA) and ɛ-polylysine (EPL), simultaneously delivering both hydrophilic and 
hydrophobic chemotherapeutics along with siRNA. Dox was packaged into the 
hydrophilic core of the nanoemulsion, while paclitaxel was encapsulated into the 
hydrophobic layer. Survivin siRNA was complexed onto the surface of the nanoemulsion 
through electrostatic interactions with EPL. Survivin siRNA, which was adsorbed on the 
outmost layer of the NPs and released first before both DOX and TAX could reach the 
tumor cells, sensitized and expanded the current chemotherapeutic regimen of DOX and 
paclitaxel [107].  
 
1.3 Pluronic® block copolymers for overcoming MDR in cancer 
23 
 
 
Polymer-based nanotechnology became one of the fastest growing areas of 
pharmaceutical research and attracted tremendous attention during the last two 
decades. As discussed above, the roles polymer nanoformulation play included: 1) 
increase of drug solubility and stability by drug encapsulation, which alone exhibit poor 
solubility, undesired pharmacokinetics and low stability in a physiological environment.; 
2) passive or active targeting of drug into tumor sites by the EPR) effect or  molecular 
targeting moieties modified on the surface of the nanoformulation; 3) increased cellular 
uptake by either “passive” endocytosis or receptor-mediated endocytosis, thus 
bypassing drug efflux transporters on the plasma member; 4) controlled and sustained 
release of the drug at the tumor site in response to specific tumor conditions, such as pH 
or presence of particular enzymes, thus reducing systemic toxicity; 5) simultaneous 
delivery of several cytotoxic drugs or cytotoxic drugs with MDR modulator/siRNA to 
achieve synergetic anti-tumor effect.  Additionally, polymeric carriers can exhibit 
biological activity of their own, acting as a biological response modifier that potentiates 
the drug cytotoxic effect in tumor cells [ 108 ]. One of the promising examples of 
amphiphilic block copolymers which benefit the above properties is Pluronic® block 
copolymers, which are listed in the U.S. and British Pharmacopoeia under the name 
“poloxamers” as excipients and are widely used in a variety of clinical applications [109, 
110]. Previous studies demonstrated that Pluronic® block copolymers sensitize MDR 
cancer cells resulting in increased cytotoxic activity of Dox, paclitaxel, and other drugs 
by 2-3 orders of magnitude [111, 112]. A lot of efforts have been spent on overcoming 
drug resistance of Pluronic® block copolymers working as drug nanocarriers as well as 
chemosensitizer for MDR cells.  
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1.3.1 Pluronic® block copolymers as micellar nanocarriers for drug delivery 
Pluronic® block copolymers consist of hydrophilic poly (ethylene oxide) (PEO) 
and hydrophobic poly (propylene oxide) (PPO) blocks arranged in A-B-A triblock 
structure: PEO-PPO-PEO, which is non-ionic in nature. Due to the amphiphilic nature of 
these block copolymers, Pluronic® block copolymers are an important class of 
surfactants and widely used in pharmaceutical systems as suspending, adjuvants, 
adhesives, emulsifying agents and coating material for controlled and site specific drug 
delivery systems [113]. Because of large solubility differences between hydrophobic and 
hydrophilic moieties, in aqueous medium they are able to self-assemble into polymeric 
micelles consist of water-insoluble cores and water-soluble shells. Depending on blocks 
length, core can assemble into various supramolecular structures characterized by 
different morphologies above a certain concentration or temperature [113]. Due to this 
characteristic, the core–shell (core of PPO and shell of PEO) micelles of Pluronic® can 
be used to solubilize poorly water soluble drugs and can function as effective drug 
carriers [114, 115].  
 
1.3.1.1 Pluronic® block copolymers structure  
Pluronic® block copolymers, PEOx-PPOy-PEOx, is an amphiphilic copolymer, in 
which the number of hydrophilic PEO and hydrophobic PPO units can be altered. The 
physical and chemical properties of Pluronic® block copolymers can be finely tuned by 
modifying the molar mass ration between the PEO and PPO blocks (from 1:9 to 8:2). 
The structure formula of Pluronic® block copolymers is shown in Fig. 1. 2. Table 
1.1 presents a list of selected Pluronic® copolymers which are commercial available from 
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BASF Corp. Copolymers with various x and y values result in variable 
hydrophilicity/hydrophobicity, which are characterized by distinct hydrophilic–lipophilic 
balance (HLB) [115]. The trade names of the Pluronic® block copolymers are also known 
such as L61, P85 and F127. The First letter L, P or F refers to the liquid, paste or solid 
form of the block copolymers. The Last digit multiplied by the gives the mass percent of 
the PEO block while the first one or two digits refer to the Pluronic® grid and provide 
1/300 of the molar mass of the PPO block. For example, L61 is liquid with 10% of molar 
mass percentage of PEO per individual block copolymer molecule (unimer) and PPO 
molecular mass of 1800 g/mol. F127 is paste with 70% of molar mass percentage of 
PEO per unimer and PPO molecular mass of 3600 g/mol [116].   
 
1.3.1.2 Micellization and solubilization 
The solubility of Pluronic® block copolymers in water depends on their structure as well 
as the temperature. Below room temperature, both types of blocks within a 
Pluronic® molecule are hydrated and are relatively soluble in water.  Increase of the 
temperature promotes dehydration of firstly, PPO block and secondly, PEO blocks, thus 
decreasing the solubility of the block copolymers. At physiological temperature, 37°C, 
PPO chains are water-insoluble while PEO chains are well-hydrated and water-soluble. 
Below critical micelle concentration (CMC), the amphiphilic molecules have a strong 
tendency to be absorbed at the air/water interface. With the increase of the 
concentration of block copolymers, a point, defined as CMC, is reached when both the 
interface and the bulk of the solvent (water) become saturated with monomeric 
copolymers. The unimer molecules aggregate to form micelles through the process 
called “micellization” at the concentrations of block copolymer above CMC in water by  
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Fig. 1.2 Pluronic® block copolymers available from BASF (Wyandotte, MI), contain two 
hydrophilic EO blocks and a hydrophobic PO block. (Adapted from [184]) 
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Table 1.1 Physicochemical characteristics of Pluronic® block copolymers 
Copolymer MWa 
Average no. 
of 
Average no. 
of HLBc 
Cloud point 
in 
CMC 
(M)d 
  
EO units (x)b PO units (y)b 
 
1% aqueous 
 
     
solution (°C)c 
 L35 1900 21.59 16.38 19 73 5.3×10−3 
L43 1850 12.61 22.33 12 42 2.2×10−3 
L44 2200 20.00 22.76 16 65 3.6×10−3 
L61 2000 4.55 31.03 3 24 1.1×10−4 
L62 2500 11.36 34.48 7 32 4.0×10−4 
L64 2900 26.36 30.00 15 58 4.8×10−4 
F68 8400 152.73 28.97 29 >100 4.8×10−4 
L81 2750 6.25 42.67 2 20 2.3×10−5 
P84 4200 38.18 43.45 14 74 7.1×10−5 
P85 4600 52.27 39.66 16 85 6.5×10−5 
F87 7700 122.50 39.83 24 >100 9.1×10−5 
F88 11 400 207.27 39.31 28 >100 2.5×10−4 
L92 3650 16.59 50.34 6 26 8.8×10−5 
F98 13 000 236.36 44.83 28 >100 7.7×10−5 
L101 3800 8.64 58.97 1 15 2.1×10−6 
P103 4950 33.75 59.74 9 86 6.1×10−6 
P104 5900 53.64 61.03 13 81 3.4×10−6 
P105 6500 73.86 56.03 15 91 6.2×10−6 
F108 14 600 265.45 50.34 27 >100 2.2×10−5 
L121 4400 10.00 68.28 1 14 1.0×10−6 
P123 5750 39.20 69.40 8 90 4.4×10−6 
F127 12 600 200.45 65.17 22 >100 2.8×10−6 
a The average molecular weights provided by the manufacturer (BASF, 
Wyandotte, MI). 
b The average numbers of EO and PO units were calculated using the average 
molecular weights. 
c HLB values of the copolymers; the cloud points were determined by the 
manufacturer. 
d CMC values were determined previously using pyrene probe [117].  
(Adapted from [139]) 
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the driving force of the hydrophobic interactions of the PPO blocks [118].The CMC of the 
block copolymers is strongly dependent on the lengths of the blocks. An increase in the 
length of the hydrophobic PPO block elevates the net hydrophobicity of the 
Pluronic® molecule and favors the segregation of the PPO chains into the micelle core, 
resulting in a CMC decrease. In contrary, an increase in the lengths of the PEO blocks 
elevates the probability of contacts of the PPO units with the PEO units within the core of 
the micelles, which decreases the hydrophobicity of the core and results in 
destabilization of the micelle. Therefore, the CMC increases as the hydrophilic PEO 
block length is increased [118].   
Pluronic® micelles are commonly pictured as spheres with a PPO inner core and 
a hydrophilic PEO corona. The micelle size, aggregation number and morphology of the 
Pluronic® block copolymers aggregates strongly depend on the block copolymer 
composition, specifically, the lengths of PEO and PPO units, the block copolymer 
concentration and environmental parameters such as temperature and the quality of the 
solvent [ 119 , 120 ]. Spherical micelles commonly have an average hydrodynamic 
diameter ranging from about 20 to 80nm, within the preferred nanoparticles size range 
10–100 nm discussed above and aggregation numbers ranging from 10 to several 
dozen [120]. Except for the spherical structure, additional micelle morphologies include 
lamella and rods (cylinders). Nagarajan predicted the formation of cylindrical and 
lamellar structures by modeling the framework of a simple molecular theory of 
solubilization. It was found that solubilization is shown to induce a transition in aggregate 
shapes from spheres to cylinders and then to lamellae [120]. For example, the lamellar 
aggregates are favored when the ratio of PEO: PPO is small while spherical aggregates 
are favored when the PEO: PPO ratio is large. Typically, for block copolymers containing 
40 or more weight percent PEO, only spherical aggregates form at 25°C. For block 
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copolymers containing 30 wt% PEO, cylindrical aggregates are possible. Block 
copolymers containing 20 or less weight percent PEO generate lamellae [120]. It has 
been demonstrated that increase of the temperature, which induced the decrease of 
solubility, led to the transition into cylindrical or lamellar geometries [121].  
The hydrophobic core can serve as a microenvironment that can enhance the 
loading efficiency of hydrophobic drugs which alone exhibit poor solubility, undesired 
pharmacokinetics and low stability in a physiological environment. This process is 
referred to as “solubilization”. The outer hydrophilic shell severs as a stabilizing interface 
between the hydrophobic core and the aqueous medium to ensure the micelles remain 
in a dispersed state and decrease undesirable drug interactions with cells and proteins 
[115]. The extent of drug incorporation in Pluronic® micelles is dependent on factors 
including the molecular volume of the solubilizate, the interfacial tension of the 
solubilizate against waster, length of the core and shell-forming blocks in the copolymer 
and the polymer and solubilizate concentrations [122]. It seems reasonable that longer 
PPO blocks would produce larger hydrophobic inner core, suggesting hydrophobic core 
of micelles as locus of solubilization [123]. Moreover, Nagarajan demonstrated that the 
amount of the incorporated solubilizate increases as the molecular volume of the 
solubilizate decreases [120]. Furthermore, the solubilization capacity is increased when 
high compatibility exsists between the micellar core and the solubilizate and the 
solubilizate-water interfacial tension is lower [122].  
 
1.3.1.3 Stability and drug release of Pluronic® micelles 
The CMC and the partition coefficient are the major thermodynamic constants 
determining the stability of the micellar carrier and the drug release in equilibrium 
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condition. The dilution of the micelles, for example, in the body fluids, leads to the 
release of the encapsulated drug. If the system is diluted below the CMC, the micelles 
are completely disintegrated and the drug is prematurely release the drug into blood 
following intravenous injection [118]. The low stability of Pluronic® micelles results in 
failure of increase in drug circulation time and delivery of the drug to the tumor site by 
the EPR effect, which limits the practical use of systemic delivery of drugs. In order to 
overcome the poor stability and low drug entrapment efficiency of Pluronic® micelles, 
several methods have been developed.  
Mixed micelles composed different Pluronic® block copolymers were explored to 
encapsulate hydrophobic drug with high drug loading capacity as well as improving the 
stability of the micellar systems. Mixed micelles composed of relatively hydrophobic 
Pluronics® L61/P123/P105 and relatively hydrophilic Pluronics® F127 incorporating 
insoluble anticancer therapeutics have been evaluated in vitro and in vivo [124, 125, 
126, 127]. The relatively hydrophobic block copolymers with a greater portion of PPO, 
was able to load satisfactory hydrophobic drug content. However, due to the rather short 
PEO length, the stability of micelles is not desirable. Owing to the high PEO-PPO ratio, 
F127 possessed a lower CMC value, creating a stable and effective delivery system. 
Mixed micelles of ionic and nonionic surfactants show advantageous solubilization 
behavior and an expanded stability when compared with the pure nonionic system. The 
phospholipids mixed micelles had lower CMC than that of polymeric micelles and 
overcame the thermodynamic instability present in polymeric micelles [128]. Vitamin E 
succinate modified pluronic® micelles showed enhanced encapsulation efficiency and 
better stability as compared to the non-modified controls [129].  
Another method to increase the stability of Pluronic® micelles is the formation of 
crosslinks within their outer shells. To form crosslinks, the two terminal alcohols on L121 
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were first chemically converted into aldehydes (L121-CHO) using the Dess–Martin 
periodinane. Diamine compounds were then used to bridge the converted aldehyde 
termini on L121-CHO via conjugated Schiff bases. After crosslinking, the morphology of 
the L121 micelles remained spherical in shape, the sizes were comparable before and 
after crosslinking and the micelle stability was greatly enhanced [130]. The stabilization 
of Pluronic® micelles composed of Pluronic® P94 and F127 was obtained through 
incorporation of a hydrophobic cross-linking agent and subsequent photo-
polymerization, which prevented micelle disruption below CMC or the critical micelle 
temperature (CMT), the temperature below which only single chains are present, while 
maintaining the integrity of the PEO corona and the hydrophobic properties of the PPO 
core [131]. 
Another attractive strategy to eliminate the burst and premature release of the 
drug could be forming polymeric micelles by conjugating drugs to the polymer backbone 
via covalent bonds, which can hold the drug firmly in the micelles during circulation in the 
blood. To form the DOX- Pluronic® F68 conjugate, the end group of pluronic® F68 was 
modified to a carboxyl group and then then chemically conjugated with DOX via an 
amide. Drug release profile showed that the DOX- Pluronic® F68 micelles maintained a 
sustained DOX release at pH 7.4. The release of DOX from the micelles was 
accelerated when the PH was reduced to 6.0 comparing with PH 7.4, due to the 
protonation of carboxylic groups at the acidic PH [132]. Another novel polymer-drug 
conjugate was prepared by the chemical reaction between the copolymer Pluronic® 
P123 and the docetaxel via a pH sensitive hydrazone bond. With a low CMC, these pH 
sensitive P123- docetaxel conjugates could self-assemble into nano-size polymeric 
micelles in aqueous solution. With the introduction of the covalent hydrazone bonds, 
these pH sensitive polymeric conjugate micelles were proved to exhibit their stability 
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against the rat plasma and show a pH dependent drug release, showing the potential to 
antitumor drug delivery [133]. 
 
1.3.1.4 Pluronic®-based drug delivery systems 
Pluronic® micelles containing water insoluble or poorly water-soluble drugs [134], 
polypeptides [135], plasmid DNA [136], oligonucleotides [137] as well as diagnostic 
imaging agents [138] have been investigated as potential drug delivery systems in 
multiple applications. For example, Pluronic® micelles were utilized for delivery of central 
nervous system (CNS) drugs across the blood brain barrier (BBB) [139, 140, 141], oral 
delivery of drugs to improve oral bioavailability [142, 143], pulmonary delivery of drugs 
by inhalation [144] and especially tumor-specific delivery of antineoplastic agents [145, 
146]. Following are the examples of Pluronic®-based drug delivery systems targeted to 
the MDR tumors.  
SP1049C, which contained DOX in the mixed micelles of Pluronics L61 and F127, 
was the first in class polymeric micelle drug to advance to clinical stage [124] and has 
successfully completed phase II clinical trial which showed high objective response rates 
(47%) in the evaluable population and increased median survival (10 months) and 
progression free survival (6.6 months) in patients with inoperable metastatic 
adenocarcinoma of the esophagus and gastro esophageal junction with toxicity profile 
similar to that of Dox at equivalent dose and administration schedule [147].SP1049C 
also have been shown recently to decrease the tumorigenicity and aggressiveness of 
cancer cells in vivo, suppress BCRP overexpression and the Wnt--catenin signaling 
activation observed with Dox alone, significantly alter the DNA methylation profiles, as 
well as depletes CD 133+ cells populations, which displayed cancer stem cells (CSCs)-
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like properties and were much more tumorigenic compared to CD133- cells in murine 
leukemia model [148]. Other systems paclitaxel, methotrexate, or docetaxel loaded 
polymeric micelles mixed with Pluronic® P105 and F127 has been evaluated in vitro and 
in vivo [125,127,127]. All the systems indicated that drug loaded Pluronic® micelles 
displayed higher anti-tumor efficacy than free drug in both MDR cancerous cell lines and 
MDR tumor xenografts with higher blood circulation time  and less systemic toxicity in 
comparison with drug alone injection. Moreover, docetaxel-loaded P105/F127 mixed 
micelles displayed a higher cytotoxicity towards  human lung adenocarcinoma  A549-
Taxol  resistant cells than Taxotere®, the commercial preparation that approved by the 
FDA in 2004 . Longer mean residence time in circulation, larger area under the plasma 
concentration-time curve and higher tumor inhibition rate were observed with docetaxel-
loaded P105/F127 mixed micelles compared to Taxotere®, indicating the potential of 
P105/F127 mixed micelle as a drug drug delivery system to overcome multidrug 
resistance in lung cancer [127]. 
Targeting moieties- conjugated Pluronic® block copolymers have been developed 
to form micelles for active targeting. cyclic RGD [arginine-glycine-aspartic acid] peptide 
(c(RGDyK)) that can bind to the integrin protein richly expressed at the site of tumor 
vascular endothelial cells and tumor cells with high affinity and specificity, was 
conjugated to the N-hydroxysuccinimide-activated PEO terminus of the Pluronic F127 
block copolymer. c(RGDyK)-decorated Pluronic F127 and P105 mixed micelles are 
developed in this study to form a dual-functional drug delivery system for the 
antiangiogenesis and modulation of drug resistance [149]. Folic acid and its conjugate 
were widely used for selective delivery of anti-cancer agents to cells with folate 
receptors. Folic acid functionalized Pluronic P123/F127 mixed micelles  was efficiently 
internalized into the cells through by  folate receptor-mediated endocytosis, leading to 
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faster and larger extent of drug delivery by folic acid-conjugated micelles compared with 
that by non-targeted micelles [125].  
Pluronic®-based drug delivery systems were also explored for gene delivery. A 
I Belenkov et al evaluated PEI grafted with nonionic amphiphilic block copolymer, 
Pluronic® P85 (P85-g-PEI) as a carrier for Ku86 ASO delivery [150]. Compared with 
PEI/DNA complex, P85-g-PEI/DNA formulations significantly reduced aggregation due to 
the effect of nonionic chains that are soluble in aqueous dispersions and prolonged the 
circulation time after systemic administration while the high transfection activity was 
remained. Jianan She and other authors developed and investigated a new co-delivery 
system, P85-PEI/ D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) complex 
nanoparticle, conveying chemotherapeutic agent and RNA for reversing drug resistance 
[151].  TPGS was used to improve micelle stability and drug loading; P85 was used for 
preparing micelles and inhibit GST activity, which may contributed to the direct decrease 
of the metabolism of drug and potentiate the drug-induced cell apoptosis and PEI was 
used to bind shRNA. The IC50 of formulation against PTX resistant human lung 
adenocarcinoma epithelial (A549/T cells) was 360-fold lower than that of free drug and 
better antitumor efficacy of formulation was observed in vivo. 
 
1.3.2 Pluronic® block copolymers acting as chemosensitizer for MDR cells 
Besides the ability to self-assemble into micelles, Relatively hydrophobic 
Pluronic® block copolymers at concentrations below the Critical Micelle Concentration 
(CMC) with intermediate length of PEO units from 30 to 60 and HLB <20 [152, 153] can 
sensitize MDR cancer cells mainly by ABC transporters inhibition and selective ATP 
depletion, which is accompanied with generation of reactive oxygen species (ROS) and 
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simultaneously inhibition of glutathione/glutathione S-transferase (GSH/GST) 
detoxification system [ 154 , 155 , 156 ]. On the other hand, the Pluronic-caused 
impairment of respiration in mitochondria decreased the mitochondrial membrane 
potential, promoted release of cytochrome c and overall enhanced pro-apoptotic 
signaling (Bax, p53, APAF1, caspase 9 and caspase 3) and mitigated anti-apoptotic 
cellular defense (Bcl-2 and Bcl-xl) of MDR cells (Fig.1.3) [157]. 
 
1.3.2.1 Structure-functional relationship of Pluronic® block copolymers 
The relationship between composition of Pluronic® block copolymers and their biological 
response-modifying effects has been investigated. Batrakova et al demonstrated that the 
MDR sensitizing effects were achieved by Pluronic® block copolymers at the 
concentration below the CMC. When the concentration below the CMC, the resistance 
reversion indexes (i.e., ratio of the IC50 of the drug in the assay buffer and Pluronic 
solution (IC50.0/IC50)) rapidly increased with increasing copolymer concentration and 
reached 400-fold (KBv) and 3400-fold (MCF-7/ADR) as copolymer concentration 
approached the CMC values. At concentration above the CMC, the leveling off of 
cytotoxicity was observed and the drug cytotoxicity decreased as concentration 
continued to rise (Fig.1.4A) [152]. Thus, the sensitizing effect on MDR cells is mediated 
by the copolymer signal chain unimers, rather than the micelles.  
The specific effects on transporter activity profiles and the critical factors that 
influence transporter activity (i.e., membrane fluidization, energy depletion) in both 
sensitive and drug resistant cells has been conducted with a series of Pluronic® block 
copolymers with a wide range of HLB [152, 153]. Results of R123 (the fluorescent dye,  
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Fig.1.3 Multiple effects of Pluronic® block copolymers in MDR cells: 1) incorporation of 
Pluronic molecules into membranes and decrease of the membrane microviscosity; 2) 
induction of ATP depletion; 3) inhibition of drug efflux transporters; 4) release of 
cytochrome c from mitochondria and increase in ROS levels in cytoplasm; 5) increase of 
pro-apoptotic signaling and decrease of anti-apoptotic defense in MDR cells; 6) inhibition 
of the glutathione/glutathione S-transferase detoxification system; and 7) abolishment of 
drug sequestration within cytoplasmic vesicles. (Adapted from [119]) 
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P-gp substrate) accumulation studies suggested that the sensitizing effects of 
Pluronic® block copolymers in MDR cells depend on the copolymer hydrophobicity.  The 
entire set of the hydrophilic Pluronic® block copolymers with HLB varying from 20-29, 
presented in Table.1.1, at concentrations below the CMC, had no or little effect on R123 
accumulation. Except for the HLB values, the length of PPO block also plays an 
important role in the inhibiting the P-gp transporters. It was found a bell-shaped 
dependency of the length of hydrophobic PPO segment in inducing R123 uptake. The 
maximal effects on the drug uptake were characteristic of Pluronic® block copolymers 
with intermediate length of PPO block ranging from 30 to 60 (Fig.1.4B) [153]. The same 
bell-shaped curves were observed of the total microviscosity factor values (value of total 
cellular membrane microviscosity in the control group in the absence of the 
Pluronic® block copolymers versus those observed in the presence of the 
Pluronic® block copolymers) or ATP depletion factor (ATP intracellular levels in the 
absence of the Pluronic® block copolymers versus those observed in the presence of the 
Pluronic® block copolymers ) corresponding to the length of PPO blocks. Lipophilic 
copolymers with intermediate PPO block decreased the microviscosity in bovine brain 
microvessel endothelial cells (BBMECs), indicating their incorporation into the lipid 
bilayer and subsequent increase in membrane fluidization and reduced the intracellular 
ATP level at significantly high extent. Very lipophilic block copolymers with long PPO 
blocks, the most membranotropic block copolymers, anchor in the plasma membranes 
and remain there for an extended period of time. As a result, although they are potent 
inhibitors of P-gp ATPase, they are less efficiently transported into the cell and cause 
less ATP depletion and, consequently, have less effect on P-gp efflux system compared 
with the intermediate block copolymers.  In contrast, the block copolymers displaying 
intermediate lipophilicity transport across the membranes, and spread throughout  
38 
 
 
A                                                                  B 
 
Fig.1.4 (A) Effects of Pluronic® block copolymers on cytotoxicity of DOX with respect to 
MDR cells: curve 1, MCF7/ADR cells were treated with doxorubicin–L61 compositions; 
curve 2, KBv cells were treated with doxorubicin–P85 compositions containing varying 
concentrations of the block copolymer. Resistance reversion indexes (ratio of IC50 of 
DOX in the assay buffer and Pluronic® solution) are plotted as functions of the 
concentration of the block copolymers. (B) Efficacy of Pluronic® block copolymer 
composition in MDR KBv cells. R123 enhancement factors are defined here as the ratios 
of R123 accumulation in the cells in the presence of the block copolymer to R123 
accumulation in the assay buffer. (Adapted from [152]) 
 
 
 
 
 
 
 
 
39 
 
 
the cytoplasm and reach cellular organelles and to some extent the nuclei. Another 
factor of low sensitization effect of very lipophilic block copolymers is due to their low 
CMC. They tend to form micelles at low concentrations of the copolymers in aqueous 
solutions and decrease the inhibition effect of Pluronic® molecules on ABC transporters 
of MDR cells. Overall, the most efficacious block copolymers are those with intermediate 
lengths of PPO block and relatively hydrophobic structure (HLB <20), such as Pluronic® 
P85 or Pluronic® L61.  
 
1.3.2.2 Inhibition of ABC transporter activity by Pluronic® block copolymers: role 
of Pluronic-membrane interaction 
ABC transporters are one of the distinctive characteristics of MDR tumors as 
discussed before. The Pluronic® copolymer-cell interaction starts from the cell 
membrane, where the ABC transporters are located. Pluronic® block copolymers binding 
to cell membrane is associated with two steps: 1) hydrophilic interactions of PEO chain 
blocks with the polar groups of the lipids at the membrane surface (absorption at the 
membrane) and the hydrophobic interactions of PPO chain blocks with the fatty acid 
residues in the lipid bilayer (insertion in the membrane) [9]. Relatively hydrophilic 
Pluronic® block copolymers could only absorb on the membrane without penetrating into 
the lipid bilayer while relatively hydrophobic copolymers could insert into the membrane 
below the polar head groups, loosen the lipid packaging and translocate through the 
membrane. The immersed Pluronic® block copolymers disrupt the plasma membrane 
integrity, which results in decreased membrane microviscosity, accompanied with 
conformational changes in the transport proteins and inhibition of P-gp or MRP ATPase 
activity in the cells overexpressing these transporters [158, 159]. Moreover, ATPase 
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activity inhibition by Pluronic® block copolymer may be attributed to sterically hindered 
protein-drug interaction in the appropriate binding sites, supported by the observation of 
the decreases in the maximal reaction rates and increases in apparent Michaelis 
constants for these transporters in the presence of Pluronic® P85 [159].  
Pluronic® P85 was found to have more pronounced inhibition effects on P-gp 
ATPase activity compared with the effects on MRP1 and MRP2 [159]. One reason could 
be the structure of MRPs is more robust and less vulnerable to the conformational 
changes caused by P85 than the structure of P-gp. The other reason is due to the high 
affinity drug-binding sites of MRPs, making less accessible for the hindrance by the 
block copolymer than similar sites of P-gp since Pluronic unimers can selectively localize 
in particular domains of cellular membrane called caveolae /lipid rafts and employ 
caveolae-mediated endocytosis pathway for cellular entry [88], where P-gp is believed to 
localize and properties of rafts are essential for the transporter’s proper function while 
MRP may have different localization [119]. 
Inhibition of drug efflux transporters and enhancement of the drug accumulation 
in MDR tumors in the presence of Pluronic® block copolymers was demonstrated in vitro 
and in vivo [110, 112]. Moreover, Pluronic® block copolymers attributed to overcome the 
BBB and achieved the brain delivery of a wide range of therapeutic agents in vitro and in 
vivo [ 160 , 161 , 162 ]. Pluronic® P85 block copolymer increases apical to basolateral 
transport of a broad spectrum of drugs in the polarized monolayers of BBMECs as in 
vitro models of the blood brain barrier. The coadministration of 1% P85 with radiolabeled 
digoxin, a P-gp substrate, in wild-type mice increased the brain penetration of digoxin 3-
fold and the digoxin level in the P85-treated wild-type mice was similar to that observed 
in the P-glycoprotein-deficient animals, indicating Pluronic® P85 can enhance the 
delivery of digoxin to the brain through the inhibition of the P-gp-mediated efflux 
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mechanism. Modification of a BBB-impermeable polypeptide, horseradish peroxidase, 
with Pluronic® P85 moieties via biodegradable disulfide links enhance the transport of 
this polypeptide across the BBB and accumulation of the polypeptide in the brain in vitro 
and in vivo, providing the potential of the brain delivery of many therapeutic polypeptides 
that severely restricted by the BBB [163].  
 
1.3.2.3 Effect of Pluronic® block copolymers on cancer cells’ metabolism  
One of the factors contributing to sensitization effects on MDR by Pluronic® block 
copolymers is the increased ATP depletion, which is crucial for the supporting of energy 
for ABC transporter activity and other life processes [158]. Pluronic® unimers translocate 
across the plasma membrane via a caveolae-mediated endocytosis pathway [88] and 
rapidly (15min after exposure to the cells) colocalizes with mitochondria [156]. It has 
been proved that Pluronic® P85 first inhibited the cytochrome c oxidase (complex IV) and 
then the NADH-ubiquinone oxidoreductase (complex I) of the mitochondria respiratory 
chain at relatively low doses (0.001% and 0.01% for complexes IV and I, respectively), 
decreased oxygen consumption and caused ATP depletion in MDR cells, while non-
MDR cells require significantly higher doses of Pluronic® copolymers to achieve similar 
functions [156]. Moreover, i.v. injections of DOX formulated with 0.2% Pluronic P85 in 
tumor bearing mice caused significant reduction in ATP levels in P388/ADR tumors, 
while P388 tumors are not affected. Similar effects were observed with P85 alone 
although Dox/P85 is considerably more effective in ATP depletion. The selectivity of 
Pluronic® copolymers to MDR phenotype may attribute to innate metabolic and 
physiological differences between MDR and non-MDR cells. Notably, MDR cells are 
associated with a drastic change in cellular metabolism by using a different major fuel 
42 
 
 
source in energy production. Specifically, the MDR cells predominantly utilize fatty acid 
as a source of electrons entering the respiration chain while the non-MDR cells 
predominantly employ glucose metabolism for this purpose. Since the PPO blocks of 
Pluronic® molecules may interact with fatty acids even at low (unimers) concentrations 
and effectively immobilize fatty molecules inside micelle cores at higher concentrations, 
it may affect the respiration mechanism at higher extent in MDR cells. Furthermore, 
MDR cells also have lower mitochondria membrane potential and more uncoupled 
respiration due to the mitochondria membrane leakage and higher level of mitochondrial 
uncoupling protein 2, resulting in inefficient ATP synthesis and thus making the  
mitochondria of MDR cells even more vulnerable to the depolarization effects compared 
with that of the sensitive cells [164]. It was observed at about an orders of magnitude 
lower concentration of P85 necessary for 50% decrease of mitochondria membrane 
potential in the MCF7/ADR cells compared to MCF7 cells [156]. 
 Interestingly, higher responsiveness of the respiratory chain to Pluronic 
copolymers appears to be at least partially associated with P-gp expression, since 
increased inhibition of oxygen consumption was observe not only in drug selected MDR 
cells, but also in MDCKII/MDR1 P-gp-transfected cells [155, 156]. P-gp plays multiple 
roles in cells, such as inducing alteration in the membrane lipid composition [165], 
increasing the synthesis of glycolipid, globotriaosylceramide [166] and pumping the 
substrates inside mitochondria [167], leading to drastic effect on membrane structure, 
cell signaling and mitochondrial activities and thus contributing to the increased 
responsiveness of molecular “targets” of Pluronic copolymers.   
 
1.3.2.4 Effect of Pluronic® block copolymers on proapoptotic signaling  
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Oxidative stress is a condition of excessive ROS formation or a diminished ability 
of cells to scavenge ROS by antioxidant networks. The formed peroxides and free 
radicals will damage various cellular components including proteins, lipids and DNA that 
can culminate in cell death [168]. GSH, the ubiquitous tripeptide, is the major cellular 
antioxidant that protects the cells against ROS, toxins and drugs. GSH has a sulfhydryl 
(SH) group on the cysteinyl portion, which accounts for its strong electron-donating 
character. As electrons are lost, the molecule becomes oxidized, and two such 
molecules become linked (dimerized) by a disulfide bridge to form glutathione disulfide 
or oxidized glutathione (GSSG). In healthy cells, more than 90% of the 
total glutathione pool is in the reduced form (GSH). When cells are exposed to increased 
levels of oxidative stress, GSSG accumulates and the ratio of GSSG to GSH increases 
[ 169 ]. An increased ratio of GSSG-to-GSH is an indication of oxidative stress.  
Additionally, GST, the major cellular detoxifying enzyme performs a range of functional 
roles using GSH as a cosubstrate or coenzyme. Researches indicated that MDR is 
associated with elevated GSH level and GST catalytic activity [170, 171]. Batrakova EV 
et al demonstrated Pluronic® P85 inhibited GSH/GST detoxification system by depleting 
levels of GSH and inactivating GST in MDR cancer cells [154]. Moreover, as discussed 
above, Pluronic® block copolymers quickly reach mitochondrial and inhibit complex I and 
IV of mitochondria electron transfer chain in MDR cells, stimulating the production of 
ROS in the resistant, but not in the sensitive cells, where it remained at the basal level 
[156].  
Pluronic® P85 was observed to localize in mitochondria after 15min of the cell 
exposure by incorporation of P85 into mitochondria membranes followed by alteration of 
the membrane structure, permeabilization of outer mitochondrial membrane, decrease of 
mitochondria membrane potential and release of cytochrome c, which are the early signs 
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of mitochondrial apoptotic pathway [156]. In cytoplasm, cytochrome c binds to apoptosis 
protease activating factor (APAR-1) and forms apoptosome, which cleaves and activates 
the procaspase-9 and forms caspase 9. The activated caspase 9 further activates the 
effector caspases, such as caspase 3, which all together contribute to the completion of 
apoptosis. Indeed, Formulation of DOX with P85 increased the expression levels of the 
proapoptotic genes (BAX, P53, APAF1, Caspase 9 and Caspase 3) 
while simultaneously downregulating the intracellular levels of antiapoptotic genes 
(BCL2 and BCLXL) compared to free DOX in MDR cells [Error! Bookmark not 
defined.]. Furthermore, the effect of DOX/P85 formulations on apoptosis was evaluated 
in vivo. Data indicated that i.v. injection of DOX/P85 into drug-resistant tumor (3LL-M27) 
-bearing mice formulations increased the level pro-apoptotic signals of caspase 8 and 
caspase 9, promoting tumor apoptosis compared to injection of DOX alone [110].  
 
1.3.2.5 Pluronic® block copolymers prevent development of MDR  
In addition to the chemosensitization effects listed above, Pluronic® block 
copolymers have been proved to prevent the development of MDR upon selection with 
cytotoxic drugs in vitro and in vivo [172, 173]. Specifically, the human breast carcinoma 
MCF7 cell line was cultured in increasing concentration of either DOX alone or DOX 
formulated with 0.001% P85 (below the CMC) in the medium. After 305 days of 
escalating the drug exposure, the cells cultured in the presence of Pluronic® P85 were 
unable to stably grow in concentrations of Dox that exceeded 10ng Dox/ml of culture 
media. However, MCF7 cells cultured in the absence of the block copolymer resulted in 
the selection and stable growth of cells that tolerated 1000 times higher concentration of 
the drug (10,000ng Dox/ml culture media) (Fig.1.5A). Detailed characterization of the 
isolated sublines demonstrated that those cells selected in the DOX-P85 formulation did 
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not show amplification of the MDR1 gene while cells selected with Dox alone showed an 
elevated level in the expression of the MDR1 gene along with a corresponding increase 
in the expression level of the drug efflux transporter, P-gp, contributing to the high 
resistance of the cells to Dox (Fig.1.5B). Moreover, it was demonstrated that selection of 
cells with DOX and DOX-P85 formulation resulted in very different changes in the gene 
expression pattern in the cells, which may potentially enhance therapeutic outcomes of 
DOX-P85 formulation [172]. Similar results were observed in murine lymphocytic 
leukemia cells (P388) when selected for DOX resistance with or without P85. Cells 
selected with DOX-P85 formulation in vitro and in vivo exhibited some increases in 
IC(50) values compared to parental cells, but these values were much less than IC50 in 
respective cells selected with DOX alone. In addition to MDR1, P85 abolished alterations 
of genes implicated in apoptosis, drug metabolism, stress response, molecular transport 
and tumorigenesis [173]. Overall, if resistance is intrinsic, Pluronic sensitizes the tumor, 
whereas if resistance is acquired, MDR cells no longer have a selective advantage as 
Pluronic prevents development of MDR.  
 
1.3.2.6 Pluronic® block copolymers suppress cancer stem cells (CSCs) 
Tumors are complex heterogeneous tissues comprising phenotypically and functionally 
different cancer cells. One theory suggests that the heterogeneity of tumor cells arises 
as a result of differentiation of small cell subpopulation within the tumor, called tumor-
initiating cells or CSCs, with indefinite potential for self-renewal that drive tumorigenesis 
[174]. CSCs are intrinsically drug resistant to chemotherapeutics by overexpressing drug 
efflux transporters such as P-gp and BCRP, having extensive survival and anti-oxidant 
networks and having most of their time in the G0 nondividing cell cycle state [175]. 
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Fig.1.5 (A) Time course of the development of drug resistance in MCF7 cell lines 
cultured with Dox either alone (filled diamonds) or in combination with 0.001% P85 
(open diamonds). [Dox] is the concentration of Dox in the growth medium. (B) Western 
blot data for expression of P-gp in MCF7 parental cells, and selected MCF7/ADR cells 
tolerating: 10ng/ml Dox; 200ng/ml Dox; 1000ng/ml Dox; 5000ng/ml Dox; 10,000ng/ml 
Dox; and 10ng/ml Dox with 0.001% P85. The cells were harvested at different points of 
selection as presented in (a) arrows 1-7. (Adapted from [172]) 
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Since CSCs share certain characteristics of MDR cells such as overexpressing drug 
efflux transporters and altered metabolic pathways, Pluronics have been applied to 
sensitize CSCs to chemotherapeutic drugs. A recent study demonstrated that SP1049C 
treatment reduced tumor aggressiveness, in vivo tumor formation frequency in mice 
bearing the leukemia ascetic cells and in vitro clonogenic potential of the leukemia cells 
derived from the treated animals compared to drug, saline and polymer controls. 
SP1049C also prevented overexpression of BCRP and activation of Wnt-β-catenin 
signaling observed with DOX alone significantly altered the DNA methylation profiles of 
the cells and decreased CD133+ P388 cells populations, which displayed CSC-like 
properties and were more tumorigenic compared to CD133− cells [148].   
 Overall, capacities of forming micelles and encapsulating water-insoluble 
anticancer drugs, MDR sensitization by multiple mechanisms, prevention of MDR 
development, depletion of tumorigenic cell subpopulations, and decrease of 
tumorigenicity and tumor aggressiveness offer significant advantages for the 
development of Pluronics formations of approved and/or experimental therapeutics. 
  
1.4 Other applications of Pluronic® block copolymers in cancer treatment  
Doxil®, the first nanoformulated drug approved by the US FDA, was designed to 
reduce cardiotoxicity of DOX by encapsulating it in PEGylated (stealth) liposome. 
However, the therapeutic effectiveness of Doxil® is limited by its penetration to the tumor 
and poor release of the active drug from the liposome at the tumor site. In clinical 
studies, Doxil® produced less cardiotoxicity but did not show significant improvement of 
progression-free survival compared with free DOX for breast cancer patients [176]. 
Thus, combination of Doxil® therapy with the regimens that enhance permeability of 
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tumor vasculature is necessary to improve the therapeutic effect. Pluronic® P85 was 
proved to increase the process of solute diffusion across planar lipid and liposomal 
membranes without affecting the overall integrity of the membranes [177].   Zhao Y et al 
demonstrated enhancement of drug release from the liposomes and increase of 
therapeutic efficacy of Doxil® by administering Pluronic® P85 once the liposomal drug 
accumulates in the tumor sites [178]. Specifically, DOX was observed to rapidly entered 
cells (15min) and then accumulated in the nucleus (60min) while  little if any drug was 
seen in the intracellular vesicles and nucleus even after 24h exposures of the cells to the 
highest dose of Doxil® (200 µg/mL).  Anti-tumor growth and distribution of drug were 
evaluated when Pluronic P85 was i.v. injected 1h, 48h, or 96h after the 
Doxil® administration in A2780 human ovarian cancer xenografts. The greatest anti-
tumor effect of single injection of Doxil® was achieved when Pluronic P85 was 
administered 48h after Doxil®, when the liposomal drug was already distributed to the 
tumor sites .The Confocal tile scanning images of tumor section showed that copolymer 
treatment induced the release of the drug in the tumors from the vessels regions to the 
bulk of the tumor. Therefore, systemic application of the Pluronic® block copolymers may 
be a useful adjuvant to the Doxil® -based chemotherapy regimens.  
Another application could be intraceullar delivery of the unimers of Pluronic® P85 
to MDR cells by mixed micellar system based mainly on the pH-sensitive copolymer of 
poly(L-histidine)-poly (D,L-lactide)-polyethyleneglycol-poly (D,L-lactide)-poly (L-histidine) 
(PHis-PLA-PEG-PLA-PHis) and Pluronic® F127, which overcomes the poor micellar 
stability of plain puronics micelles [ 179 ]. The micelles with inserted Pluronic® P85 
unimers demonstrated more efficient intracellular delivery of Pluronic® P85 unimers to 
the cytosol of the MDR cells than the triple-component mixed micelles and plain 
Pluronic® micelles, which was confirmed by the subcellular colocalization of Pluronic® 
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P85 unimers with mitochondria and led to enhanced MDR reversal effect. In addition, the 
potential of such system has been confirmed by the higher antitumor efficiency against 
MCF-7/ADR tumors and lower cellular ATP levels in the isolated tumors. The idea of 
incorporation of Pluronic®P85 unimers and drug together into the mixed micelles may 
contribute to more efficient MDR reversal by Pluronic® block copolymers. 
Besides acting as chemosensitzer for MDR cells, Pluronic® block copolymers 
were also shown to improve the outcome of the radiofrequency ablation induced 
hyperthermia in solid and tumors and sensitize cancer cells to hyperthermia in vitro and 
in vivo [180]. Consistent with the structure-functional relationships as chemosensitzer for 
MDR cells, the thermosensitzing activity of Pluronic® block copolymers was associated 
with copolymer structure properties including molecular weight, HLB values and PO 
length. Pluronics with lower molecular weight between 1100 to 3200 Da and a HLB <8 
demonstrated the highest thermossensitizing ability with Pluronics L31, L61, L62, L10 
and L64 among the most effective copolymers for hyperthermia sensitization under 
tested conditions. Most encouraging, L61 in synergy with hyperthermia significantly 
reduced tumor growth progression in vivo compared to tumors treated with hyperthermia 
alone [ 181 ]. The thermosensitization ability of Pluronic® block copolymers may be 
directly linked to its ability to interact with plasma membrane and induce membrane 
fluidization as cells become more sensitive to treatment when hyperthermia induced 
increase of membrane fluidity [ 182 ]. Another factor contributing to the 
thermosensitization effect is that the combination of low-grade hyperthermia 
and Pluronic treatment induced depletion of ATP levels and decreased expression of 
heat shock protein 70 (HSP 70), the chaperone molecules that assist in protein folding in 
the active confirmation and are expressed rapidly as a result of cellular stresses such as 
hyperthermia to increase the thermoresistance of the tumors [183].  
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Pluronic® block copolymers also demonstrated exciting opportunities for 
development of novel gene therapies [184]. It was discovered SP1017 (0.25% Pluronic 
L61 and 2% Pluronic F127) significantly increases intramuscular expression of plasmid 
DNA by 5- to 20- fold compared to naked DNA [185]. Pluronic® P85 enhanced levels of 
expression of a reporter gene (luciferase) by 17 to 19-fold in immunocompetent C57Bl/6 
and Balb/c mice by activating the p53 and NFκB signaling pathways. High levels of 
expression of a reporter gene (luciferase) were sustained for at least 40 days and the 
area under the gene expression curve increased by at least 10 times compared to the 
DNA alone in mice. In addition Pluronic increased the number of DNA copies and thus 
affected initial stages of gene transfer in a promoter selective manner [ 186 ]. 
Pluronic® P85 was also shown to enhance gene transfection in HepG2 cells under 
ultrasound irradiation in vitro. The transfection efficacy in ulstrasound+P85 group was 
three times higher than in single ultrasound group [ 187 ]. Thus, Pluronic® block 
copolymers could be a good candidate applicable in multiple gene therapy protocols 
involving intramuscular injection of plasmid DNA by 1) enhancing the gene transfer and 
2) activating the transcription of the genes.   
 
1.5 Statement of purpose 
MM is the second most common hematologic malignancy characterized by 
infiltration in the bone marrow (BM) of malignant plasma cells with production of 
monoclonal proteins. In the last decade, the introduction of immunomodulatory drugs 
(IMIDs), and of new front-line agents such as the proteasome inhibitors (Bortezomib, 
BTZ or Carfilzomib, CFZ) have significantly improved overall survival [188]. In spite of 
current efficient therapeutic regimens for MM patients, like almost all anti-cancer 
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drugs, drug resistance becomes a major concern and almost all patients eventually 
relapse or become refractory to current treatment regimens [189, 190]. For instance, 
BTZ (PS-341, Velcade), the first proteasome inhibitor approved by U.S. FDA, used as a 
first-in-class drug in MM by reversibly inhibiting the chymotrypsin-like activity at the β5-
subunit and to a lesser extent inhibit the trypsin-like activity at the β1-subunit. However, 
many patients may be intrinsically resistant to it or develop resistance in the course of 
treatment [191]. Although real mechanisms of resistance to BTZ in MM patients are not 
yet deciphered, mutation in β5-subunit of proteasome (PSMB5) which impair BTZ 
binding, alterations of gene and protein expression in stress response, cell survival and 
antiapoptotic pathways and MDR have been indicated to be involved [192]. The BM 
microenvironment supported by fibroblast-like BM stromal cells, osteoblasts, and 
osteoclasts which secrete soluble factors and extracellular matrix proteins can facilitate 
the survival, differentiation, and proliferation of MM cells and offer protection from 
chemotherapeutic agents, thereby increases the probability for the development of 
drug resistance [193, 194]. According to the chemosensitization effect on MDR cells by 
Pluronic® block copolymers discussed above, we propose to use the combination of 
proteasome inhibitors together with mixture of Pluronics (SP1017) for MM treatment to 
increase the drug sensitivity of cancer cells. Moreover, almost all of the previous studies 
on sensitizing effect indicated that Pluronic® block copolymers only sensitize MDR cells 
but have little effects on sensitive cells [155, 156]. Here our study mainly focuses on the 
effect of Pluronic® block copolymers on sensitive MM cells and the related targets of the 
sensitization effect. 
Our hypothesis of this research is that SP1017 will sensitize multiple myeloma in 
vitro and in vivo by targeting multiple molecular mechanisms. To test this hypothesis, the 
following specific aims will be addressed.  
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Specific aim 1: To determine the chemosensitization effect of SP1017 on both sensitive 
and drug-resistant MM cell lines combined with proteasome inhibitors.  
 
Specific aim 2: To investigate the related molecular mechanisms of the sensitization 
effect of SP1017 combined with proteasome inhibitors. 
 
Specific aim 3: To evaluate the treatment efficacy of the combination of SP1017 with 
proteasome inhibitor BTZ in human MM/SCID mice model. 
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CHAPTER II: SP1017 SENSITIZE BOTH SENSITIZE AND RESISTANT MM CELLS 
BUT NOT NORMAL HEMATOLOGICAL CELLS OR NON-HEMATOLOGICAL 
CANCER CELLS   
 
2.1 Introduction 
MM is a complex and heterogeneous neoplastic disorder due to the 
proliferation of clonal plasma cells in BM with production of monoclonal protein, which 
is associated with a spectrum of clinical symptoms including bone destruction, anemia, 
hypercalcemia, and renal failure [1]. It has a prevalence of 70,000 patients in the 
United States, occurring in approximately 20,000 new individuals each year [2], with 
the median overall survival of patients estimated at 5 to 7 years [3] and with median 
age at diagnosis being 66 years [4]. In the last decade, the introduction of IMIDs, and 
of new front-line agents such as the proteasome inhibitors have significantly improved 
overall survival [5]. Among the proteasome inhibitors, BTZ, a reversible inhibitor with 
the boronic acid group binding and forming a complex with the active site of threonine 
hydroxyl group in the β5-subunit, is the first proteasome inhibitor approved by 
U.S.FDA for treatment of relapsed/refractory MM in 2003 [6, 7]. However, not all 
patients respond to BTZ -based therapies and relapse occurs in many patients who 
initially responded. Only about 30 – 40% of mantle cell lymphoma patients and 35% 
multiple myeloma patients are sensitive to BTZ, indicating that more than half of 
patients possess intrinsic resistance to proteasome inhibition, which is a critical 
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limitation of BTZ therapy [8, 9,10]. Several clinical studies showed that the median 
duration of response to BTZ treatment ranged from half a year to a year, supporting 
the theory that in most of cases of continuous BTZ treatment, MM eventually acquired 
BTZ resistance within a year [11]. Although real mechanisms of acquired resistance to 
BTZ in MM patients are not yet deciphered, mutation in PSMB5 which impair BTZ 
binding, alterations of gene and protein expression in stress response, cell survival 
and antiapoptotic pathways and MDR have been indicated to be involved [12].  
Moreover, BTZ treatment is often limited by BTZ-induced, dose-limiting side effects, 
mostly consequent to peripheral neuropathy [13 ]. CFZ, the second generation 
epoxyketone-based irreversible proteasome inhibitor, was approved by U.S. FDA in 
2012 for patients with MM who had relapsed and were refractory to BTZ and at least 
one thalidomide derivative, associated with less peripheral neuropathy compared to 
BTZ [14]. CFZ However, acquired CFZ-resistance has been observed by increased 
resistance to CFZ in sensitive MM cells following drug selection, which was 
associated with up-regulation of P-glycoprotein, suggesting that drug transport may 
contribute to resistance [15]. Due to the development of drug resistance, MM remains 
an incurable disease and almost all patients eventually relapse or become refractory 
to current treatment regimens [16,17]. So the current challenge of MM treatments is to 
maintain treatment response (or even improve it), to prevent relapse and eventually to 
prolong survival [18]. In the clinical, BTZ is combined with several other classes of 
drugs used in the treatment of MM, including alkylating agents, anthracyclines and 
immunomodulatory drugs to achieve synergistic anti-myeloma activity by targeting 
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different apoptotic pathways and/or alleviate side effects [14, 19] .  
Previous studies demonstrated that Pluronic® block copolymer 
(PEO-PPO-PEO) sensitize MDR cancer cells resulting in increased cytotoxic activity 
of Dox, paclitaxel, and other drugs by 2-3 orders of magnitude [20, 21]. Improved 
treatment of drug resistant and metastatic cancers with Dox/Pluronic formulations was 
also reported using several in vivo tumor models [22,23].SP1049C, a solution of Dox 
with a mixture of SP1017 (0.25% Pluronic L61 and 2% Pluronic F127) in isotonic 
buffered saline, has completed Phase II clinical trial and demonstrated safety and 
efficacy in patients with advanced adenocarcinoma of the esophagus and 
gastroesophageal junction [24]. Relatively hydrophobic Pluronics at concentrations 
below the CMC with intermediate length of PEO units from 30 to 60 and HLB <20 [25, 
26] can sensitize MDR cancer cells mainly by Pgp inhibition and selective ATP 
depletion, which is accompanied with generation of ROS and simultaneously 
inhibition of GSH/GST detoxification [ 27 , 28 , 29 ]. On the other hand, the 
Pluronic-caused impairment of respiration in mitochondria decreased the 
mitochondrial membrane potential, promoted release of cytochrome c and overall 
enhanced pro-apoptotic signaling (Bax, p53, APAF1, caspase 9 and caspase 3) and 
mitigated anti-apoptotic cellular defense (Bcl-2 and Bcl-xl) of MDR cells [30].  
  Based on the promising previous results of Pluronic® block copolymers in 
MDR cells, we explored the synergistic effect of SP1017 and proteasome inhibitors on 
both BTZ/CFZ-resistant MM cell lines which are selected by drug exposure for a 
period of time. In addition, previous studies indicated that Pluronic® block copolymers 
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did not have a pronounced sensitization effect in sensitive cells compared to resistant 
cells or non-MDR cells require significantly higher doses of Pluronic® copolymers to 
achieve similar functions [27, 29]. So here our studies also examined the effect of 
SP1017 at the inert concentration on different sensitive MM cells to explore the way 
SP1017 works on non-MDR cells. Furthermore, we examined the cytotoxicity of the 
combination of BTZ with SP1017 in normal hematological cells (PBMC) to ensure the 
safety and in several non-hematological cancer cells to explore its specificity.  
 
2.2 Materials and Methods 
2.2.1 Cell culture 
RPMI 8226 human MM cell line and ARH-77 human MM cell line were 
generous gifts from Dr. Sagar Lonial (Emory University, Atlanta, GA, USA). U266 
human MM cell line and NCI-H929 human MM cell line were generous gifts from Dr. 
Adriana Zingone (Multiple Myeloma Section/Metabolism Branch, NCI/NIH, Bethesda, 
MD, USA). BTZ/CFZ-resistant RPMI 8226 MM cell lines were selected and 
established by exposure to sensitive RPMI 8226 MM cells of gradually increasing 
concentrations of BTZ /CFZ  starting at 0.2nM. Consequently, the BTZ/CFZ-resistant 
RPMI 8226 cell lines stably growing in the presence of 40nM of BTZ or CFZ within 6 
months. Peripheral Blood Mononuclear Cells (PBMC) were provided by the Elutriation 
Core Facility in the Department of Pharmacology and Experimental Neuroscience 
(UNMC, Omaha, NE, USA). MCF-7 human breast adenocarcinoma cell line, 
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ADR-resistant cancer cell line MCF-7/ADR, HepG2 human liver carcinoma cell line 
and Hela human cervix adenocarcinoma cell line were from our own lab. All MM cell 
lines were grown in Roswell Park Memorial Institute (RPMI)-1640 medium with 100 
I.U/ml penicillin, 100ug/ml streptomycin and 10% of fetal bovine serum (FBS). MCF-7, 
HepG2 and Hela cells were grown in Dulbecco's Modified Eagle Medium (DMEM) 
with 100 I.U/ml penicillin, 100ug/ml streptomycin and 10% of FBS. MCF-7/ADR cells 
was grown in DMEM with 100 I.U/ml penicillin, 100ug/ml streptomycin and 10% of 
FBS in the presence of free DOX at 1 μg/ml.  
2.2.2 Materials 
Bortezomib was purchased from Selleck Chemicals (Houston, TX, USA). 
Carfizomib was purchased from Chemie Tek (Indianapolis, IN, USA). SP1017 was 
kindly provided by Supratek Pharma. Inc (Montreal, Canada).  Cell counting kit-8 
(CCK-8) was purchased from Dojindo Molecular Technologies (Kumamoto, Japan). 
MTT reagent (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was 
purchased from Research Products International (Prospect, IL). Annexin V-FITC/ 
propidium iodide (PI) Apoptosis Kit was purchased from Biovision (Milpitas, CA, USA). 
Rhodamine 123 was purchased from Fisher Scientific (Waltham, MA). Verapamil and 
Dulbecco's phosphate buffered saline solution (PBS) was purchased from 
Sigma-Aldrich (St. Louis, MO).  Anti-P-Glycoprotein mouse mAb (C219) was 
purchased from EMD Millipore (Darmstadt, Germany). Cleaved caspase-8 and -9 
rabbit antibodies, anti-rabbit IgG HRP-linked antibody, cell Lysis Buffer (10×) and 
protease inhibitor cocktail (100×) were purchased from cell signaling technology 
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(Danvers, MA, USA). Anti-mouse IgG HRP-linked antibody was purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). FBS, RPMI 1640 medium, DMEM 
medium, penicillin, streptomycin, Trypsin–ethylenediaminetetraacetic acid (EDTA) 
(0.5% trypsin, 5.3 mM EDTA tetra-sodium) were purchased from Invitrogen (Carlsbad, 
CA, USA). 
2.2.3 Cytotoxicity in human MM cell lines by CCK-8 assay 
Cytotoxicity of SP1017 alone was assessed in sensitive RPMI 8226 human 
MM cell line and cytotoxicity of BTZ/ CFZ ± 0.005% SP1017 was assessed in 
sensitive RPMI 8226 human MM cell line, ARH-77 human MM cell line, H929 human 
MM cell line and BTZ/CFZ-resistant RPMI 8226 cell lines by a standard CCK-8 assay. 
Briefly, cells were seeded in a 96-well microtiter plates with 104 of cells per well and 
exposed to various doses of SP1017 alone or BTZ/CFZ± 0.005% SP1017 for 24h at 
37 ℃ in a humidified, 5% CO2 atmosphere. 10ul of CCK-8 was added to each well 
and the cells were incubated for 1-4 h (when the absorption value ranges from 0.2-0.8, 
which shows better linearity) at 37 ℃ in the dark. Absorption was measured at 450nm 
in a microplate reader (SpectraMax M5, Molecular Devices Co., Sunnyvale, CA, USA) 
using wells without cells as blanks. The net absorbance was taken as index of cell 
viability. The reading taken from the wells with cells cultured with control medium was 
used as 100% viability value. The cell viability was calculated as Asample/Acontrol ×100%. 
Each concentration point was determined from samples from eight separate 
wells.  Based on the results of the test, the IC50 values (the concentration which kill 50% 
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of cells) were calculated by using GraphPad Prism Software (Version 5.0, GraphPad 
Software, San Diego, CA, USA).  
2.2.3 Overall apoptosis in human MM cell lines by Annexin V/PI assay 
Cytotoxicity of BTZ ± 0.005% SP1017 was accessed in normal hematologic 
cells (PBMC) by Annexin V/PI assay. Briefly, 2×105 of PBMC and RPMI 8226 MM 
cells were seeded in 24-well plate per well and treated with Media as control, 0.005% 
SP1017, 10nM of BTZ and 10nM of BTZ+ 0.005% SP1017 for 20h. After treatment, 
cells were washed twice with PBS and treated with Annexin V-FITC and PI in 1X 
Binding Buffer according to the manufacturer’s instructions. The labeled cells were 
analyzed using Becton Dickinson FACSCalibur™ flow cytometer in Fluorescence 
Activated Cell Sorting (FACS) cell analysis core facility and FACSDiva software 
(Version 8.0, Becton Dickinson, San Jose, CA).  
2.2.4 Rhodamine 123 (Rh 123) uptake in both sensitive and resistant MM 
cell lines  
Determination of the function of Pgp was assessed by the efflux of Rh123, the 
Pgp substrate. Briefly, 105 of RPMI 8226 human MM cells, ARH 77 human MM cells, 
H929 human MM cell line BTZ/CFZ-resistant RPMI 8226 human MM cells were 
exposed to 3.2 uM Rh123, 3.2uM Rh123+5uM Verapamil (Pgp inhibitor), 3.2uM 
Rh123+0.005%SP1049 for1h, 2h, 4h respectively. After the incubation, the 
suspension cells were centrifuged, washed three times with PBS and solubilized in 
100 ul M-PER® Mammalian Protein Extraction Reagent. After 5-10mins, 70ul of lysed 
cell solutions were taken for determination of the cellular dye content using 
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fluorescent spectrophotometer with λex=505nm and λem=540nm. The results were 
normalized by protein content determined by BCA assay.  
2.2.5 Western blot 
Determination of Pgp expression levels, cleaved caspase 8 and cleaved 
caspase 9 were assessed by immunoblot technique. Briefly, 1.5×106 of RPMI 8226 
human MM cells, ARH 77 human MM cells, BTZ/CFZ-resistant RPMI 8226 human 
MM cells were lysed with 100ul of Cell Lysis Buffer supplemented with protease 
inhibitor cocktail for Pgp detection. 1.5×106 of RPMI 8226 human MM cells treated 
with different concentrations of SP1017 for 24h were lysed in lysis buffer for caspases 
detection. Supernatant were collected after removing cell debris by centrifugation 
(14000 rpm for 10 min) and protein content was determined by BCA assay. 30μg of 
proteins were resolved by 10% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred onto PVDF membranes. The 
membranes were blocked by incubation in 5% dry milk in TBST (0.1% Tween-20 in 
Tris-buffered saline, TBS) and probed with the relative monoclonal antibodies were 
used at 1:100 dilutions.  The secondary horseradish peroxide anti-mouse Ig antibody 
was used at 1:5000 dilutions. Blots were then visualized by enhanced 
chemiluminescence (ECL) substrates. To correct for loading differences, the levels of 
protein expression were normalized to a constitutively expressed GAPDH. Intensity of 
the bands was quantified by Image J software.  
2.2.6 Cytotoxicity in non-hematological cancer cells by MTT assay 
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Cytotoxicity of BTZ ± 0.005% SP1017 was accessed in different 
non-hematologic tumor cells by MTT assay. Briefly, 104 of MCF-7 human breast 
adenocarcinoma cells, HepG2 human liver carcinoma cells, Hela human cervix 
adenocarcinoma cells per well were seeded in a 96-well microtiter plates, respectively. 
After 24h of attachment, cells were treated with various doses of BTZ ± 0.005% 
SP1017 for 24h at 37 ℃ in a humidified, 5% CO2 atmosphere. Following treatment, 
the medium was removed and the cells were rinsed three times by PBS. 20ul of MTT 
(5mg/ml) was added to each well and the cells were incubated for 2h at 37℃ in the 
dark to form insoluble formazan, which was then solubilized by 100ul of 20% SDS in 
50% Dimethylformamide (DMF), and the absorbance was determined by at 570 nm 
using a microplate reader (SpectraMax M5, Molecular Devices Co., Sunnyvale, CA, 
USA) using wells without cells as blanks. The net absorbance was taken as index of 
cell viability. The reading taken from the wells with cells cultured with control medium 
was used as 100% viability value. The cell viability was calculated as Asample/Acontrol 
×100%.  Each concentration point was determined from samples from eight separate 
wells.  Based on the results of the test, IC50 values were calculated by using 
GraphPad Prism 5 Software (GraphPad Software, San Diego, CA).  
2.2.7 Cytotoxicity in normal hematological cells by Annexin V/PI assay 
Cytotoxicity of BTZ ± 0.005% SP1017 was accessed in normal hematologic 
cells (PBMC) by Annexin V/PI assay. Briefly, 2×105 of PBMC and RPMI 8226 MM 
cells were seeded in 24-well plate per well and treated with Media as control, 0.005% 
SP1017, 10nM of BTZ and 10nM of BTZ+ 0.005% SP1017 for 20h. After treatment, 
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cells were washed twice with PBS and treated with Annexin V-FITC and PI in 1X 
Binding Buffer according to the manufacturer’s instructions. The labeled cells were 
analyzed using Becton Dickinson FACSCalibur™ flow cytometer and FACSDiva 
software (Version 8.0, Becton Dickinson, San Jose, CA). 
2.2.8 Statistical analysis 
Statistical comparisons between two groups for in vitro studies were evaluated 
using Student’s t-test. Two-tailed P values less than 0.05 were considered significant. 
 
2.3 Results and discussion 
SP1017 alone showed dose-dependent cytotoxicity in RPMI 8226 human MM 
cells (Figure 2.1A). 0.005% was the maximum concentration of SP1017 which 
showed no cytotoxicity in RPMI 8226 MM cells after 24h exposure. The 
concentrations above 0.005% of SP1017 induced cell death associated with 
apoptosis-associated caspase 9 and caspase 8 activations (Fig 2.1B). We chose 
0.005% as the concentration of SP1017 (below the CMC of Pluronic® L61) in the 
combination therapy to investigate the sensitization effect of SP1017 on MM when 
combined with proteasome inhibitors. 
The responses to the combination of proteasome inhibitors+SP1017 in 
different MM cell lines (RPMI 8226 human MM cell line, ARH-99 human MM cell line 
and H929 human MM cell line) were evaluated. As seen in Table.2.1, 0.005% SP1017 
triggered 2-fold of increase of cytotoxicity in three different MM cell lines when 
combined with the reversible proteasome inhibitor BTZ or the irreversible proteasome  
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Fig.2.1. (A) Cytotoxicity of SP1017 with different concentrations to RPMI 8226 MM 
cells after 24h treatment. Data presented as mean ± SD. N=3.  (B) Increased 
expression of cleaved caspase 9 and caspase 8 in RPMI 8226 MM cells after 24h 
treatment of different concentrations of SP1017.  
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Table 2.1 (A) IC50 of BTZ ± Pluronics in different human MM cell lines. 
IC50±SD  
(nM) 
BTZ BTZ+ 
0.005%SP1017 
BTZ+ 
0.0006%L61 
BTZ+ 
0.0044%F127 
BTZ+ 
0.002% SP1017 
RPMI 8226 14.6 ± 3.0a 8.1 ± 1.6 a *** 9.7 ± 1.5 b ** 15.7 ± 2.2 b 10.5 ± 0.5 b * 
ARH-77 17.1 ± 1.7 9.7 ± 2.3* 
H929 4.3 ± 0.6 2.4 ± 0.2** 
 
 Table 2.1 (B) IC50 of CFZ ± Pluronics in different human MM cell lines. 
IC50±SD  
(nM) 
CFZ CFZ+ 
0.005%SP1017 
CFZ+ 
0.0006% L61 
CFZ+ 
0.0044%F127 
CFZ+ 
0.002% SP1017 
RPMI 8226 13.9 ± 2.4c 6.3 ± 1.2c *** 6.3 ± 1.0** 12.2 ± 2.0 8.0 ± 1.6** 
ARH-77 11.7 ± 0.8 5.7 ± 1.0** 5.1 ± 2.3** 9.3 ± 2.0 
H929 16.5 ± 2.4 6.1 ± 1.0** 
Cells were treated for 24h. Data presented as mean ± SD. N=3 
aN=10; bN=4; cN=5; *p<0.05,**p<0.01,***p<0.001;compared to drug alone. 
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inhibitor CFZ after 24h treatment. Lower concentration of SP1017 (0.002%) showed 
lower, but still significant increased cytotoxicity when combined with proteasome 
inhibitors compared to drugs alone. To confirm whether the decrease of MM cell 
viability in response to BTZ + SP1017 combination was due to apoptosis, we 
performed Annexin V/ PI assay by flow cytometry. BTZ+SP1017 combination showed 
much more early and late apoptosis compared with BTZ alone in both time- and 
dose-dependent manner (Fig.2.2), which further confirming the 
chemosensitizationeffect of SP1017 on MM cells when combined with proteasome 
inhibitors. Pluronic® L61 (HLB=3; PPO units=30; CMC=0.02%), which is more 
hydrophobic than Pluronic® F127 (HLB=22, PPO units=65; CMC=0.0035%) [31], 
played the major role in the chemosensitization effect (Table 2.1). This could be 
explained by previous studies which demonstrated the hydrophobic PPO chains with 
intermediate length of PEO units from 30 to 60 and HLB <20 [25, 26] of Pluronic® 
unimers immerse into the membrane hydrophobic areas, resulting in alterations of the 
membrane structure, and triggering subsequent biological effects [32]. Different drug 
treatment schedules were investigated by treating RPMI 8226 MM cells with 
BTZ+SP1017 concomitantly or sequentially. Maximal anti-MM activity was noted 
when SP1017 and BTZ were given concomitantly than in other order drug treatment 
schedules (Table2.2).  
Acquired BTZ and CFZ resistance have been observed in MM cells as well as 
clinical patients, which makes proteasome inhibitors unappealing for long-term 
administration and limit the efficacy to be used as anti-MM drugs [33]. According to 
current researches, BTZ-resistance is mainly due to the impaired BTZ binding to 
mutant β5 subunits or the overexpression of β5 subunits while CFZ-resistance is 
associated with overexpression of Pgp protein [15,34]. Our lab developed the 
BTZ/CFZ resistant RPMI 8226 cell lines by the stepwise increase of BTZ/CFZ  
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A 
 
B 
 
Fig.2.2 Percentage of overall cell apoptosis (early and late apoptosis) of RPMI 8226 
MM cells treated with BTZ± 0.005% SP1017 for (A) 8h and (B) 24h by flow cytometric 
analysis using annexin V and PI staining.  Data presented as mean ± SD. N=3 
(*p<0.05, **p<0.01, ***p<0.001).  
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Table.2.2. IC50 of BTZ ± Pluronics in RPMI 8226 human MM cell line with different 
treatment schedules  
IC50±SD 
(nM) 
[BFZ] 24h 
[BTZ+0.005%SP101
7] 24h 
[0.005% SP1017] 
24h+[BTZ]24h 
RPMI 8226 14.6 ± 3.0a 8.1 ± 1.63 a *** 
12.43 ± 1.33 
 
Data presented as mean ± SD. N=3 (a N=10; ***p<0.001, compared to [BTZ] 24h).  
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concentration to the final concentration to 40nM by 6 months [35]. BTZ-resistant 
(9-fold) RPMI 8226 cells gained a marked but less pronounced cross-resistance to 
CFZ (5-fold) and CFZ-resistant (23-fold) RPMI 8226 cells also exhibited less 
cross-resistant to BTZ (6-fold).  The results was in consist with previous findings that 
THP1 myeloid sublines with acquired resistance to BTZ (54- to 235-fold) caused by 
mutations in the PSMB5 gene displayed less pronounced cross-resistance to CFZ (9- 
to 32-fold) while MDR lymphoid CEM/VLB cells with Pgp overexpression exhibited 
substantial resistance to carfilzomib (114-fold) whereas less resistance to BTZ 
(4.5-fold) was observed [36]. Around 2.8-fold of sensitizing effect of SP1017 could be 
observed in BTZ-resistant cell lines when combined with BTZ or CFZ, which was 
comparable to that on sensitive cells. However, interestingly, we observed the 
significant increase of sensitizing factor (6.61±1.07) of SP1017 in CFZ resistant cell 
line when combined with CFZ rather than BTZ (Table.2.3). The reason of higher 
sensitizing factor of SP1017 in CFZ- resistant cell line could be explained by the Pgp 
expression in CFZ-resistant cell line rather than sensitive or BTZ-resistant MM cell 
lines, which is confirmed by western blot (Fig.2.3) and functional analysis, Rh123 
accumulation (Fig.2.4) as Pluronics inhibiting Pgp drug efflux system of MDR 
phenotype has been already proved [37, 38]. We found Pgp expression in selected 
BTZ-resistant RPMI 8226 MM cells rather than sensitive RPMI 8226 MM cells, H929 
MM cells, ARH-77 MM cells or BTZ-resistant RPMI 8226 MM cells (Fig.2.4), though 
the expression was lower than that of the positive control, MCF-7/ADR cells. 
Moreover, the uptake of Rh123, the Pgp substrate in sensitive RPMI 8226 MM cells,  
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Table.2.3. IC50 of BTZ/CFZ± 0.005%SP1017 in BTZ/CFZ-resistant RPMI 8226 MM cell 
lines (RPMI 8226/BTZ cell line and RPMI 8226/CFZ cell line) 
Cells were treated for 24h.  Data presented as mean ± SD. N=3 (aN=10,bN=5, 
p<0.01,***p<0.001, compared to relative drug alone). aSensitization factor= [IC50of 
drug] / [IC50 of drug+SP]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IC50±SD  
(nM) 
BTZ BTZ+SP Sensitization 
factora 
CFZ CFZ+SP Sensitization 
factora 
Sensitive 
RPMI 8226  
14.6 ± 3.0a 8.1 ± 1.6 a *** 1.8 ± 0.2 13.9 ± 2.4b 6.3 ± 1.2b *** 2.3 ± 0.2 
RPMI 
8226/BTZ 
127.7 ± 29.2b 50.2 ± 17.1b*** 2.7 ± 0.7 64.2 ± 20.9b 24.7 ± 5.9b** 2.6 ± 0.1 
RPMI 
8226/CFZ 
86.0 ± 9.3 29.1 ± 8.6** 3.0 ± 0.7 324.1 ± 77.1b 49.4 ± 7.3b*** 6.6 ± 1.1 
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Fig 2.3 Pgp expression by western blot of Rh123 accumulation of sensitive MM cell 
lines and BTZ/CFZ-resistant MM cell lines.  
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Fig.2.4 Pgp functional activity of Rh123 accumulation of (A) RPMI 8226 MM cell line, 
(B) ARH-77 MM cell line, (C) BTZ-resistant RPMI 8226 MM cell line and (D) 
CFZ-resistant RPMI 8226 MM cell line. Data presented as mean ± SD. N=3 (*P <0.05, 
**P<0.01, ***p<0.001).  
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ARH-77 MM cells and BTZ-resistant RPMI 8226 MM cells was higher than that in 
CFZ-resistant RPMI 8226 MM cells and was not increased in the presence of SP1017 
or the Pgp inhibitor, verapamil. However, the intracellular Rh123 was much higher in 
CFZ-resistant RPMI 8226 MM cells in the presence of SP1017 or verapamil in a time 
dependent manner, indicating the inhibition of Pgp in CFZ-resistant MM cells 
significantly increase the uptake of Pgp substrate. Therefore, Pgp upregulation plays 
a major role in the development of CFZ resistance in MM exposed to prolonged CFZ 
therapy. Since CFZ received U.S.FDA approval in 2012, the Pluronics have greater 
potential to work in a combination regimen in clinical for treatment of patients with MM 
who were refractory to CFZ.  The sensitization effect of SP1017 in CFZ-resistant MM 
cells when combined with BTZ was comparable to that in BTZ-resistant MM cells. 
Though previous studies indicated that BTZ is a substrate for Pgp and the most 
synergy of BTZ combined with Pgp inhibitor, elacridar was found the cells with highest 
Pgp level [39], BTZ exhibited as a poor Pgp substrate and that Pgp upregulation may 
be not the overwhelming mechanism of BTZ resistance, which was mainly related 
with point mutation or overexpression of PSMB5 gene and alterations of gene and 
protein expression in stress response, cell survival and antiapoptotic pathways[12]. 
For example, Pgp-expressing leukemic cells (CEM/VLB) are markedly resistant to 
CFZ (114-fold increase in IC50) yet only a slight (4.5-fold) increase in IC50 was 
observed for BTZ. Furthermore, the Pgp inhibtor completely reversed carfilzomib 
resistance with little to no effect on BTZ sensitivity [36]. Despite of the 
chemosensitization effects with anticancer drugs, Pluronic® block copolymer was 
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reported to prevent the development of multidrug resistance in the cells exposed to 
drug in the selection as MDR cells selected in the presence of Pluronic® P85 tolerated 
a 1000 times less concentration of the drug compared with that selected in the 
absence of Pluronic® P85 [40]. Thus, the co-administration of SP1017 with anti-MM 
drugs might prevent or delay the emergence of acquired resistance, showed the great 
potential the combination of Pluronic® block copolymers with anticancer drugs. The 
detailed molecular mechanisms of sensitization effect of SP1017 on both BTZ and 
CFZ resistant MM cells need further investigation and elucidation.   
Hematologic toxicity is commonly encountered in patients with MM owing to 
the nature of the disease and the adverse effects related to myeloma treatment. BTZ 
has been proved to be associated with increased rates of anemia, neutropenia, and 
thrombocytopenia, as well as greater incidences of infection caused by associated 
immunosuppression [41]. To ensure the safety of the BTZ+SP1017 combination, the 
cytotoxicity of the combined therapy to normal hematological cells (PBMC) was 
examined by Annexin V/PI assay. Though previous studies indicated that normal 
PBMC cell viability was relatively less affected by proteasome inhibitors as compared 
with that of myeloma cells [42,43], we found 10nM BTZ induced similar toxicity to 
RPMI 8226 MM cells and normal hematological cells after 20h treatment. However, 
the combination was not more toxic than single drug in PBMC while significant 
increase of the overall apoptosis of RPMI 8226 MM cells was induced by BTZ in the 
presence of SP1017 (Fig.2.5). Therefore, SP1017 showed its potential to be used as 
a sensitizer in the combination therapy.  
The ubiquitin-proteasome pathway (UPP) plays a critical role of intracellular 
protein degradation and cellular homeostasis maintenance. More than 80% of cellular 
proteins are degraded through this pathway including those involved in a broad array 
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of processes such as cell cycle, apoptosis, transcription, DNA repair, protein quality 
control and antigen presentation [44]. As the essential role of the proteasome in cell 
function (up-regulation of cell proliferation and down-regulation of cell death in human 
cancer cells), proteasome becomes the drug target for anti-cancer agents. There are 
two types of proteasomes, the constitutive form (20S), expressed in most cell types, 
and the immunoproteasome (i20S), a unique target found in lymphoid-derived cells 
[45].  Both BTZ and CFZ have been validated to target both the constitutive and 
immunoproteasomes indiscriminately in myeloma and other model systems [46]. By 
selectively inhibiting the i20S, it may be possible to maintain anti-myeloma and 
anti-lymphoma efficacy while reducing these toxicities, thereby increasing the 
therapeutic index. Researches also indicated cell lines representing hematologic 
cancers were more sensitive to immunoproteasome-specific inhibitors, which retained 
its preferential i20S activity in cytotoxicity assays, than a panel of solid tumor cell lines 
that were tested [46]. Clinical trials of BTZ also indicated the unsatisfied efficacy in 
treatment of solid tumors such as metastatic breast cancer, metastatic 
neuroendocrine tumors and advanced renal cell carcinoma [7]. For instance, from 
their clinical trials on 12 enrolled metastatic breast cancer patients, no objective 
responses were observed. One patient had stable disease, and 11 others 
experienced disease progression. The median survival time was only 4.3 months 
[47].To ensure the specificity of the BTZ+SP1017 combination to MM, we also 
examined the cytotoxicity of the BTZ+/-SP1017 to other non-hematologic tumor cells, 
such as MCF-7 human breast adenocarcinoma cells, HepG2 
human liver carcinoma cells and Hela human cervix adenocarcinoma cells. BTZ alone 
giving less than encouraging results in non-hematologic tumor cells compared with 
that to RPMI 8226 MM cells and SP1017 did not showed the significant sensitization 
effect on non-hematological tumor cells as what showed in MM cells (Fig.2.6). 
Therefore, the chemosensitization effect of SP1017 was proved to be specific to MM 
cells rather than non-hematologic tumor cells, showing the promising potential of  
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Fig.2.5. PBMC and RPMI 8226 MM cells were exposed to 10nM BTZ ± 0.005% 
SP1017 for 20h and assessed for apoptosis by flow cytometric analysis using annexin 
V and PI staining. Data presented as mean ± SD. N=6. (*p<0.05, **p<0.01, NS=no 
significant difference).  
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Fig.2.6. Cytotoxicity of BTZ± 0.005% SP1017 in (A) RPMI 8226 human MM cell line, (B) 
MCF-7 human breast adenocarcinoma cell line, (C) Hela human cervix 
adenocarcinoma cell line, and (D) HepG2 human liver carcinoma cell line. Cells were 
treated for 24h. Data presented as mean ± SD. N=6. 
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using the combination of BTZ+SP1017 in hematologic malignancies. 
2.4 Conclusions 
SP1017 is the mixed micelles formed by Pluronic® L61 which exhibited the biological 
effects due to its relative hydrophobicity and Pluronic® F127 as a stabilizer due to its 
relative hydrophilicity. 0.005% SP1017 (below the CMC of Pluronic® L61) potentiated 
2-fold of both the reversible proteasome inhibitor (BTZ)- and irreversible proteasome 
inhibitor (CFZ)- induced cell cytotoxicity of three different MM cell lines. The increased 
cytotoxicity in response to BTZ + SP1017 combination was due to apoptosis analyzed 
by annexin V/ PI assay. Lower concentration of SP1017 (0.002%) showed lower, but 
still significant sensitization effect on RPMI 8226 MM cells when combined with 
proteasome inhibitors compared to drugs alone. BTZ-resistant RPMI 8226 cells 
gained a marked but less pronounced cross-resistance to CFZ and CFZ-resistant 
RPMI 8226 cells also exhibited less cross-resistant to BTZ. SP1017 remained the 
comparable sensitization effect in BTZ-resistant RPMI 8226 cells while gained 
significant higher sensitization factor in CFZ-resistant RPMI 8226 cells. The reason of 
higher sensitization effect in CFZ-resistant RPMI 8226 cell line was attributed to the 
Pgp expression in CFZ-resistant MM cells, which indicated that Pgp upregulation 
plays a major role in the development of CFZ resistance in multiple myeloma exposed 
to prolonged CFZ therapy while not contribute to BTZ resistance. Interestingly, 
SP1017 did not sensitize BTZ-induced apoptosis of normal hematological cell 
(PBMC), which indicates the potential of maintaining the anti-MM efficacy of the 
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combination therapy while reducing hematological toxicities. Moreover, BTZ alone 
exhibiting less than encouraging results in non-hematologic tumor cells compared 
with that to RPMI 8226 MM cells. The BTZ-induced cytotoxicity of non-hematological 
cells was not increase in the presence of SP1017, indicating the specificity of the 
combination therapy in dealing with hematologic malignancies. 
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CHAPTER III: THE MOLECULAR MECHANISM OF THE SENSITIZATION EFFECT OF 
THE COMBINATION THERAPY TO MM.  
 
3.1 Introduction 
MM is a neoplastic proliferation of plasma cell within the BM  in association with 
abnormal production of monoclonal immunoglobulin, also called M-protein or paraprotein  
detected in either serum and/or urine, decreased normal immunoglobulin levels and lytic 
bone disease. Over the past ten years, proteasome inhibition has emerged as an 
effective therapeutic strategy for treating MM and some lymphomas. Two typical 
examples of proteasome inhibitors used in MM are BTZ, the reversible inhibitor of the 
20S proteasome and CFZ, the irreversible inhibitor of the 20S proteasome, which are 
U.S.FDA approved for relapsed or refractory MM [1].    
The UPP degrades the majority of damaged/mutated/misfolded proteins in the 
cell to maintain the protein homeostasis [2]. Conversely, blockade of protein degradation 
by proteasome inhibitors causes accumulation of ubiquitinated 
damaged/mutated/misfolded proteins, which in turn up-regulates heat-shock response 
and cell death [ 3 ]. Degradation of a protein via UPP involves two discrete and 
successive steps: 1) tagging of the substrate protein by the covalent attachment of 
multiple ubiquitin molecules (conjugation); 2) the subsequent degradation of the tagged 
protein and free ubiquitin for recycling by the barrel-shaped 26S proteasome, composed 
of two 19S regulatory complex, separated in lid and base, and the 20s proteasome core, 
separated in 2 flanking α rings and 2 central β rings (degradation) [4,5].  Specifically, 
protein is first marked with a chain of small polypeptides called ubiquitin; ubiquitin-
activating enzyme E1 then activates ubiquitin and links it to the ubiquitin-conjugating 
112 
 
enzyme E2 in an ATP-dependent manner; ubiquitin protein ligase E3 then links the 
ubiquitin molecule to the protein; a long polypeptide chain of ubiquitin moieties is formed; 
and finally, the 19S regulatory complexes recognize the poly-ubiquitinated proteins , 
unfold the protein substrates and assist in their translocation through a narrow gate into 
the 20S core particle where degradation takes place (Fig 3.1) [6, 7].   The 20S (or 
constitutive) catalytic core is barrel-shaped by 4 stacked rings, 2 outer α and 2 inner β 
rings, each formed by 7 subunits with an overall architecture of α1–7β1–7β1–7α1–
7 (Fig.3.2).The α rings serve as “gatekeepers” for the “proteolytic core” that is composed 
of the β rings. The active sites reside in three β subunits, β1, β2, and β5, exhibiting 
chymotrypsin-like, trypsin-like, and peptidyl-hydrolase (caspase)-like activities 
respectively [5]. Another form of the proteasome that is primarily expressed in cells of 
hematopoietic origin and cells exposed to inflammatory cytokines, known as the 
immunoproteasome (i20s) , is composed of iβ1 (LMP2), iβ2 (MECL-1), and iβ5 (LMP7) 
subunits which replace the constitutive β1, β2, and β5 subunits in the 20S core 
proteasome [8]. BTZ, a boronic dipeptide, reversibly inhibit the chymotrypsin-like (ChT-L) 
activity at the β5-subunit or LMP7 subunit with high potency and to a lesser 
extent (approximately 10-fold lower affinity )  inhibit the caspase-like activity at the β1-
subunit, thus leading to the accumulation of ubiquitinated proteins [ 9 , 10 ]. CFZ, 
irreversible epoxomicin-related proteasome inhibitor, has been demonstrated sustained 
inhibition of proteasomal ChT-L activity and greater selectivity for the β5 subunit and 
LMP7 than BTZ, which contributes to its greater cytotoxic response and improved 
tolerability profile relative to BTZ [11, 12].   
The imbalance of cellular protein homeostasis can lead to proteotoxic stress due 
to accumulation of misfolded proteins in the (endoplasmic reticulum) ER lumen and 
cytosol, resulting in harmful cellular effects known as proteotoxicity [13]. Cells respond to  
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Fig.3.1 The ubiquitin-proteasome pathway. The ubiquitination of target proteins is 
mediated by Ub-activating (E1), Ub-conjugating (E2), and Ub-ligating (E3) enzymes. 
Substrate proteins tagged with a multiple-ubiquitin chain are then degraded by the 26S 
proteasome which is composed of a 20S catalytic core and two 19S subunits. (Adapted 
from [7])  
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Fig.3.2 (A) The 26S proteasome consists of the 20S core capped with the 19S 
regulatory complexes that recognize ubiquitinated protein substrates designated for 
proteolysis. (Adapted from Bardag-Gorce F. Effects of ethanol on the proteasome 
interacting proteins. World J Gastroenterol. 2010 Mar 21; 16 (11): 1349-1357).  (B) One 
of the constitutive 20S proteasome core β rings which has seven nonidentical subunits. 
BTZ binds slowly and reversibly inhibits the chymotrypsin-like activity and with lower 
affinity targets the caspase-like activity. CFZ irreversibly binds and inhibits predominantly 
the chymotrypsin-like activity. In the immunoproteasome, BTZ binds the β5i and β1i 
subunits while CFZ binds the β5i subunit. (Adapted from Orlowski RZ, Kuhn DJ. 
Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 
2008 Mar 15; 14 (6): 1649-1657).  
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proteotoxic stress in a compartment-specific manner. For example, the heat-shock 
response is triggered by proteotoxic stress in the cytosol, and the unfolded protein 
response (UPR) is activated by misfolded proteins in the ER, a condition referred to as 
ER stress [14]. The cellular heat-shock response is manifested by increased expression 
of heat-shock proteins (HSPs) , represents a basic defense mechanism employed by 
cells to protect themselves against stressors such as cold, UV light, and environmental 
toxins [15]. Most of the major HSPs function as molecular chaperones serve a wide 
variety of functions in cellular processes, but are primarily involved in the folding, 
assembly, and/or degradation of proteins and therefore appear to prevent the 
accumulation of aggregated, misfolded, or damaged proteins in the affected cell [16, 
17] . Upregulation of heat shock protein expression by proteasome inhibition has been 
explored in the previous studies. A marked increase in HSP70 and a more than two-fold 
increase in HSP27 and HSP90 were observed in cells treated by the proteasome 
inhibitor, MG132 [18]. BTZ induced a pronounced upregulation of HSP 27, HSP70 and 
HSP90 in MM.1S cells, which reflected a stress response. The functional significance of 
up-regulation of HSPs in conferring a protective effect against BTZ is confirmed by the 
fact that HSPs inhibitors sensitized MM cells to BTZ-mediated apoptosis. The HSP90 
inhibitor 17-AAG showed in vitro synergistic apoptotic effect on MM cells when combined 
with BTZ [19]. Another Hsp90 inhibitor IPI-504, overcame BTZ resistance in mantle cell 
lymphoma when combined with BTZ in vitro and in vivo by down-regulation of pro-
survival ER chaperone Grp 78/Bip [20].  The ER is arranged in a dynamic tubular 
network involved in metabolic processes, which serves several important functions, 
including the post-translational modification and folding and assembly of newly 
synthesized secretory proteins. The accumulation of unfolded and/or misfolded proteins 
in ER lumen causes the failure of the ER to cope with the excess protein load, which is 
termed ER stress [ 21 ]. ER stress may elicit a series of complementary adaptive 
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mechanisms collectively referred to as the UPR activation, which results in a transient 
attenuation in the rate of protein synthesis, an upregulation of genes encoding 
chaperones and other proteins that prevent polypeptide aggregation and participate in 
polypeptide folding, and retro-translocation and degradation of ER-localized proteins, in 
order to maintains the protein-folding homeostasis within the ER [22]. Activation of the 
UPR depends on three ER stress sensors, including protein kinase RNA-like ER kinase 
(PERK), inositol-requiring protein 1α (IRE1α) and activating transcription factor 6 (ATF6). 
Under basal conditions these proteins are bound by the ER chaperone immunoglobulin 
heavy-chain-binding protein (Grp 78/Bip) and maintained in an inactive state. When ER 
stress develops, Grp 78/Bip is sequestered by the misfolded peptides and, as a 
consequence, released from the three sensor proteins, which triggers activation of the 
UPR branch [ 23 ]. For instance, PERK, a transmembrane serine/threonine kinase 
localized in the ER membrane, is activated by ER stress via dimerization and 
autophosphorylation, leading to phosphorylation of eIF2α and resulting in a global 
inhibition of translation [24].  However, if ER stress persists or is aggravated, ER stress 
signaling appears to switch from pro-survival to pro-apoptosis which is initiated through 
the activation of CCAAT/enhancer-binding homologous protein (CHOP), also known as 
growth arrest- and DNA damage-inducible gene 153 (GADD153), whose expression is 
low under non-stressed conditions, but markedly increases in response to ER stress 
through IRE1-, PERK- and ATF6-dependent transcriptional induction [25]. CHOP has 
been proved to play an important role in ER stress-induced apoptosis [26, 27]. Moreover, 
elevated CHOP expression results in the down-regulation of anti-apoptotic Bcl-
2 expression, translocation of Bax protein from the cytosol to the mitochondria and 
perturbation of the cellular redox state by depletion of cellular glutathione and 
exaggerated production of reactive oxygen species, which functions as an integrator and 
amplifier of the death pathway [28]. 
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The involvement of oxidative stress, an imbalance in the ratio of pro- and 
antioxidants has been observed in cells treated with proteasome inhibitors. The 
proteasome inhibitor, MG 132 induced calf pulmonary artery endothelial cells death via 
caspase-dependent apoptosis and GSH (an important buffering agent that maintains 
redox homeostasis) depletion [29].  Pretreatment with GSH or N-acetyl-L-cysteine (NAC, 
a precursor of glutathione and elevates glutathione contents) significantly suppressed 
BTZ-induced ROS generation and provided significant protection against apoptosis 
caused by BTZ in thyroid cancer cells [30]. BTZ treatment decreases intracellular GSH 
both in MM cell lines and in malignant plasma cells obtained from MM patients. 
Decreasing intracellular glutathione through buthionine sulfoximine treatment strongly 
enhanced BTZ toxicity while antioxidant NAC protected MM cells from BTZ-mediated 
cell death [31]. All of the above evidences indicate that oxidative stress is involved in 
BTZ-induced cell apoptosis  
It is suggested a dual apoptotic mechanism induced by BTZ in MM cells: one is 
the intrinsic apoptotic pathway (mitochondrial mediated), and the other is extrinsic 
apoptotic pathway (death receptor mediated) [3]. The two apoptotic pathways showed in 
(Fig.3.3). The intrinsic stimuli, such as DNA damage or ER stress, activate BH3-only 
proteins leading to BAX and BAK activation, which insert into the mitochondrial 
membrane, compromising its integrity. Mitochondrial membrane permeabilization results 
in the release of cytochrome c. In the cytoplasm, cytochrome c interacts with APAF-1, 
inducing its oligomerization and thereby forming a structure termed the apoptosome that 
recruits and activates an initiator caspase, caspase 9. Caspase 9 cleaves and activates 
executioner caspases, caspase 3 and caspase 7, leading to apoptosis. The extrinsic 
apoptotic pathway is initiated by the ligation of death receptors with their cognate 
ligands, leading to the recruitment of adaptor molecules such as FAS-associated 
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Fig.3.3 Intrinsic and extrinsic apoptotic pathways. (Adapted from Tait SW, Green DR. 
Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev 
Mol Cell Biol. 2010 Sep;11(9):621-632). 
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death domain (FADD) protein and then caspase 8. The dimerization and activation of 
caspase 8 directly cleave and activate caspase 3 and caspase 7, leading to apoptosis. 
Caspase 8 can cleave and activate BH3-only protein BH3-interacting domain death 
agoinst (BID), the resulting truncated BID (tBID) lead to mitochondrial membrane 
permeabilization [ 32 ]. BTZ was explored to elevate ROS generation, increase in 
mitochondrial membrane potential (Δψm), and release of cytochrome c into the cytosol in 
a time-dependent manner. Co-incubation with rotenone and antimycin A, inhibitors of 
mitochondrial electron transport chain complexes I and III, or with cyclosporine A, an 
inhibitor of mitochondrial permeability transition pore, resulted in inhibition of BTZ-
induced ROS generation, increase in Δψm, and cytochrome c release. Tiron, an 
antioxidant agent, blocked the BTZ-induced ROS production, Δψm increase, and 
cytochrome c release [33]. In primary chronic lymphocytic leukemia (CLL) cells, BTZ 
induced Bax accumulation, translocation to mitochondria, conformational change, and 
oligomerization [34 ], which can lead to inhibition of anti-apoptotic Bcl-2, release of 
cytochrome c/Smac from mitochondria and activation of caspase-9 [35]. Further, it was 
elucidated that BTZ induced caspase-dependent apoptosis by down-regulation of 
apoptosis inhibitors, such as Bcl-2, A1, cIAP-2, and (at higher concentration) FLIP and 
XIAP, but did not change the protein levels of cIAP-1 and Bcl-XL [3]. Another mechanism 
of BTZ-mediated apoptosis is via activation of extrinsic apoptotic pathway, as was 
demonstrated by an increased activity of c-Jun N-terminal kinase (JNK) and increase in 
death-inducing receptors Fas and DR5 and the death ligand FasL that further enhanced 
Fas-mediated signalling and caspase-8 activation [3].  
BM microenvironment, which is composed of a cellular compartment (stromal 
cells, osteoblasts, osteoclasts, endothelial cells, and immune cells) and a noncellular 
compartment including the extracellular matrix (ECM) and the liquid milieu (cytokines, 
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growth factors, and chemokines), appears to be responsible for homing of specific cells 
in the BM niche, their proliferation, survival, and in the case of MM cells, resistance to 
chemotherapy [36]. The interaction of MM and bone marrow stromal cells (BMSCs) 
triggers cell-adhesion-medicated drug resistance and cytokine-mediated drug resistance 
(Fig.3.4). Specifically, MM cells adhere ECM  proteins, such as type I collagen and 
fibronectin via syndecan 1 and very late antigen 4 on MM cells and to BMSC vascular 
cell adhesion molecule 1 via VLA-4 on MM cells [37]. MM cells bind to fibronectin, which 
in turn induces G1 arrest associated with elevated levels of p27kip1 protein levels, which 
could potentially be causative for resistance [38]. Adhesion of MM to BMSC induces the 
activation of p42/44 mitogen-activated protein kinase (MAPK) and nuclear factor NF-κB 
in BMSCs, which upregulates adhesion molecules on both MM cells and BMSCs. 
Moreover, the adhesion of tumor cells to BMSCs further upregulates the transcription 
and secretion of the cytokines by BMSCs and/or MM cells [39,40]. Cytokines secreted 
from MM cells induce interleukin-6(IL-6) secretion, tumor-necrosis factor-α (TNF-α), 
vascular endothelia growth factor and NF-κB activation in BMSCs, which activate the 
main signaling pathways (p42/44 MAPK, Janus kinase (JAK)/signal transducer and 
activator of transcription 3 (STAT3) and/or phosphatidylinositol 3-kinase (PI3K/AKT)) and 
induces the intracellular expression of downstream inhibitor of apoptosis proteins (IAPs), 
FLICE-inhibitory protein (FLIP), survival, cellular inhibitor of apoptosis-2 (cIAP2), 
A1/BFL1, and XIAP in MM cells, associated with MM cell proliferation and survival [41]. It 
has been proved that BTZ inhibited MM cells growth by downregulating the expression 
of adhesion molecules on MM cells and BMSCs and their related adherence and NF-κB-
dependent induction of IL-6 secretion and/or BMSC/MM cell adherence-induced p42/p44 
MAPK activation [42]. Therefore, BTZ not only acts directly on MM cells, but alters 
cellular interactions and cytokine secretion in the BM milieu to inhibit tumor cell growth, 
induce apoptosis, 
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Fig.3.4 The binding of MM cells to the BMSCs triggers adhesion- and cytokine-mediated 
MM cell growth, survival and migration. (Adapted from [41]).  
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and overcome drug resistance.  
Based on the sensitization effect of SP1017 on MM cells combined with the 
proteasome inhibitor BTZ as discussed in Chapter II, we explored the molecular 
mechanisms of the sensitization effect of the combination of SP1017 and BTZ on RPMI 
8226 MM cells, including the proteasome inhibition, accumulation of poly-ubiquitinated 
proteins, proteotoxic stress, ER stress, Golgi fragmentation, oxidative stress and the 
downstream apoptotic signaling cascades. We also explored the role of SP1017 played 
in the BM microenvironment to conquer environment-induced drug resistance. 
 
3.2 Materials and Methods 
3.2.1 Cell culture 
RPMI 8226 human MM cell line was generous gifts from Dr. Sagar Lonial (Emory 
University, Atlanta, GA, USA). BTZ/CFZ-resistant RPMI 8226 MM cell lines were 
selected and established by exposure to sensitive RPMI 8226 MM cells of gradually 
increasing concentrations of BTZ /CFZ  starting at 0.2nM. Consequently, the BTZ/CFZ-
resistant RPMI 8226 cell lines stably growing in the presence of 40nM of BTZ or CFZ 
within 6 months. OMA-AD BM stromal cell line was a kind gift from Dr Shantaram Joshi 
(UNMC, Omaha, NE, USA). All MM cell lines were grown in Roswell Park Memorial 
Institute (RPMI)-1640 medium with 100 I.U/ml penicillin, 100ug/ml streptomycin and 10% 
of fetal bovine serum (FBS). MCF 7, HepG2 and Hela cells were grown in Dulbecco's 
Modified Eagle Medium (DMEM) with 100 I.U/ml penicillin, 100ug/ml streptomycin and 
10% of FBS. OMA-AD BM stromal cell line was grown in Roswell Park Memorial Institute 
(RPMI)-1640 medium with 100 I.U/ml penicillin, 100ug/ml streptomycin and 20% of FBS. 
3.2.2 Materials 
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Bortezomib was purchased from Selleck Chemicals (Houston, TX, USA). 
Carfizomib was purchased from Chemie Tek (Indianapolis, IN, USA). SP1017 was kindly 
provided by Supratek Pharma. Inc (Montreal, Canada).  Cell counting kit-8 (CCK-8) was 
purchased from Dojindo Molecular Technologies (Kumamoto, Japan). Proteasome-
Glo™ Chymotrypsin-Like Cell-Based assay kit was purchased from Promega (Madison, 
WI, USA). Bioxytech GSH-400 kit was purchased from Oxis International Inc. (Portland, 
OR, USA). Caspase-3 Fluorogenic substrate (AD-DEVD-AMC), Caspase-8 Fluorogenic 
substrate (Ac-IETD-AFC), APC annexin V and anti-GRP 78/BiP were purchased from 
BD Bioscience (San Jose, CA, USA). Caspase-9 Fluorogenic substrate (Ac-LEHD-AFC), 
Anti-P-Glycoprotein (C219) mouse antibody and the mouse IL-6 enzyme linked 
immunosorbent assay (ELISA) kit were purchased from EMD Millipore 
(Darmstadt, Germany). Human lambda EILSA kit was purchased from Bethyl 
Laboratories Inc (Montgomery, TX, USA). Mitoprobe JC-1 assay kit was purchased from 
Life technologies (Grand Island, NY, USA). Cyanine 5 NHS ester was obtained from 
Lumiprobe (Hallandale Beach, FL, USA). Annexin V-FITC/ propidium iodide (PI) 
Apoptosis Kit was purchased from Biovision (Milpitas, CA, USA). Mitochondria 
Isolation Kit for Cultured Cells, enhanced chemilumescent (ECL) substrates and M-
PER® Mammalian Protein Extraction Reagent were purchased from Thermo 
Scientific Inc. (Waltham, MA, USA). Cleaved Caspase-3 (Asp175), Cleaved Caspase-8 
(Asp391), Cleaved Caspase-9 (Asp330), Cytochrome c (D18C7), Hsp 70, XIAP(3B6), 
Bxl-xL (54H6), Survivin (71G4B7), GAPDH (14C10)  rabbit antibodies, CHOP(L63F7), 
Ubiquitin (P4D1) mouse antibodies, anti-rabbit IgG HRP-linked antibody, cell Lysis 
Buffer (10×) and protease inhibitor cocktail (100×) were purchased from cell signaling 
technology (Danvers, MA, USA). Anti-mouse IgG HRP-linked antibody was purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 1,1′-carbonildiimidazole (CDI), 
ethylenediamine, N-Acetyl-L-cysteine (NAC) and other chemicals were purchased from 
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Sigma-Aldrich (St Louis, MO, USA) and were used without further purification. 
MitoTracker® Red CMXRos, ProLong Gold antifade reagent with DAPI, Fetal bovine 
serum (FBS), RPMI 1640 medium, DMEM medium, penicillin, streptomycin, Trypsin–
ethylenediaminetetraacetic acid (EDTA) (0.5% trypsin, 5.3 mM EDTA tetra-sodium) and 
other chemicals were purchased from Invitrogen (Carlsbad, CA, USA). 
3.2.3 Cytotoxicity in human MM cell line by CCK-8 assay 
Cytotoxicity of BTZ ±0.005% SP1017 in the presence with 10mM NAC or BTZ 
±0.005% SP1017 in the presence with 1uM Dexamethasone (DEX) or DEX alone was 
assessed in different MM cell lines by a standard CCK-8 assay. Briefly, cells were 
seeded in a 96-well microtiter plates with 104 of cells per well and exposed to various 
doses BTZ ± 0.005% SP1017 in the presence with 10mM NAC or various doses BTZ ± 
0.005% SP1017 in the presence with 1uM DEX or various doses of DEX alone for 24h at 
37 ℃ in a humidified, 5% CO2 atmosphere. 10ul of CCK-8 was added to each well and 
the cells were incubated for 1-4 h (when the absorption value ranges from 0.2-0.8, which 
shows better linearity) at 37 ℃ in the dark. Absorption was measured at 450nm in a 
microplate reader (SpectraMax M5, Molecular Devices Co., Sunnyvale, CA, USA) using 
wells without cells as blanks. For the experiments in the presence of NAC, cells were 
collected, washed with PBS twice and resuspended in the fresh RPMI 1640 medium 
before added the CCK-8 to prevent the effect of NAC on dye in the CCK-8. The net 
absorbance was taken as index of cell viability. The reading taken from the wells with 
cells cultured with control medium was used as 100% viability value. The cell viability 
was calculated as Asample/Acontrol ×100%. Each concentration point was determined from 
samples from eight separate wells.  Based on the results of the test, the IC50 values (the 
concentration which kill 50% of cells) were calculated by using GraphPad Prism 
Software (Version 5.0, GraphPad Software, San Diego, CA, USA).  
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3.2.4 Proteasome activity 
The chymotrypsin-like proteasome activity was evaluated by Proteasome-Glo 
Chymotrypsin-Like Cell-Based Assays. Briefly, 1.5×104 of RPMI 8226 cells per well in a 
96-well microtiter plates were treated with Media as control, 0.005% SP1017, 10nM of 
BTZ and 10nM of BTZ+ 0.005% SP1017 for 1h, 2h and 4h. Cells were collected, washed 
with PBS and resuspended in 1ml fresh RPMI 1640 medium. 100ul of cells were taken 
and plated in white polystyrene, flat opaque bottom Corning® 96-well plate (Sigma-
Aldrich, St Louis, MO, USA). Proteasome-Glo™ Cell-Based Reagents were prepared 
according to the manufacturer’s instructions. 100ul reagents were added to 100ul/well 
drug-treated samples. Luminescence was determined as relative light units (RLU) using 
the SpectraMax M5 microplate reader and the results were normalized by protein 
content determined by BCA assay.   
3.2.5 Measurement of reduced glutathione (GSH) levels 
GSH levels were evaluated by Bioxytech GSH-400 kit. Briefly, 107 of sensitive or 
resistant RPMI 8226 cells per sample were treated with Media as control, SP1017, BTZ 
and BTZ+ SP1017 in relative dose for 12h. Cells were collected and lysed in 100ul fresh 
Metaphosphoric acid (MPA) working solution. Reagents were added to each of samples 
according to the manufacturer’s instructions and the final absorbance was measured at 
400 nm using the SpectraMax M5 microplate reader and the results were normalized by 
protein content determined by BCA assay.  
3.2.6 Measurement of membrane potential in mitochondria 
Measurement of the membrane potential is based on potential dependent 
accumulation of a dye, JC-1, in mitochondria, which is monitored by fluorescence 
emission shift from green (~529 nm) to red (~590 nm). Consequently, mitochondrial 
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depolarization is indicated by the increase of percentage of green positive cells. 5*105 of 
RPMI 8226 MM cells were seeded in 24-well plates per well and exposed to different 
concentrations of BTZ± 0.005% SP1017 for 12h and 24h. After the drug treatment, 50 
μM CCCP (as the positive control) and 0.75 μM JC-1 were added in each well for 20 min 
incubation. Cells were then collected, washed three times with PBS and analyzed by 
Becton Dickinson FACSCalibur™ flow cytomerter and FACSDiva software (Version 8.0, 
Becton Dickinson, San Jose, CA). 
3.2.7 The translocation of Cyanine 5-labeled L61 Pluronic® (Cy5-L61) to 
subcellular organelles by confocal analysis 
3.2.7.1 Preparation of Cy5-L61 
 Pluronic® L61 was labeled with Cyanine 5 fluorophore according to the method 
described before [43]. Briefly, Pluronic® L61were activated with CDI, and then modified 
with excess of ethylenediamine and purified by dialysis against 20% ethonal. Amino-
modified L61 was conjugated with Cyanine5 NHS ester (1:1) in dimethylformamide in the 
presence of 1.2 eq of tertiary amine. Free Cyanine5 and Cy5-L61 were separated by 
Sephadex LH-20 (Sigma-Aldrich, St Louis, MO, USA) column in methonal/ 
dichloromethane (1:1) phase.  
3.2.7.2 Mitochondria staining 
3*105 of cells were seeded in 24 well plate per well, incubated with 0.00055% 
Cy5-L61 for 20min. Meanwhile, cells were treated for 20 min with a staining solution 
containing 100 nM of the mitochondrial dye, MitoTracker® Red CMXRos. Cells were then 
washed with PBS three times, fixed with 4% paraformaldehyde (PFA) for 10min, 
centrifuged onto glass slides, mounted by coverslips with Prolong Gold antifade reagent 
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with DAPI. Cells were visualized by confocal imaging system (Carl Zeiss LSM 510 Meta, 
Peabody, MA, USA).  
3.2.7.3 Golgi and ER staining  
Cells (3*105) were seeded in 24 well plate per well, incubated with Cy5-L61 
(0.00055% L61 equivalent) for 0.5 h, 2 h and 8 h. Then, cells were washed with PBS 
three times, fixed with 4% PFA for 10min, and centrifuged onto glass slides. After 
blocking with 1% donkey serum, cells were incubated with primary antibodies at 37°C for 
1 h followed by washing with PBST three times. Further, cells were stained with DyLight 
secondary antibodies. After the final wash in PBST, cells were mounted in ProLong Gold 
antifade reagent with DAPI. The following primary antibodies were used: rabbit 
polyclonal – giantin (ab24586), and Calreticulin (ab4) (Abcam). The secondary antibody 
(Jackson Immuno Research) was donkey anti-rabbit Alexa Fluor 594 (711-585-152).  
Colocalization was determined by Pearson’s coefficient, which represents a correlation 
of channels inside the colocalized regions, using ImageJ JACoP plugin. 
3.2.8 Caspases activation  
5*105 or 3*106 of RPMI 8226 MM cells per sample were treated with BTZ ±0.005% 
SP1017 for 24h for the measurement of caspase 3 and caspase 8/9 activity, respectively. 
After the drug treatment, cells were collected, washed three times with PBS and lysed in 
400ul lysis buffer [10mM Tris-HCl (pH 7.5), 10mM NaH2PO4/Na2HPO4, 130mM NaCl, 1% 
Triton X-100, 10mM Na4P2O7 · 10 H2O] by sonication. 100ul of the lysed cell solution 
were mixed with 5ug of the fluorogenic caspase 3 substrate Ac-DEVD-AMC, caspase 9 
substrate Ac-LEHD-AFC and caspase 8 substrate Ac-IETD-AFC, respectively and 
incubated for 1h at 37℃. The activity was evaluated by measuring the cleavage of the 
Ac-DEVD-AMC substrate in the Perkin Elmer luminescence spectrometer LS 50B with 
λex=380nm, λem=440nm and the cleavage of the Ac-LEHD-AFC and Ac-IETD-AFC 
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substrates in the spectrometer λex=400nm, λem=505nm. The results were normalized 
by protein content determined by BCA assay.   
3.2.9 Western blot 
Identification of cleaved caspase 3, caspase 8, and caspase 9, Pgp, ubiquitnated 
proteins, HSP70, CHOP, GRP78/BiP, cytochrome c, survivin, XIAP, BCL-xl was done 
using immunoblot technique. Briefly, Cells were treated with BTZ ±0.005% SP1017 for 
relative period of time and lysed with Cell Lysis Buffer supplemented with protease 
inhibitor cocktail. Supernatant were collected after removing cell debris by centrifugation 
(14000 rpm for 10 min) and protein content was determined by BCA assay. Cytoplasmic 
extraction for cytochrome c was separated and collected by Mitochondria Isolation 
Kit for Cultured Cells according to the manufacturer’s instructions. 15-30μg of 
proteins were resolved by 10%,12% or 15% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred onto PVDF membranes. The membranes 
were blocked by incubation in 5% dry milk in TBST (0.1% Tween-20 in TBS) and probed 
with the relative monoclonal antibodies were used at 1:1000 dilutions.  The secondary 
horseradish peroxide Ig antibodies were used at 1:5000 dilutions. Blots were then 
visualized by ECL substrates. To correct for loading differences, the levels of protein 
expression were normalized to a constitutively expressed GAPDH. Intensity of the bands 
was quantified by Image J software.  
3.2.10 In vitro tumor microenvironment models 
3.2.10.1 CM culture model 
OMA-AD stromal cells were cultured in T-75 flask until they were grown to 80-90% 
confluence. Old medium were removed and 15ml new fresh media (RPMI 1640 medium 
with 20% FBS) were added. Conditioned medium (CM) from stromal cells cultures was 
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collected following 24h of incubation and contaminated suspended cells were removed 
by centrifugation. 104 of RPMI 8226 MM cells were seeded per well and exposed to 
various doses of BTZ ± 0.005% SP1017 for 24h in RPMI 1640 meidum with 10% FBS, 
RPMI 1640 meidum with 20% FBS and CM, respectively. Cell viabilities were analyzed 
by the CCK-8 method. 
3.2.10.2 Adhesion model 
 105 of OMA-AD stromal cells were seeded in 12-well-plate per well and 
incubated for 24h for attachement at 37°C. After that, 105 GFP+ RPMI 8226 cells were 
allowed to adhere for 12h. Nonadhered cells were removed and samples were exposed 
to different concentration of BTZ+/-SP1017 for 24h. For a control, myeloma cells were 
treated in same concentrations of BTZ+/-SP1017 in suspension. Cells were stained with  
annexin V-APC and PI staining as per the manufacturer’s instructions.  Apoptotic-
induced cell death was analyzed by Becton Dickinson FACSCalibur™ flow cytometer 
and FACSDiva software (Version 8.0, Becton Dickinson, San Jose, CA). In coculture 
experiments with stromal cell line, GFP+ populations were gated as tumor cells for the 
analysis of apoptosis.  
3.2.10.3 IL-6 secretion 
105 of OMA-AD stromal cells were seeded in 12-well-plate and incubated for 24h 
for attachment. Old media were removed and fresh media or fresh media containing 105 
RPMI 8226 MM cells were added, followed by 4h or 24h of cell adhesion and another 
24h BTZ ±0.005% SP1017 treatments. Supernatant were collected and IL-6 levels were 
analyzed by the mouse IL-6 ELISA kit according to the manufacturer’s instructions.  
3.2.12 Paraprotein Level 
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105 of RPMI 8226 MM cells were  seeded in 24 well plate per well, treated with 
Medium as control, 0.005% SP1017, 5nM of BTZ and 5nM of BTZ+ 0.005% SP1017 for 
2h (total media volume 2ml). Supernatant were collected and the paraprotein levels were 
analyzed by human Lambda ELISA kit the according to the manufacturer’s instructions. 
The results were normalized by protein content determined by BCA assay. 
3.2.13 Statistical analysis 
Statistical comparisons between two groups for in vitro studies were evaluated 
using Student’s t-test. Two-tailed P values less than 0.05 were considered significant. 
 
3.3 Results and discussion 
3.3.1 SP1017 potentiate BTZ-induced proteasome inhibition  
The ubiquitin-proteasome pathway plays a vital role in regulating protein stability 
and thus normal cellular function. It involves two distinct, critical steps: covalent 
attachment of multiple ubiquitin molecules to a protein substrate, and degradation of the 
tagged substrate protein by the 26S proteasome. BTZ, a boronic dipeptide operating as 
a reversible inhibitor of the 26S proteasome, mainly binds and forms a complex with the 
active site of threonine hydroxyl group in the β5-subunit and blocks the chymotrypsin-like 
activity of the proteasome, thus leading to the accumulation of ubiquitinated proteins [7]. 
We found that BTZ effectively inhibited about 50% of chymotrypsin-like proteasome 
activity after 1h treatment and the inhibition increased when the treatment period 
extended. The combination induced significantly higher proteasome activity inhibition 
compared with BTZ alone after 1h, 2h and 4h treatment (Fig.3.5A). As a result, 
BTZ+SP1017 combination further potentiated the BTZ-induced accumulation of poly-
ubiquitinated proteins, proved by higher accumulation of poly-ubiquitinated proteins in  
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Fig.3.5 (A) Chymotrypsin-like proteasome activity of RPMI 8226 MM cells treated with 
BTZ± 0.005% SP1017 for 1h, 2h and 4h. Data presented as mean ± SD. N=3 (*P<0.05, 
***p<0.001). (B) Accumulation of ubiquitinated proteins in RPMI 8226 MM cells treated 
with BTZ± 0.005% SP1017 for 4h, 8h and 24h. Data represented as a set out of three 
experiments.  
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cells treated with BTZ+SP1017 combination compared with BTZ alone after 4h, 8h and 
24h (Fig.3.5B). 
3.3.2 SP1017 potentiate BTZ-induced Proteotoxic stress and ER stress 
An imbalance of cellular protein homeostasis can lead to proteotoxic stress due 
to accumulation of misfolded proteins, resulting in harmful cellular effects known as 
proteotoxicity. Cells respond to proteotoxic stress by triggering the heat-shock response 
which leads to the rapid and robust expression of molecular chaperones to prevent 
protein misfolding and aggregation in the cytosol, and the UPR, the signaling network 
activated by misfolded proteins in the ER, called ER stress [14]. BTZ+SP1017 
combination enhanced levels of ubiquitinated proteins compared with BTZ alone (Fig 
3.5B), indicating proteotoxic stress in the cytosol. Additionally, the effect of the 
combination on cytosolic proteotoxicity was reconfirmed by measuring protein levels of 
the HSP70 chaperone. HSP 70 levels of cells treated with combination were observed to 
be significantly higher than that treated with BTZ alone after 8h, 12h and 24h treatment, 
indicating the cellular response to alleviate proteotoxic stress in cytosol (Fig.3.6A). Upon 
ER stress, GRP78/Bip, a master regulator of the UPR is released from ER 
transmembrane signal transducers, including PERK, IRE1 and ATF6, leading to the 
activation of URP signaling pathways. Release from GRP78/Bip allows ATF6 to 
translocate from ER to Golgi where it is cleaved. The cleaved form of ATF6 migrates into 
the nucleus and acts as an active transcription factor to upregulate proteins that 
augment ER folding capacity, including the ER chaperones GRP78/Bip [44,45]. However, 
under severe and prolonged ER stress, ER stress signaling appears to switch from pro-
survival to pro-apoptosis which is initiated through the activation of CHOP, which plays 
an important role in ER stress-induced apoptosis [25]. In our study, we found CHOP 
levels of cells treated with combination were significantly higher than that  
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Fig.3.6 (A) HSP70 and (B) CHOP expressions of RPMI 8226 MM cells treated with BTZ± 
0.005% SP1017 for 8h, 12h and 24h. (C) GRP 78/BiP expression of RPMI 8226 MM 
cells treated with BTZ± 0.005% SP1017 for 4h and 8h. Data represented as a set out of 
three experiments.  
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treated with BTZ alone after 8h, 12h and 24h treatment (Fig.3.6B), indicating the ER 
stress. However, GRP78/BiP expression was slightly up-regulated by both BTZ and 
combination after 4h treatments, but down-regulated after 8h treatments (Fig.3.6C). It 
may be explained by the fact that upregulation of GRP78/BiP was involved in the initial 
phase of UPR activation. In conditions of prolonged stress, the goal of the UPR changes 
from promotion of cellular survival to commitment of cellular apoptosis.  
3.3.3 Pluronic® L61 translocates to ER and Golgi complex and the 
combination therapy reduced paraprotein associated with Golgi fragmentation  
According to previous studies, hydrophobic PPO chains with intermediate length 
of PEO units from 30 to 60 and HLB <20 [46, 47] of Pluronic®  unimers immerse into the 
membrane hydrophobic areas, resulting in alterations of the membrane structure, and 
triggering subsequent biological effects [48]. In our study we labeled Pluronic® L61, the 
component which played major role of chemosentization effect with dye cyanine 5 to 
explore its trafficking in the cells. Cy5-L61 was observed to be accumulated in both Golgi 
apparatus and ER after 8h treatment (Fig. 3.7A, 3.7B), which could be another factor 
contributing to the increased ER stress and Golgi fragmentation (Fig.3.8) under 
combination treatment. Interestingly, we found 0.005% SP1017 alone at the inert 
concentration induced significant Golgi fragmentation (Fig.3.8). The colocalization of 
Pluronic® L61 with subcellular membrane components, ER and Gogli and subsequent 
specific cellular responses, could be attributed by the interaction of the Pluronic® 
unimers and lipid membranes [49]. Relatively hydrophobic copolymers could insert into 
the membrane below the polar head groups, loosen the lipid packaging and translocate 
through the membrane. The immersed Pluronic® block copolymers disrupt the 
membrane integrity, which results in decreased membrane microviscosity and the 
subsequent specific cellular response [50, 51]. Newly synthesized secretory  
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Fig.3.7 Translocation of Cy5-L61 (0.00055% L61 equivalent) into (A) the Golgi apparatus 
(Giantin as the Golgi marker) and (B) ER (Calreticulin as the ER marker) of RPMI 8226 
MM cells after 8h incubation. Nuclei were counterstained with DAPI (blue). Quantification 
of Pearson’s coefficient in cells presented in (C); n = 30 cells for each series of 
experiments; Data presented as mean ± SD.  
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Fig.3.8 Golgi fragmentation of RPMI 8226 MM cells treated with BTZ± 0.005% SP1017 
for 8h, as measured by the number of Golgi fragments stained with Giantin. The low 
panel shows high magnifications of the highlighted area (white boxes). Nuclei were 
counterstained with DAPI (blue), n = 30 cells for each series of experiments; Data 
presented as mean ± SD. N=10 (***P<0.001).  
 
 
137 
 
glycoproteins, such as the paraprotein, are transported from the ER to the plasma 
membrane or other destinations via the Golgi complex.  In the secretory pathway, the 
Golgi complex is a central organelle essential for processing and sorting of lipids and 
proteins [ 52 , 53 ]. Therefore, Golgi disorganization may block secretory traffic and 
plasma membrane delivery of proteins [54,55]. Indeed, here observed that there was 
significant reduce of paraprotein (human monoclonal immunoglobulin (Ig) lambda which 
is produced in excess in MM) when treated with the combination compared to drug alone 
or control (Fig. 3.9). 0.005% SP1017 alone also induced slightly decrease of the 
secretion of paraprotein compared to control (Fig. 3.9). As clonal expansion of the MM 
results in the excessive production of monoclonal Ig light chains and the deposition in 
the kidneys can lead to renal failure which is a clinical hallmark of MM [56],  the 
reduction of secretion of Ig lambda from MM cells treated with combination therapy 
determines the potential as an anti-myeloma therapy in prevent renal failure. 
3.3.4 SP1017 potentiate BTZ-induced oxidative stress 
The biologically active form, GSH, plays key role in the cellular antioxidant 
defense system. The imbalance of intracellular GSH homeostasis could lead to oxidative 
stress and apoptosis [ 57 ]. SP1017 potentiated the BTZ-induced GSH depletion in 
sensitive RPMI 8226 MM cell line after 12h treatment (Fig.3.10A). In addition, the 
antioxidant, NAC, significantly reversed the BTZ+SP1017 induced cell death at BTZ 5nM 
and 10nM (Fig.3.11), which proved that oxidative stress was at least partially involved in 
the combination-induced cell death. In the Chapter II, we proved the SP1017 could still 
sensitize both BTZ -resistant MM cells and CFZ-resistant MM cells to proteasome 
inhibitors. Strikingly, SP1017 showed drastic sensitization effect (sensitization factor=6.6) 
on CFZ-resistant RPMI 8226 MM cell line as the MDR phenotype was only observed in 
CFZ-resistant MM cells rather than BTZ-resistant MM cells. The basal level  
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Fig.3.9 Paraprotein (human lambda) level from the supernatant of RPMI 8226 MM cells 
treated with BTZ± 0.005% SP1017 for 8h (statistics calculated by N=12). Data presented 
as mean ± SD. N=12 (*P<0.05, **P<0.01, ***P<0.001).  
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of GSH in BTZ-resistant RPMI 8226 MM cells was higher than that of sensitive RPMI 
8226 MM cells (Fig.3.10B), which may contribute to the resistance to anticancer drugs.   
SP1017 potentiated the drug-induced GSH depletion in both BTZ- and CFZ-resistant 
MM cell lines (Fig.3.10B, 3.10C), indicating the potential of SP1017 in overcoming 
acquired resistance of MM. Drug+SP1017 combination increased the GSH depletion 
even at quite low concentration of drug in CFZ-resistant MM cell line compared that in 
BTZ-resistant MM cell line, which was due to the Pgp expression in CFZ-resistant MM 
cell line as SP1017 is quite effective in inhibiting Pgp, thus increasing the intracellular  
CFZ to exhibit the anticancer effect. 
3.3.5 SP1017 potentiate BTZ-induced intrinsic and extrinsic apoptotic 
pathways 
As shown in Fig.2.2, MM cells underwent more apoptosis in BTZ + SP1017 
combination, which was linked to activation of apoptosis signal transduction pathways 
such as intrinsic and/or extrinsic pathway in cancer cells [58,59]. Here we explored 
whether the BTZ + SP1017 combination induced the MM cells apoptosis via both 
intrinsic and extrinsic pathways. Cy5-L61 was found to translocate into mitochondria 
after 20min exposure of the copolymer to RPMI 8226 MM cells (Fig.3.12), which was 
consistent with the previous work that Pluronic® P85 can rapidly transport to 
mitochondrial of both MCF7 and MCF7/ADR cells [ 60 ]. Moreover, we observed 
significant increased loss of mitochondrial membrane potential in cells treated with the 
BTZ + SP1017 combination for 12h and 24h (Fig. 3.13A, 3.13B) and increased release 
of cytochrome c into cytoplasm in cells treated with the BTZ + SP1017 combination for 
12h (Fig.3.13C). The caspase 9 and caspase 3 activations were proved by both 
functional fluorogenic assay and western blot of the expression of the active forms of 
caspases. Both caspase 9 and caspase 3 activities were significantly increased in cells  
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Fig.3.10. GSH level of (A) sensitive, (B) BTZ- resistant RPMI 8226 MM and (C) CFZ-
resistant RPMI 8226 MM cells treated with drug ± 0.005% SP1017 for 12h. Data 
presented as mean ± SD. N=3 (**P<0.01, ***P<0.001).  
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Fig.3.11 Cell survival of sensitive RPMI 8226 MM cells treated with BTZ± 0.005% 
SP1017 in presence of antioxidant 10mM NAC. Cells were treated for 24h. Data 
presented as mean ± SD. N=3 (*P<0.05, **P<0.01, ***P<0.001). 
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Fig.3.12. Co-localization of Cy5-L61 with mitochondria marker (MitoTracker-Red) in 
RPMI 8226 MM cell after 20min exposure. The low panel shows high magnifications of 
the highlighted area. Nuclei were counterstained with DAPI (blue). 
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 Fig 3.13 Loss of mitochondrial membrane potential (green positive %) of cells treated 
with BTZ± 0.005% SP1017 for (A)12h and (B) 24h, CCCP used as positive control; (C) 
Cytochrome c release into cytoplasm of cells were treated with BTZ+/-SP for 12h. Data 
presented as mean ± SD. N=3 (*P<0.05, **P<0.01, ***P<0.001) or as a set out of three 
experiments.  
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treated with the combination for 24h compared with BTZ alone (Fig.3.14A, 3.14C). 
Significant increased expression of cleaved caspase 9 and caspase 3 were observed in 
the combination treatment for both 8h and 24h compared with BTZ alone (Fig.3.15).  All 
the above evidence showed SP1017 was involved in mitochondria-dependent apoptotic 
(intrinsic) pathway. In the previous work, Pluronic® P85 at relative low concentration can 
only induce inhibition of mitochondria respiration, decrease of mitochondrial membrane 
potential, release of cytochrome c from mitochondria in MDR cells, but not in the 
sensitive cells [60, 61]. Our study proved SP1017 at quite low concentration could 
sensitize sensitive MM cells to proteasome inhibitors via mitochondria-dependent 
apoptotic pathway. On the other hand, the increased activation of caspase 8 and 
caspase 3 proved by both functional assay and western blot in MM cells treated the 
combination treatment compared with BTZ alone (Fig.3.14B, 3.14C, 3.15) showed 
SP1017 was involved in mitochondria-independent (extrinsic) apoptosis pathway as well. 
Extrinsic apoptotic pathway is involved in stimulation of Fas/CD95 death receptor, which 
results in receptor aggregation and recruitment of the adaptor molecule FADD and 
procaspase-8 to form the so-called death-inducing signaling complex (DISC) that 
eventually leads to activation of downstream signaling and apoptosis [ 62 ]. It was 
reported that Fas/CD95 is translocated and aggregated into lipid raft clusters during 
Fas/CD95-mediated apoptosis and a group of lipid analogies behaved promising anti-
MM activity by targeting and accumulating in lipid rafts of malignant cells, inducing raft 
aggregates that act as scaffolds for the recruitment of Fas/CD95 death receptor, FADD, 
and pro-caspase-8 into lipid rafts leading to the formation of DISC and apoptosis [63, 64,  
65]. Previous studies also showed the hydrophobic PPO chains of Pluronic® unimers can 
immerse into the biomembrane hydrophobic areas, resulting in the alternations of the 
membrane structure and decreasing its microviscosity (“membrane fluidization”) [50]. 
More specifically, Pluronic® unimers were proved to selectively localize in particular  
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Fig 3.14 (A) caspase 9 activation, (B) caspase 8 activation and (C) Caspase 3 activation 
of cells treated with BTZ± 0.005% SP1017 for 24h, evaluated by measuring the cleavage 
of the fluorogenic substrate Ac-IETD-AFC, Ac-LEHD-AFC and Ac-DEVD-AMC, 
respectively.  Data presented as mean ± SD. N=3 (*P<0.05, **P<0.01, ***P<0.001).  
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Fig 3.15. Western blot of cleaved caspase 9, cleaved Caspase 8 and cleaved caspase 3 
of cells treated with BTZ± 0.005% SP1017 for 8h and 24h. Data represented as a set out 
of three experiments.  
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domains of cellular membrane called lipid rafts/caveolae [66]. So the potentiation of the 
activation of extrinsic apoptotic pathway by SP1017 may attribute to its ability to target 
lipid rafts and recruit the death receptors. Increase expressions of cleaved caspase 9/8/3 
were observed in RPMI 8226 MM cells treated with CFZ+ SP1017 combination for 24h 
compared with CFZ alone (Fig.3.16). Besides the potentiation of drug-induced pro-
apoptotic signaling, SP1017 further decreased the expression of anti-apoptotic proteins 
when combined with BTZ. The anti-apoptotic proteins, Survivin and XIAP were 
significantly decreased under the BTZ+SP1017 combination treatment for both 12h and 
24h compared with drug alone (Fig.3.17), which could be another factor inducing cell 
apoptosis. 
3.3.6 SP1017 sensitize MM cells in tumor microenvironment 
Besides triggering apoptotic signaling pathways, the combination therapy also 
overcomes the major chemoresistance mechanisms in MM cells. Resistance to tumor 
therapy can be subdivided into two broad categories: acquired and de novo. Acquired 
resistance develops in the course of treatment as a result of sequential genetic changes 
that eventually culminate in complex therapy-resistant phenotypes. In the Chapter II, we 
have proved that SP1017 overcome the acquired drug resistance of MM.   Environment-
medicated drug resistance is one form of de novo drug resistance to protect tumor cells 
from anticancer drugs. The interaction of MM and BMSCs triggers cell-adhesion-
medicated drug resistance and cytokine-mediated drug resistance [36]. Our data 
showed RPMI 8226 MM cells cultured in BM stroma (OMA-AD stromal cells) -derived 
CM were more resistant to BTZ compared with cells in RPMI 8226 media with 10% or 20% 
FBS. However, SP1017 still had the ability to sensitize cells cultured in CM to BTZ 
(Fig.3.18). In cell adhesion model, GFP-labeled RPMI 8226 MM cells adhered to OMA-  
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Fig.3.16. Western blot of cleaved caspase 9, cleaved Caspase 8 and cleaved caspase 3 
of cells treated with CFZ ± 0.005% SP1017 for 24h.  
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Fig 3.17. Western blot of anti-apoptotic proteins (Survivin, XIAP, BCL-xl) of cells treated 
with BTZ± 0.005% SP1017 for 12h and 24h. Data presented as a set out of three 
experiments.  
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Fig.3.18. Cell survival of sensitive RPMI 8226 MM cell line treated with BTZ± 0.005% 
SP1017 for 24h. Tumor cells were maintained as follows: RPMI 1640 medium with 10% 
FBS, CM, RPMI 1640 medium with 20% FBS. Data presented as mean ± SD. N=3 
(*P<0.05, **P<0.01, ***P<0.001).  
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AD stromal cells and exposed to BTZ +/- SP1017 for 24h. For a control, MM cells were 
treated in same concentrations of BTZ+/-SP1017 in suspension.  Apoptotic-induced cell 
death was determined by Annexin V-APC/ PI assay. From the result showed in Fig.3.19, 
more cell apoptosis were observed in MM cells in suspension than MM cells in the 
adhesion model to both BTZ and the combination therapy. However, the combination 
therapy still induced more apoptosis in MM cells in the adhesion model compared with 
BTZ alone, indicating the sensitization of SP1017 in the BM microenvironment-mediated 
drug resistance. Though the BTZ+SP1017 co-treatment sensitize MM cells in stromal 
cell microenvironment in both models, OMA-AD stromal cells survived under treatment 
of BTZ+SP1017 combination even at a very high concentration, proving the combination 
therapy is well tolerated (Fig.3.20).The adhesion of tumor cells to BMSCs is proved to 
upregulate the transcription and secretion of the cytokines by BMSCs, such as IL-6, a 
major growth and survival factor for MM cells by triggering signaling pathways that exert 
a pro-survival effect [40]. Here we proved that adherence of multiple myeloma cells to 
BM stromal cells upregulated the secretion of IL-6 compared with that secreted by OMA-
AD stromal cells alone (Fig.3.21). However, the BTZ +SP1017 combination significantly 
inhibited the IL-6 secretion from stromal cells (Fig.3.21), which makes the combination 
therapy more promising in the treatment of MM.  
3.3.6 Dexamethasone (DEX)+BTZ+SP1017 combination 
Since the approval of BTZ by U.S.FDA in 2003, several BTZ-based combination 
therapies have emerged, including the IMiDs-BTZ-based combinations and 
combinations of BTZ with conventional chemotherapeutic agents such as melphalan-
BTZ based combinations, cyclophosphamide-BTZ based combinations, anthracyclines-
BTZ based combinations [67].Combinations should ideally take into account the different 
mechanisms of action, drug resistance pathways, and incorporate strategies designed to  
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Fig 3.19. Stromal cells protect multiple myeloma cells by direct contact in Adhesion 
Model.  GFP+RPMI8226 MM cells were cultured alone (the upper two lines, BTZ and 
BTZ+SP) or  co-cultured (the bottom two lines, Co-BTZ and Co-BTZ+SP) with stromal 
cells directly and exposed to BTZ ± 0.005% SP1017 for 24h and assessed for apoptosis 
by flow cytometric analysis using allophycocyanin (APC)-conjugated annexin V and 
propidium iodide (PI). Percentages of cells in each quadrant are shown and represented 
as a set out of three experiments. Left bottom quadrant (annexin V-/PI-, viable cells), 
right bottom quadrant (annexin V+/PI-, early apoptotic cells), right upper quadrant 
(annexin V+/PI+, late apoptotic cells) and left upper quadrant (annexin V-/PI+, necrotic 
cells). 
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Fig.3.20. Cytotoxicity of BTZ ± 0.005%SP1017 to OMA-AD stromal cells after 24h 
treatment. Data presented as mean ± SD. N=3. 
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Fig 3.21. IL-6 level in the supernatant of stromal cells and stromal cells co-cultured with 
MM cells in Adhersion Model after (A) 4h and (B) 24h adhesion, followed by another 24h 
drug treatments. Data presented as mean ± SD. N=3 (*P <0.05, **P<0.01).  
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improve sensitivity of myeloma cells to the drug. DEX, a glucocorticoid analog, used in 
certain hematological malignancies, especially in the treatment of MM, in which DEX is 
given alone in a high dose [68] or together with other anti-MM drugs. Combination 
therapies with DEX plus BTZ, thalidomide, or lenalidomide have been extensively used 
and are among the most effective treatments for patients with relapsed or refractory MM 
[69, 70].  The combination of DEX with BTZ along with other drugs such as thalidomide, 
doxorubicin, cisplatin, cyclophosphamide, and etoposide has resulted in improvements 
in both response rates and long-term outcomes [69, 71]. Hematologic toxic effects are 
quite frequent when thalidomide, lenalidomide, or bortezomib is used together with 
conventional chemotherapy but are less frequent when these drugs are used with DEX 
alone[69].  It is widely accepted that the ability of glucocorticoids like DEX to achieve MM 
cell apoptosis is mediated via initial binding to their cognate receptor, the glucocorticoid 
receptor (GR). Ligand binding to the GR could result in inhibition of NFκB activity by 
‘‘transactivation’’ via transcription of IκB and by ‘‘transrepression’’ via a reduction in 
transcription of the NFκB genes, thus decreasing the NFκB-dependent anti-apoptotic 
proteins [72,73]. Here we examined the effectiveness of the BTZ+DEX+SP1017 3-drug 
combination in MM. DEX itself didn’t induce any cytotoxicity to both RPMI 8226 MM cell 
line and ARH-77 MM cell line even at quite high concentration (Fig.3.22a, 3.22b). 
However, the addition of DEX (1uM) potentiated the BTZ- or BTZ+SP1017- induced cell 
death in both RPMI 8226 MM cell line and ARH-77 MM cell line (Fig.3.23a, 3.23b). 
Meanwhile, SP1017 potentiated the BTZ-induced cell death in both absence and 
presence of DEX. SP1017 was proved to potentiate the BTZ-induce of XIAP(one of 
NFκB-dependent anti-apoptotic protein) deduction (Fig.3.17). Here we observed that 
XIAP was further reduced by the addition of DEX (Fig.3.24).  
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Fig.3.22. Cell survival of (A) sensitive RPMI 8226 MM cell line and (B) ARH 77 cell line 
treated with DEX with different doses for 24h. Data presented as mean ± SD. N=3.  
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Fig 3.23. Cell survival of (A) sensitive RPMI 8226 MM cell line and (B) ARH 77 cell line 
treated with 3-drug combination (BTZ+0.005%SP1017+1uMDEX) for 24h. Data 
presented as mean ± SD. N=3 (***P<0.001,**P<0.01, and *P<0.05). 
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Fig.3.24. Expression of XIAP of sensitive RPMI 8226 MM cell line treated with 3-drug 
combination for 24h. Data represented as a set out of three experiments.  
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3.4 Conclusions 
In the previous published work, Pluronics at relative low concentration can 
sensitize MDR cancer cells mainly by Pgp inhibition,  selective ATP depletion, ROS 
generation, inhibition of GSH/GST detoxification as well as triggering mitochondria 
apoptotic signals, but not in sensitive cells [74, 75, 76, 77]. Here in our study we firstly 
proved that at quite low concentration, the mixture of Pluronics SP1017 sensitize 
sensitive MM cells to proteasome inhibitors discussed in Chapter II.  Mechanistic studies 
showed that the BTZ+SP1017 combination–induced apoptosis is associated with : 1) 
increase of suppression of ChT-L proteolytic activity, concomitant with increased 
accumulation of ubiquitinated proteins and proteotoxic stress; 2) accumulation of 
Pluronic® L61 in ER and increase of ER stress response; 3) accumulation of Pluronic® 
L61 in Golgi apparatus, increase of Golgi fragmentation and reduction of secretion of 
paraprotein; 4) increase of GSH depletion, resulting in less ability to neutralize drug-
induced oxidative stress; 5) increase of activation of both mitochondria-dependent (quick 
translocation of Pluronic® L61 into mitochondria, mitochondrial membrane potential loss, 
cytochrome c release and activation of caspase 9/3 ) and independent (activation of 
caspase 8/3) apoptotic pathways; 6) decrease of the expression of anti-apoptotic 
proteins. Studies in the BM microenvironment models showed that the combination of 
SP1017 and BTZ effectively overcame both adhesion-mediated drug resistance and 
cytokines-mediated drug resistance, indicating the great potential to use the combination 
for MM. One of the mechanisms is due to the significant reduction of secretion of IL-6, 
the major growth factor by BMSCs treated by the combination rather than BTZ alone. 
The findings provide the strong rationale for our further investigation of the treatment 
efficiency of the combination therapy in human myeloma/SCID mice model and the 
future clinical evaluation in patients with relapsed and refractory myeloma. In addition, 
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SP1017 in combination with BTZ and DEX leads to most pronounced anti-proliferative 
effect, indicating the potential of SP1017 used in corticosteroid sparing regimens to 
further improve the therapeutic efficacy as well as limiting significant side effects that 
patient with multiple myeloma often experience. 
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CHAPTER IV: THE ANTI-TUMOR ACTIVITY OF THE BTZ+SP1017 COMBINATION 
THERAPY IN HUMAN MM/SCID MODELS.  
 
4.1 Introduction 
To further evaluate potential of SP1017+BTZ combination for treating MM, an in 
vivo murine model that recapitulates the characteristics of human disease condition of 
MM is required. An animal model that accurately reflects human MM and takes into 
account the protective nature of BMSCs would be powerful in confirming the efficacy of 
therapeutic agents in vivo. There are currently three types of MM animal models: 1) 
injection of pristane oil in BALB/c mice leads to intraperitoneal plasmacytomas but 
without BM colonization and osteolysis; 2) injection of allogeneic malignant plasma cells 
(5T2MM, 5T33) in the C57BL/KalwRij mouse induces BM proliferation and osteolytic 
lesions; 3) injection of malignant plasma cell lines in immunodeficient mice SCID or 
NOD/SCID [1].  The BALB /c oil-induced and transplantable plasmacytomas resemble 
human MM in their ability to produce a monoclonal immunoglobulin [2]. The major 
disadvantage of the first model is that plasma cells are restrictively localized in the 
peritoneum and do not extend to the BM, which does not faithfully resemble human MM 
[1]. The 5TMM model originates from spontaneously developed MM in aged 
C57BL/KalwRij mice and has since been propagated by intravenous injection of BM cells 
from MM bearing mice, into young naive syngeneic recipients. This model has been 
extensively used for studying homing mechanisms of MM cells to BM, interaction of MM 
cells with the BM environment, and evaluation of new therapies [3, 4]. However, the 
5TMM models are limited by being solely murine-derived and representative of only one 
type of myeloma. Xenograft models, in which human MM cell lines are injected into 
immune compromised mice (for example, severe combined immunodeficient (SCID), 
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nude, NOD/SCID gamma (NSG) mice, etc.), can be used to establish systemic disease 
(via intravenous injection of MM cells) or local disease (via subcutaneous or intratibial 
injections) [5]. The models allow for the implantation of human MM cells, which are more 
relevant for investigating therapeutic targets and preclinical therapeutic testing than 
murine MM cells. Subcutaneous xenograft models not only fail to reflect the systemic 
nature of diffuse lesions of MM but also place tumor cells in the cutaneous 
microenvironment, which is radically different from the BM microenvironment, which 
appears to play an important role in differentiation, migration, proliferation, survival, and 
drug resistance of the malignant plasma cells [6], thus influencing the responsiveness to 
therapy. Several NOD/SCID MM models using intravenous injection of human MM cell 
lines, including U266, MM.1S, RPMI-8266 or primary human MM cells have been 
described [7, 8, 9, 10]. MM cells are preferentially homing into BM via selective binding 
of adhesion molecules on their surface to BMSCs and ECM proteins. For example, the 
very-late antigen 4 on MM cells binds to fibronectin and lymphocyte function-associated 
antigen-1 on MM cells binds to intercellular adhesion molecule-1 on BMSCs [11]. 
NOD/SCID IL-2Rγ(null) mice (NSG) mice, which lack the interleukin-2 (IL-2) gamma 
chain, have recently been used to develop models of MM [12]. Compared to the SCID 
and NOD/SCID strains which lack mature B and T lymphocytes, this strain lacks NK 
cells, characterized by defects in macrophages, complement and dendritic cell function 
and shows  significant improvements in tumor cell engraftment associated with 
abolishment of residual immune function and lack of thymic lymphoma development 
accompanied by an extended lifespan [13, 14]. NSG mice were injected intravenously 
via the tail vein with U266, XG-1, OPM-2 or patient-derived MM cells, and provided MM 
models which feature consistent tumor burden and osteolytic bone disease including 
paraplegia, paraprotein in the serum, osteolytic lesions and loss of trabecular bone 
[15]. Though tumor growth was observed in the BM of xenograft models, some of 
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previous studies indicated that MM cells  were found in  various sites, including the 
lungs, liver, kidneys, spleen [9, 10, 16]. Intra-tibial inoculation of tumor cells in NSG mice 
has been developed as well, which exhibited typical disease symptoms exclusively 
without organ involvement [17, 18].  
In order to evaluate therapeutic benefit of SP1017+BTZ combination for treating 
MM and provide more accurate preclinical evaluations of investigational therapies, we 
successfully established the human MM/SCID mice model by injecting Luc+/GFP+ RPMI 
8226 MM cells (2×106/100ul PBS/Mouse) into NSG mice. In 4 weeks post tumor 
implantation, mice were treated with saline, SP1017, BTZ or combination of SP1017 and 
BTZ via tail vein injections twice weekly for 4 weeks. Total body bioluminescence 
imaging (BLI), the serum levels of human immunoglobulin lambda paraprotein, changes 
in the body weight and onset of hind limb paralysis at the late stages of the disease were 
used to monitor the treatment efficacy.  
 
4.2 Materials and methods 
4.2.1 Materials 
Bortezomib was purchased from Selleck Chemicals (Houston, TX, USA). SP1017 
was kindly provided by Supratek Pharma. Inc (Montreal, Canada).  F-Luc-GFP Lentivirus 
was purchased from Capital Biosciences (Rockville, MD, USA). Human lambda EILSA 
kit was purchased from Bethyl Laboratories Inc (Montgomery, TX, USA). Luciferase 
assay system and cell culture lysis reagent were purchased from Promega (Madison, 
WI, USA). Hank’s Balanced Salt Solution (HBSS), ACK lysing buffer were purchased 
from Fisher Scientific (Pittsburgh, PA, USA). Hexadimethrine bromide (Polybrene) was 
purchased from Sigma-Aldrich (St Louis, MO, USA). FITC anti-mouse CD 45 antibody 
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was purchased from Biolegend (San Diego, CA, USA). PE anti-mouse CD11b and 
Purified Rat Anti-Mouse CD16/CD32 was purchased from BD Biosciences (San Jose, 
CA, USA).  
4.2.2 Labeling of RPMI 8226 MM cells with Luciferase (Luc) and GFP 
To prepare stably transfected Luc+/GFP+ MM cells, RPMI 8226 MM cells were 
infected with F-Luc-GFP Lentivirus. Briefly, 10^5 of cells were seeded in one well of a 
24-well plate and mixed with 100ul of F-Luc-GFP Lentivirus (10^8 TU/ml) in 1ml of the 
complete media in the presence of Polybrene (8 µg/mL). Cells was centrifuged at 300Xg 
for 1h at room temperature and incubated at 37 ℃ in a humidified, 5% CO2 atmosphere 
overnight. The cells were washed with PBS, fresh culture medium was added the next 
morning and cells were incubated for the enlargement of the cell number. To enrich for 
Luc positive cells, cells were sorted by Becton Dickinson FACSAria™ flow 
cytometer with GFP expression.  
4.2.3 The establishment of the human MM/SCID model 
A three mice pilot study was conducted to establish the human MM/SCID 
models. MM was generated by i.v. injection of Luc+ /GFP+ RPMI-8226 cells (2 ×106 cells 
suspended in 100 ul of PBS) via tail vein of NSG mice. The tumor progression was 
evaluated by BLI, the serum levels of human immunoglobulin lambda paraprotein, 
changes in the body weight and onset of hind limb paralysis. The BM of one the tumor-
beaing mouse and one control mouse was extracted by ice-cold HBSS. All cells were 
collected and centrifuged down at 1500rpm for 10min. The supernatant was removed 
and cells were incubated with 2ml of ACK lysis buffer in 37°C water bath for 2min to 
remove the red cells. Another 25ml of HBSS was added to stop the lysis reaction. The 
GFP positive tumor cells were analyzed using Becton Dickinson FACSCalibur™ flow 
cytomerter and FACSDiva software (Version 8.0, Becton Dickinson, San Jose, CA). 
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4.2.4 The evaluation of the combination of SP1017+BTZ in human MM/SCID 
model 
Female six-week old NOD/SCIDγc null (NSG) mice were obtained from The 
Jackson Laboratories and housed in AAALAC accredited facility. Food and reverse 
osmosis water were available ad libitum throughout the study. Animals were quarantined 
for 7 days prior to study initiation. All animal studies were conducted in accordance with 
the protocol approved by the University of Nebraska Medical Center Institutional Animal 
Care and Use Committee. MM was generated by i.v. injection of Luc+/GFP+ RPMI-8226 
cells (2 ×106 cells suspended in 100 ul of PBS) via tail vein of NSG mice. After 
development of tumors (4 weeks after injection), animal were randomized (4 treatment 
groups, n=10) and treated with saline, 0.1% SP1017 (100ul), 0.5mg/kg BTZ or 
combination of 0.1% SP1017 (100ul) and 0.5mg/kg BTZ. Treatments were administrated 
via tail vein injections twice weekly for 4 weeks (On day 1, 4, 8, 11, 15, 18, 22, 25). 
Tumor progression was monitored by bioluminescence imaging (BLI) once weekly, the 
procedure of which had been detailed in [19]. Blood samples were collected twice a 
week prior to drug injection from each mouse from facial vein by using 4-5mm lancet for 
the measurement of human Igλ in murine serum using human lambda ELISA Kit 
according to the manufacturer’s instructions. Animal body weight was monitored every 
second day starting from the day of malignant cell infusion and during tumor 
development and drug treatment.  General physical conditions, clinical signs and 
ascending paralysis were assessed using a four-stage scale of 0-3, with “0” being 
clinically normal, “1” being decreased tail tone or weak tail only, “2” being hind limb 
weakness and “3” being hind limb paralysis. Upon initial stages of disease progression, 
animals were monitored for clinical signs every second day. When initial clinical signs 
are noticed (score 1-2), animals were monitored on daily basis. The paralyzed mice or 
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non-paralyzed mice with 20% of body weight loss or those becoming moribund were 
euthanized via CO2 asphyxiation.  
4.2.5 Preparation of Cy5-L61 
 Pluronic® L61 was labeled with Cyanine 5 fluorophore according to the method 
described before20. Briefly, Pluronic® L61were activated with CDI, and then modified with 
excess of ethylenediamine and purified by dialysis against 20% ethonal. Amino-modified 
L61 was conjugated with Cyanine5 NHS ester (1:1) in dimethylformamide in the 
presence of 1.2 eq of tertiary amine. Free Cyanine5 and Cyanine5-labeled L61 were 
separated by Sephadex LH-20 (Sigma-Aldrich, St Louis, MO, USA) column using 
methonal/ dichloromethane (1:1) as elution phase. 
  4.2.6 Biodistribution of Cy5-L61 in both tumor-bearing mice and control 
mice 
5 Female six-week old NOD/SCIDγc null (NSG) mice were inoculated with 
Luc+/GFP+ RPMI-8226 cells as described above. In 6 weeks post MM cell inoculation, 
saline (100ul as control) and Cy5-L61 (0.011% L61 equivalent) mixed with 0.089% F127 
in saline (100ul), which compose 0.1% SP1017 were injected into both tumor-bearing 
mice and control mice without tumor. After 24h, the images of the whole body, skeleton 
as well as organs were taken using IVIS imaging system to track the distribution of Cy5-
L61. In addition, the BM of the tumor-bearing mice and control mice were extracted by 
ice-cold HBSS. All cells were collected and centrifuged down at 1500rpm for 10min. The 
supernatant was removed and cells were incubated with 2ml of ACK lysis buffer in 37°C 
water bath for 2min to remove the red cells. Another 25ml of HBSS was added to stop 
the lysis reaction. The Cy5-positive cells were analyzed using Becton Dickinson LSR 
II flow cytometer and FACSDiva software (Version 8.0, Becton Dickinson, San Jose, 
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CA). An aliquot of bone morrow cells was lysed with cell culture lysis reagent and 
supernatant was collected after removing cell debris by centrifugation (14000 rpm for 10 
min). 20ul of supernatant were taken and plated in white polystyrene, flat opaque bottom 
Corning® 96-well plate (Sigma-Aldrich, St Louis, MO, USA). Luciferase assay reagents 
were prepared according to the manufacturer’s instructions. 100ul reagent was added to 
each sample. Luminescence was determined as relative light units (RLU) using the 
SpectraMax M5 microplate reader and the results were normalized by protein content 
determined by BCA assay.   
4.2.7 Cy5-L61 uptake in CD45+ hematopoietic cells and CD11b+ cells 
(macrophages/monocytes) in BM in control mice. 
6 male six-week old NOD/SCIDγc null (NSG) mice were injected with saline (100ul 
as control) and Cy5-L61 (0.011% L61 equivalent) mixed with 0.089% F127 in saline 
(100ul), which compose 0.1% SP1017. The BM of control mice were extracted by ice-
cold HBSS 24h post-injection. All cells were collected and centrifuged down at 1500rpm 
for 10min. The supernatant was removed and cells were incubated with 2ml of ACK lysis 
buffer in 37°C water bath for 2min to remove the red cells. Another 25ml of HBSS was 
added to stop the lysis reaction. Cells were stained with FITC-CD45 and PE-CD11b 
according to the manufacturer’s instructions.  The cells were analyzed using Becton 
Dickinson LSR II flow cytometer and FACSDiva software (Version 8.0, Becton 
Dickinson, San Jose, CA).  
4.2.8 Statistical analysis 
For the antitumor study, the Kruska-Wallis test, a nonparametric test was used 
for overall comparison of the group means for paraprotein and BLI under different types 
of treatments as the data did not follow a normal distribution. To evaluate specific 
differences between BTZ and BTZ+SP1017 groups, Tukey’s nonparametric multiple-
179 
 
comparison method was used. Two-tailed P values less than 0.05 were considered 
significant in both tests.  
 
4.3 Results and discussion 
The human MM/SCID mice model was successfully established by injecting 
Luc+/GFP+ RPMI 8226 MM cells (2×106/100ul PBS/Mouse) into mice via tail vein. The 
tumor formation was validated by increased BLI signal observed in femur and other parts 
of skeleton (some mice also had increased BLI signal in soft tissue), increased 
expression of human lambda paraprotein, huge body weight loss and the progressing 
hind limb paralysis in the late stage. Tumor engraftment was observed 4 weeks post-
inoculation by BLI, with concomitant elevation of serum human lambda levels. The 
presence of tumor cells in the BM microenvironment was confirmed by whole-body and 
skeleton BLI as well as the presence of GFP+ tumor cells in the extracted BM analyzed 
by flow cytometry.  From the BLI of skeleton, the tumor signal was observed in femur.  
Among the BM extracted from the femur about 2.6% of cells are GFP+ tumor cells, 
indicating the tumor cells homing to the BM (Fig.4.1). In addition, MM foci and osteolytic 
lesions were observed to be present in multiple sites of the axial skeleton and confirmed 
by histopathology and X-ray imaging, respectively (Data not shown). Thus, MM cells 
were proven to effectively home to skeleton and develop MM lesions in skeletal sites in 
this model. For the evaluation of treatment efficiency, 40 NSG mice were injected with 
Luc+/GFP+ RPMI 8226 MM cells (2*10^6/100ul PBS/Mouse) via tail vein. In 4 weeks post 
tumor implantation, tumor-bearing NSG mice were divided into 4 groups randomly (10 
mice per group), treated with 1) 0.9% saline; 2) 0.1% SP1017 (100ul); 3) 0.5mg/kg BTZ; 
4) 0.5mg/kg BTZ+0.1% SP1017 (100ul) for 4 weeks, twice weekly (on day 1, 4, 8, 11, 
15, 18, 22, 25), which resemble the clinical BTZ regimen for MM. Treatment efficiency  
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A: Control mice without tumor 
       Left femur                                                             Right femur  
 
B: Tumor-bearing mice 
       Left femur                                                              Right femur  
        
Fig.4.1 Luc+/GFP+ RPMI 8226 MM cells in the femur of (A) one control mouse and (B) 
one tumor-bearing NSG mouse.  
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was elevated by measuring serum paraprotein levels twice a week and by weekly BLI 
imaging. After 4 weeks of treatments (day 24), the serum paraprotein level in the 
untreated controls was significantly elevated (85-fold increase) while both BTZ and 
BTZ+SP1017 combination treatments greatly suppressed the elevation of paraprotein 
over the whole treatment regimen and delayed the disease progression (Fig.4.2A). 
Notably, serum level of paraprotein was significantly lower in the group of mice treated 
with BTZ+SP1017 combination compared to that of the BTZ alone after only 2 injections 
(insert enlarged, Fig.4.2A) and the significant differences between treatments 
continued to be observed even after the treatments were completed. These results were 
validated by BLI data, which also showed significantly higher inhibition of disease 
progression in mice treated with the combination therapy compared to BTZ alone 
(Fig.4.2B). Fig.4.3 showed the BLI images of four treatment groups on Day 28 (the third 
day after final injection), which visually indicates the better treatment efficiency of the 
combination therapy.  The two parameters, the level of serum paraprotein and BLI 
signal, are well-correlated in indicating the tumor progression and the anti-tumor 
efficiency.  The serum level of paraprotein can be a more quantitative indicator of 
disease progression while the BIL data can be a visualized reporter, which demonstrated 
bone morrow tropism of the RPMI 8226 MM cells. In addition, the combination therapy 
did not show systemic toxicity (no significant body weight change between groups, 
Fig.4.4) or hematological toxicity (no significant differences were observed between the 
treatment and control groups as determined by cell blood counting, Table.4.1) at the 
dosage (0.5 mg/kg BTZ and 0.1% SP1017 (100ul)) we used.  
In previous work, Pluronic® block copolymer P85 was found to be accumulated in 
various tissues in the following order: liver>spleen>kidney>lung>brain [21]. However, no 
previous studies indicated whether the Pluronic® block copolymer can accumulate in the  
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                  A                                                           B                                  
           
           
                   
Fig.4.2 In vivo antitumor efficacy of BTZ+SP1017 combination therapy in Luc+/GFP+ 
RPMI 8226 human MM xenograft-bearing NSG mice. (A) Relative paraprotein levels 
(Pt/P0) and (B) changes in tumor volume as indicated by relative radiance units (Rt/R0) 
measured by means of BLI over time following IV administration of 1) 0.9% saline; 2) 
0.1% SP1017 (100ul); 3) 0.5mg/kg BTZ; 4) 0.5mg/kg BTZ+0.1% SP1017 (100ul) on Day 
1, 4, 8, 11, 15, 18, 22 and 25. Paraprotein level and radiance are normalized to 
respective values at the day before treatments were initiated (P0 and R0, respectively).  
Insert in panel A shows close-up of results up to 21 days following treatment initiation.  
Data presented as mean ± SEM.N=10 (*P<0.05, **P<0.01). Statistical significance 
between BTZ+SP1017 and BTZ groups was determined using Tukey’s nonparametric 
multiple-comparison method.  
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Fig.4.3. BLI images on the third day after all the 8 injections (Day 28) of four groups of 
NSG mice treated with of 1) 0.9% saline; 2) 0.1% SP1017 (100ul); 3) 0.5mg/kg BTZ; 4) 
0.5mg/kg BTZ+0.1% SP1017 (100ul).  
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SP1017 
Ventral 
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Fig.4.4. Body weight of tumor-bearing NSG mice which are received treatments of 1) 
0.9% saline; 2) 0.1% SP1017 (100ul); 3) 0.5mg/kg BTZ; 4) 0.5mg/kg BTZ+0.1% SP1017 
(100ul) on Day 1, 4, 8, 11, 15, 18, 22 and 25.  
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Table.4.1. Blood cell counting after 4 injections and 8 injections of 1) 0.9% saline; 2) 
0.1% SP1017 (100ul); 3) 0.5mg/kg BTZ; 4) 0.5mg/kg BTZ+0.1% SP1017 (100ul). 
 
The data represent mean ±SD (n=3) 
*Significantly different compared to control group, p<0.05 
** Significantly different compared to control group, p<0.01 
 
 
 
 
 
 
 
 After 4 injections After 8 injections 
 
Control  SP1017 BTZ BTZ+SP Control  SP1017 BTZ BTZ+SP 
WBC(10^3/ul) 6.0±0.9 10.1±0.9** 13.4±3.9* 9.5±1.9* 8.1±2.7 7.2±1.4 12.4±4.5 7.2±2.3 
RBC (10^6/ul) 9.3±0.1 8.2±1.3 9.0±0.4 8.5±0.6 9.2±0.2 8.8±0.6 8.0±1.2 8.5±0.3* 
PLT (10^3/ul) 38.0±5.7 102.7±24.9* 110.7±89.6 83.3±26.8 38.7±18.9 65.0±5.7 93.7±43.4 43.8±25.2 
HGB(g/dL) 15.5±0.5 14.8±0.4 15.2±0.3 14.9±0.1 14.4±0.4 14.6±1.3 14.0±0.5 14.2±0.3 
HCT (%) 43.3±0.7 38.5±5.4 42.8±1.9 40.5±2.2 41.7±0.4 40.3±2.6 37.9±5.5 40.3±1.2 
MCV (fL) 46.7±0.9 47.7±0.9 47.0±0.0 47.7±0.9 45.3±0.9 45.7±1.2 47.3±0.5* 47.5±0.5* 
MCHC (g/dL) 35.8±0.7 39.5±7.2 35.7±1.4 37.0±2.3 34.7±0.8 36.2±3.3 37.7±4.5 35.4±1.7 
RDWc (%) 19.5±0.2 19.3±0.4 20.5±0.3* 20.7±0.6 19.0±0.0 18.7±0.2 20.6±0.4* 21.1±0.5* 
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A 
                 Dorsal                                             Ventral 
 
B 
                      Dorsal                                             Ventral 
 
Fig. 4.5 The fluorescence (Cy5) images of mice skeleton of both (A) tumor-bearing mice  
and (B) control mice without tumor after 24h of injection of 0.011% Cy5-L61detected by 
IVIS with Ex=640nm and Em=680nm.  
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A                                                              B 
 
Fig. 4.6 The fluorescence (Cy5) images of mice organs (liver, heart, lung, kidney, 
spleen) of both (A) tumor-bearing mice  and (B) control mice without tumor after 24h of 
injection of Cy5-L61 (0.011% L61 equivalent) detected by IVIS with Ex=640nm and 
Em=680nm.  
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Fig. 4.7 (A) Cy5+ cells in BM extracted from both tumor-bearing mice and control mice 
with or without injection of Cy5-L61 (0.011% L61 equivalent). N=3 (B) Cy5+ cells in 
CD45+ hematopoietic cells and CD11b+ cells (macrophages/monocytes) in BM extracted 
from control mice with injection of Cy5-L61 (0.011% L61 equivalent).  N=5 
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BM. Interestingly, the fluorescent signal of Cy5 was observed in the femur and spine in 
both tumor-bearing mice and control mice 24h post-injection of Cy5-L61 (Fig. 4.5). We 
also found the accumulation of Cy5-L61 in the organs, such as liver, kidney and lung in 
both tumor-bearing mice and control mice (Fig 4.6). The BM from femur was extracted 
and the Cy5+ cells were analyzed by flow cytometry. We found about 63% of Cy5+ cells 
in tumor-bearing mice and 51% of Cy5+ cells in control mice (Fig. 4.7A). These data 
indicate that Pluronic® L61 could accumulate in BM, thus playing an important role in 
sensitizing MM cells in the BM to proteasome inhibitors. Moreover, 45.1% of CD45+ and 
44.5% CD11b+ cells in BM were associated with Cy5-L61 (Fig. 4.7B), indicating the 
uptake of the Pluronic® L61 by hematopoietic cells.  
Dose-limiting peripheral neuropathy is the major toxicity issue with bortezomib, 
which leads to dose reductions or discontinuation and may impact both long-term quality 
of life and the ability to get subsequent therapies[22].  One way to reduce the systemic 
toxicity could be using nanocarrier to encapsulate the hydrophobic drug BTZ or drug 
combinations. Despite of the carrier function of Pluronic® micelles, the major limitations 
of Pluronic® block copolymers include the low micellization and solubilization capacity to 
hydrophobic drugs, as well as poor micellar stability upon dilution in the blood-steam due 
to relatively high CMC values. In addition, whether and how much the Pluronic® unimers 
can be truly transported to the tumor sites are big concerns.  Thus, establishing a 
micellar formation of BTZ or CFZ based on amphiphilic block copolymers which have 
better micellar stability and can incorporate Pluronic® unimers to tumor sites as well as 
releasing the Pluronic® unimers into cytosol for exerting chemosensitization effect could 
be our future direction.  
 
4.4 Conclusions 
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We demonstrated that combination of BTZ and SP1017 exerted enhanced 
antitumor efficacy compared to BTZ, delaying the disease progression without causing 
systemic toxicity or hematological toxicity. Moreover, we observed the accumulation of 
the Cy5-L61 in the BM which was proved by both fluorescence imaging and flow 
cytometry, indicating the Cy5-L61 could target and accumulate in the skeleton, thus 
playing an important role in sensitizing MM cells in the BM to proteasome inhibitors.
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CHAPTER V: SUMMARY 
 
During the last decades, nanotechnology has provided new drug delivery 
systems for anti-cancer drugs which can improve its water solubility, minimize the side 
effects, increase the tumor-targeting distribution by passive or active targeting and 
overcome MDR drug resistance. Pluronic® block copolymers are found to be an efficient 
drug delivery system as well as chemosensitizers for MDR tumor cells. Here, in our 
study, we investigated the sensitization effect of SP1017 (the mixture of Pluronic® L61 
and F127 with ratio 1:8 w/w) on both sensitive and resistant MM cell lines to proteasome 
inhibitors, explored the related molecular mechanisms and evaluated the treatment 
efficiency of the combination of SP1017 and proteasome inhibitor BTZ in human 
MM/SCID mice model.  
Chapter II focuses on the sensitization effect of SP1017 on both sensitive and 
resistant MM cells to both the reversible BTZ and CFZ rather than normal hematological 
cell (PBMC) and non-hematological cells (MCF-7 human breast adenocarcinoma cells, 
HepG2 human liver carcinoma cells and Hela human cervix adenocarcinoma cells). 
0.005% SP1017 (below the CMC of Pluronic
® 
L61) potentiated 2-fold of both BTZ- and 
irreversible CFZ- induced cell cytotoxicity of three different sensitive MM cell lines due to 
cell apoptosis. SP1017 remained the comparable sensitization effect in BTZ-resistant 
RPMI 8226 cells while gained significant higher sensitization factor in CFZ-resistant 
RPMI 8226 cells due to the Pgp expression in CFZ-resistant MM cells rather than BTZ-
resistant RPMI 8226 MM cells. SP1017 did not sensitize BTZ-induced apoptosis of 
normal hematological cell (PBMC), which indicates the potential of maintaining the anti-
MM efficacy of the combination therapy while reducing hematological toxicities. 
Moreover, BTZ alone exhibiting less than encouraging results in non-hematologic tumor 
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cells compared with that to RPMI 8226 MM cells, indicating the specificity of the 
combination therapy in dealing with hematologic malignancies.  
Chapter III focuses on the molecular mechanisms of the combination of 
SP1017+BTZ –induced MM cell apoptosis. Previous work indicated that Pluronics at 
relative low concentration can only sensitize MDR cancer cells rather than sensitive 
cells. Here in our study we firstly proved that at quite low concentration, SP1017 
sensitized sensitive MM cells to proteasome inhibitors associated with : 1) increase of 
suppression of ChT-L proteolytic activity, concomitant with increased accumulation of 
ubiquitinated proteins and proteotoxic stress; 2) accumulation of Pluronic® L61 in ER and 
increase of ER stress response; 3) accumulation of Pluronic® L61 in Golgi apparatus, 
increase of Golgi fragmentation and reduction of secretion of paraprotein; 4) increase of 
GSH depletion, resulting in less ability to neutralize drug-induced oxidative stress; 5) 
increase of activation of both mitochondria-dependent (quick translocation of Pluronic® 
L61 into mitochondria, mitochondrial membrane potential loss, cytochrome c release and 
activation of caspase 9/3 ) and independent (activation of caspase 8/3) apoptotic 
pathways; 6) decrease of the expression of anti-apoptotic proteins. Moreover, the 
combination of SP1017 and BTZ effectively overcame both adhesion-mediated drug 
resistance and cytokines-mediated drug resistance (significant reduction of IL-6 
secretion by BMSCs), indicating the great potential to use the combination for MM. The 
findings provide the strong rationale for the further investigation of the treatment 
efficiency of the combination therapy in human MM/SCID mice model and the future 
clinical evaluation in patients with relapsed and refractory myeloma. In addition, SP1017 
in combination with BTZ and DEX leads to most pronounced anti-proliferative effect, 
indicating the potential of SP1017 used in corticosteroid sparing regimens to further 
196 
 
improve the therapeutic efficacy as well as limiting significant side effects that patient 
with multiple myeloma often experience. 
Chapter IV focuses on the evaluation of the treatment efficacy of the combination 
of SP1017+BTZ in human MM/SCID mice model. The combination of BTZ and SP1017 
exerted enhanced antitumor efficacy compared to BTZ, delaying the disease 
progression without causing systemic toxicity or hematological toxicity. Moreover, we 
observed the accumulation of the Cy5-L61 in the BM which was proved by both 
fluorescence imaging and flow cytometry, indicating the Cy5-L61 could target and 
accumulate in the skeleton, thus playing an important role in sensitizing MM cells in the 
BM to proteasome inhibitors. 
Overall, the research supports the hypothesis SP1017 can sensitize multiple 
myeloma in vitro and in vivo by targeting multiple molecular mechanisms. Therefore, 
Pluronic® block copolymers are expected to be potential chemosensitizer used to 
sensitize MM cells via not only overcoming drug efflux pumps, but also involving multiple 
molecular mechanisms.  
Our future study will focus on the evaluation of the sensitization effect of SP1017 
on BTZ- and CFZ-resistant cells in vitro and in vivo and the exploration of the related 
molecular mechanisms. In addition, establishing a micellar formation of BTZ or CFZ 
based on amphiphilic block copolymers which have better micellar stability and can 
incorporate Pluronic® unimers to tumor sites as well as releasing the Pluronic® unimers 
into cytosol for exerting chemosensitization effect could be another future direction.  
  
 
